Inhibition of receptors by phosphatase recruitment
Patent Information
- Application Number
- JP2024104366
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-05-17
- Filing Date
- 2024-06-27
- Publication Date
- 2024-11-29
AI Technical Summary
Current immunotherapeutic approaches for treating diseases like cancer are limited by the inability to effectively inhibit intracellular signaling activities of cell surface receptors, such as PD-1 and cytokine receptors, beyond traditional ligand blocking, which does not fully address basal and ligand-induced signaling.
Development of multivalent polypeptides and antibodies that recruit phosphatases, like CD45, to the spatial vicinity of cell surface receptors, directly modulating receptor signaling through phosphatase activity to antagonize both basal and ligand-induced phosphorylation.
This approach enhances T-cell activity by fully or partially inhibiting immune checkpoint receptors and cytokine receptors, overcoming the limitations of traditional ligand-blocking antibodies by directly reducing receptor phosphorylation, thereby restoring T-cell function.
Smart Images

Figure 00000000_0000_ABST 
Figure 00000000_0001_ABST
Abstract
Description
[Technical field]
[0001] STATEMENT REGARDING FEDERALLY SPONSORED R&D This invention was made with Government support under Grant No. CA 177684 awarded by the National Institutes of Health (NIH). The Government has certain rights in this invention. CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 673,049, filed May 17, 2018, which is expressly incorporated herein by reference in its entirety, including all drawings. [Inclusion of sequence listing]
[0003] The contents of the attached sequence listing are incorporated by reference into this application. The sequence listing text file with the file name 078430-504001WO_Sequence Listing.txt was created on May 8, 2019 and is 102 KB in size. [Field]
[0004] The present disclosure relates generally to the field of immunotherapeutics, and more particularly to multivalent protein binding molecules that specifically bind to cell surface receptors and antagonize receptor signaling through recruitment of phosphatase activity. The present disclosure also provides compositions and methods useful for the production of such molecules, as well as methods for treating diseases associated with the inhibition of signaling mediated by cell surface receptors. [Background technology]
[0005] BACKGROUND OF THEINVENTION The use of pharmaceutical compositions containing therapeutic proteins for the treatment of diseases or health conditions is a central strategy for many pharmaceutical and biotechnology companies. For example, in cancer immunotherapy, the development of agents that activate T cells of the host's immune system to prevent the proliferation or kill cancer cells has emerged as a promising therapeutic approach that complements the current standard of care. An example of such an immunotherapy approach is the development of antibodies that are used to activate the immune system to kill cancer cells. For example, antagonism of a specific activity of a receptor can be achieved by blocking (blocking) ligand binding to the extracellular domain (ECD) of the receptor, for example through the use of antagonist antibodies directed against the ECD. In this scenario, the blocking molecule (e.g., antagonist antibody) functions by competing with the natural ligand for binding to the receptor ECD. Illustrative of this approach are the numerous blocking antibodies specific for the ECD of the immune receptor PD-1 or its ligand PD-L1, which have been approved in the United States (US) and European Community (EU) to treat diseases such as unresectable or metastatic melanoma and metastatic non-small cell lung cancer. In another example, efforts to inhibit immune suppressive proteins such as CTLA-4 have led to the commercial development and clinical evaluation of anti-CTLA-4 blocking antibodies that function by binding to the ECD and blocking its binding to natural ligands. However, these blocking antibodies are reported to be ineffective in many patients and cannot eliminate the basal intracellular signaling activity (also referred to as resting intracellular signaling activity) of receptors, such as PD-1 and other receptors that signal through phosphorylation mechanisms. The inability to eliminate such basal signaling activity often limits the effectiveness of ECD ligand blockade strategies. Thus, there is a need for novel methods to directly reduce or eliminate intracellular signaling of such receptors by alternative mechanisms distinct from the ECD ligand blockade mechanism that would reduce or eliminate both resting and ligand-activated signaling. For example, with respect to immune checkpoint receptors, it is desirable to completely remove checkpoint inhibition to allow full amplification of T cell activity.Furthermore, there is a need for novel approaches to inhibit the signaling of other receptors, such as cytokine receptors, which signal through a phosphorylation mechanism and for which inhibition of their ligands shows limited efficacy.
[0006] Thus, there remains a need for alternative approaches, other than direct receptor-ligand blockade with antibodies or other agents, to complement the current standard of care (SOC) for the immunotherapy of cancer and other immune disorders. Summary of the Invention
[0007] The present disclosure relates to immunotherapeutic agents, such as multivalent polypeptides, multivalent antibodies, and pharmaceutical compositions comprising the same, for example, used to treat various diseases, such as diseases associated with inhibition of cell signaling mediated by cell surface receptors. As described in more detail below, the present disclosure provides compositions and methods for modulating cell surface receptor signaling by specifically recruiting membrane phosphatases to spatial proximity of a signaling receptor of interest, for example, through direct ligation with a multivalent agent. This novel methodology is referred to as "receptor inhibition by phosphatase recruitment" (RIPR). More specifically, the present disclosure provides novel chimeric protein binding molecules that specifically bind to cell surface receptors, thereby fully or partially antagonizing receptor signaling through recruitment of phosphatase activity. In some particular embodiments, the disclosed chimeric protein binding molecules are multivalent antibodies. The present disclosure also provides compositions and methods useful for making such compounds, as well as methods for treating diseases associated with inhibition of cell surface receptor-mediated signaling.
[0008] In one aspect, a multivalent polypeptide is disclosed that comprises (i) a first amino acid sequence that comprises a first polypeptide module capable of binding to one or more receptor protein tyrosine phosphatases (RPTPs), and (ii) a second amino acid sequence that comprises a second polypeptide module that can bind to one or more cell surface receptors that signal through a phosphorylation mechanism, wherein said first polypeptide module is operably linked to said second polypeptide module.
[0009] Non-limiting example embodiments of the multivalent polypeptides of the present disclosure may include one of the following features: In some embodiments, the first polypeptide module is operably linked to the second polypeptide module via a polypeptide linker sequence. In some embodiments, at least one of the first and second polypeptide modules comprises the amino acid sequence of a protein-binding ligand or antigen-binding moiety. In some embodiments, the protein-binding ligand is a cytokine, a growth factor, a receptor extracellular domain (ECD) of a cell surface receptor or of a RPTP, or a functional variant of any of them. In some embodiments, the antigen-binding moiety is an antigen-binding fragment (Fab), a single chain variable fragment (scFv), a nanobody, a VFv ... H Domain, V L Domain, Single Domain Antibody (dAb), V NAR Domain, and V H The antigen-binding portion may be selected from the group consisting of a heavy chain variable region, a diabody, or a functional fragment thereof. In some embodiments, the antigen-binding portion comprises a heavy chain variable region and a light chain variable region.
[0010] In some embodiments, the one or more RPTPs comprise CD45 phosphatase or a functional variant thereof. In some embodiments, the one or more cell surface receptors comprise an immune checkpoint receptor, a cytokine receptor, or a growth factor receptor. In some embodiments, the one or more cell surface receptors comprise an immune checkpoint receptor selected from the group consisting of an inhibitory checkpoint receptor and a stimulatory checkpoint receptor. In some embodiments, the one or more cell surface receptors comprise PD-1, CTLA-4, A2AR, B7-H3, B7-H4, BTLA, CD5, CD132, IDO, KIR, LAG3, TIM-3, TIGIT, VISTA, or a functional variant of any of these. In some embodiments, the one or more cell surface receptors comprise a stimulatory checkpoint receptor selected from the group consisting of CD27, CD28, CD40, OX40, GITR, ICOS, CD137, and a functional variant of any of these. In some embodiments, the one or more cell surface receptors mediate signaling through specific tyrosine-based motifs selected from ITAM motifs, ITSM motifs, ITIM motifs, or related intracellular motifs that act as phosphorylation substrates. In some embodiments, the one or more cell surface receptors are selected from the group consisting of DAP10, DAP12, SIRPa, CD3, CD28, CD4, CD8, CD200, CD200R, ICOS, KIR, FcR, BCR, CD5, CD2, G6B, LIRs, CD7, BTNs, and functional variants of any thereof. In some embodiments, the one or more cell surface receptors include a cytokine receptor. In some embodiments, the cytokine receptor is selected from the group consisting of an interleukin receptor, an interferon receptor, a chemokine receptor, a growth hormone receptor, an erythropoietin receptor (EpoR), a thymic stromal lymphopoietin receptor (TSLPR), a thrombopoietin receptor (TpoR), a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor, and a granulocyte-colony stimulating factor (G-CSF) receptor. In some embodiments, the one or more cell surface receptors comprise a growth factor receptor.In some embodiments, the growth factor receptor is a tyrosine receptor kinase (TRK) belonging to the TRK family selected from the group consisting of EGF receptor family (ErbB family), insulin receptor family, PDGF receptor family, VEGF receptor family, FGF receptor family, CCK receptor family, NGF receptor family, HGF receptor family, Eph receptor family, AXL receptor family, TIE receptor family, RYK receptor family, DDR receptor family, RET receptor family, ROS receptor family, LTK receptor family, ROR receptor family, and MuSK receptor family. In some embodiments, the growth factor receptor is a stem cell growth factor receptor (SCFR) or epidermal growth factor receptor (EGFR) selected from the group consisting of ErbB-1, ErbB-2 (HER2), ErbB-3, ErbB-4, and c-Kit (CD117).
[0011] In some embodiments, the polypeptide linker sequence comprises 1-100 amino acid residues. In some embodiments, the polypeptide linker comprises at least one glycine residue. In some embodiments, the polypeptide linker comprises a glycine-serine linker. In some embodiments, the heavy chain variable region and the light chain variable region are operably linked to each other via one or more intervening amino acid residues interposed between the heavy chain variable region and the light chain variable region. In some embodiments, the intervening amino acid residue comprises 1-100 amino acid residues. In some embodiments, the intervening amino acid residue comprises at least one glycine residue. In some embodiments, the intervening amino acid residue comprises a glycine-serine linker.
[0012] Some embodiments disclosed herein relate to a multivalent polypeptide comprising, from N-terminus to C-terminus, (a) a domain A comprising a binding region of a heavy chain variable region of a first scFv specific for an epitope of a RPTP; (b) a domain B comprising a binding region of a light chain variable region of a second scFv specific for an epitope of a cell surface receptor; (c) a domain C comprising a binding region of a heavy chain variable region of a second scFv specific for an epitope of a cell surface receptor; and (d) a domain D comprising a binding region of a light chain variable region of a first scFv specific for an epitope of a RPTP. In some embodiments, the multivalent polypeptide according to this aspect of the disclosure further comprises an amino acid sequence of a signal peptide. In some embodiments, the multivalent polypeptide according to this aspect of the disclosure comprises an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 10, 12, 14, 16, 20, 22, 24, 26, 28, and 54.
[0013] In one aspect, some embodiments of the present disclosure relate to a multivalent antibody or functional fragment thereof, which comprises (i) a first polypeptide module specific for one or more receptor protein tyrosine phosphatases (RPTPs) and (ii) a second polypeptide module specific for one or more cell surface receptors that signal through a phosphorylation mechanism, wherein the first polypeptide module is operably linked to the second polypeptide module.
[0014] Non-limiting example embodiments of the multivalent polypeptides of the present disclosure can include one of the following features: In some embodiments, the first polypeptide module is operably linked to the second polypeptide module via a polypeptide linker sequence. In some embodiments, at least one of the first and second polypeptide modules comprises the amino acid sequence of a protein binding ligand or antigen binding moiety. In some embodiments, the antigen binding moiety is an antigen binding fragment (Fab), a single chain variable fragment (scFv), a nanobody, a VH domain ... L Domain, Single Domain Antibody (sdAb), V NARDomain, and V H In some embodiments, the antigen binding portion comprises a heavy chain variable region and a light chain variable region.
[0015] In some embodiments, the one or more RPTPs comprise CD45 or a functional variant thereof. In some embodiments, the one or more cell surface receptors comprise an immune checkpoint receptor, a cytokine receptor, or a growth factor receptor. In some embodiments, the one or more cell surface receptors comprise an immune checkpoint receptor selected from the group consisting of an inhibitory checkpoint receptor and a stimulatory checkpoint receptor. In some embodiments, the one or more cell surface receptors comprise an inhibitory checkpoint receptor selected from the group consisting of PD-1, CTLA-4, A2AR, B7-H3, B7-H4, BTLA, CD5, CD132, IDO, KIR, LAG3, TIM-3, TIGIT, VISTA, and any functional variant thereof. In some embodiments, the one or more cell surface receptors comprise a stimulatory checkpoint receptor selected from the group consisting of CD27, CD28, CD40, OX40, GITR, ICOS, CD137, and any functional variant thereof. In some embodiments, the one or more cell surface receptors mediate signaling through specific tyrosine-based motifs selected from ITAM motifs, ITSM motifs, ITIM motifs, or related intracellular motifs that act as phosphorylation substrates. In some embodiments, the one or more cell surface receptors are selected from the group consisting of DAP10, DAP12, SIRPa, CD3, CD28, CD4, CD8, CD200, CD200R, ICOS, KIR, FcR, BCR, CD5, CD2, G6B, LIR, CD7, BTN, and any functional variants thereof. In other embodiments, the cell surface receptor is a cytokine receptor. In some embodiments, the cytokine receptor is selected from the group consisting of an interleukin receptor, an interferon receptor, a chemokine receptor, a growth hormone receptor, an erythropoietin receptor (EpoR), a thymic stromal lymphopoietin receptor (TSLPR), a thrombopoietin receptor (TpoR), a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor, a granulocyte-colony stimulating factor (G-CSF) receptor, and in some further embodiments, the cell surface receptor is a growth factor receptor.In some embodiments, the growth factor receptor is a tyrosine receptor kinase (TRK) belonging to the TRK family selected from the group consisting of EGF receptor family (ErbB family), insulin receptor family, PDGF family, VEGF receptor family, FGF receptor family, CCK receptor family, NGF receptor family, HGF receptor family, Eph receptor family, AXL receptor family, TIE receptor family, RYK receptor family, DDR receptor family, RET receptor family, ROS receptor family, LTK receptor family, ROR receptor family, and MuSK receptor family. In some embodiments, the growth factor receptor is a stem cell growth factor receptor (SCFR) or epidermal growth factor receptor (EGFR) selected from the group consisting of ErbB-1, ErbB-2 (HER2), ErbB-3, ErbB-4, and c-Kit (CD117).
[0016] In some embodiments of the present disclosure, the polypeptide linker sequence comprises 1-100 amino acid residues. In some embodiments, the polypeptide linker comprises at least one glycine residue. In some embodiments, the polypeptide linker comprises a glycine-serine linker.
[0017] In some embodiments, the heavy and light chain variable regions of the antigen-binding portion are operably linked to one another by one or more intervening amino acid residues located between the heavy and light chain variable regions. In some embodiments, the intervening amino acid residues comprise 1-100 amino acid residues. In some embodiments, the intervening amino acid residues comprise at least one glycine residue. In some embodiments, the intervening amino acid residues comprise a glycine-serine linker.
[0018] Some embodiments disclosed herein relate to a multivalent antibody comprising, from N-terminus to C-terminus, (a) a domain A comprising a binding region of a heavy chain variable region of a first scFv specific for an epitope of a RPTP; (b) a domain B comprising a binding region of a light chain variable region of a first scFv specific for an epitope of a cell surface receptor; (c) a domain C comprising a binding region of a heavy chain variable region of a second scFv specific for an epitope of a cell surface receptor; and (d) a domain D comprising a binding region of a light chain variable region of a second scFv specific for an epitope of a RPTP. In some embodiments, the multivalent antibody according to this aspect of the disclosure further comprises an amino acid sequence of a signal peptide. In some embodiments, the multivalent antibody according to this aspect comprises an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 10, 12, 14, 16, 20, 22, 24, 26, 28 and 54.
[0019] In another aspect, some embodiments of the present disclosure relate to a pharmaceutical composition comprising: (i) a multivalent polypeptide as disclosed herein; or (ii) a multivalent antibody as disclosed herein, and a pharma- ceutically acceptable excipient.
[0020] In another aspect, some embodiments disclosed herein relate to a recombinant nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising: (i) an amino acid sequence having at least 80% identity to an amino acid sequence of a multivalent polypeptide of the present disclosure; or (ii) an amino acid sequence having at least 80% identity to a multivalent antibody or functional fragment thereof of the present disclosure. In some embodiments, the nucleotide sequence has at least 80% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 9, 11, 13, 15, 19, 21, 23, 25, 27, and 53. In some related embodiments, the present disclosure further provides an expression cassette or vector comprising a recombinant nucleic acid molecule of the present disclosure.
[0021] In another embodiment, some embodiments of the present disclosure relate to a recombinant cell comprising a nucleic acid molecule of the present disclosure. The recombinant cell according to this aspect comprises a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising (i) an amino acid sequence having at least 80% identity to an amino acid sequence of a multivalent polypeptide of the present disclosure; or (ii) an amino acid sequence having at least 80% identity to a multivalent antibody or functional fragment thereof of the present disclosure. In some embodiments, the nucleotide sequence has at least 80% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 9, 11, 13, 15, 19, 21, 23, 25, 27, and 53. In another related aspect, some embodiments disclosed herein relate to a cell culture comprising one or more recombinant cells of the present disclosure.
[0022] In another aspect, disclosed are embodiments of methods for producing a polypeptide or a multivalent antibody, including (i) a multivalent polypeptide of this disclosure, or (ii) a multivalent antibody of this disclosure. In some embodiments, the method according to this aspect is performed in vitro, in vivo, or ex vivo.
[0023] In another aspect, a method is disclosed for modulating cell signaling mediated by a cell surface receptor that signals through a phosphorylation mechanism in a subject, the method comprising administering to the subject a first treatment comprising an effective amount of (i) a multivalent polypeptide of the present disclosure, or (ii) a multivalent antibody of the present disclosure.
[0024] In yet another aspect, disclosed are embodiments of methods for treating a disease in a subject in need of treatment, the method comprising administering to the subject a first treatment comprising an effective amount of (i) a multivalent polypeptide of the disclosure, or (ii) a multivalent antibody of the disclosure.
[0025] Non-limiting example embodiments of the disclosed method embodiments can include one or more of the following features. In some embodiments, the administered multivalent polypeptide or multivalent antibody recruits receptor protein tyrosine phosphatase (RPTP) activity to the spatial vicinity of the cell surface receptor and reduces the phosphorylation level of the cell surface receptor. In some embodiments, administration of the multivalent polypeptide or multivalent antibody reduces the activity of an immune checkpoint receptor in the subject. In some embodiments, administration of the multivalent polypeptide or multivalent antibody provides enhanced T cell activity in the subject. In some embodiments, administration of the multivalent polypeptide or multivalent antibody provides suppression of T cell activity in the subject. In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human. In some embodiments, the subject has or is suspected of having a disease associated with inhibition of signal transduction mediated by a cell surface receptor. In some specific embodiments, the disease is cancer or a chronic infection.
[0026] In some embodiments, the disclosed therapeutic methods further include administering a second therapeutic agent to the subject. The second therapeutic agent is selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, hormone therapy, and toxin therapy. In some embodiments, the first and second therapeutic agents are administered concomitantly. In some embodiments, the first therapeutic agent is administered simultaneously with the second therapeutic agent. In some embodiments, the first and second therapeutic agents are administered sequentially. In some embodiments, the first therapeutic agent is administered before the second therapeutic agent. In some embodiments, the first therapeutic agent is administered after the second therapeutic agent. In some embodiments, the first therapeutic agent is administered before and / or after the second therapeutic agent. In some embodiments, the first and second therapeutic agents are administered cyclically. In some embodiments, the first therapeutic agent and the second therapeutic agent are administered together in a single formulation.
[0027] Each of the aspects and embodiments described herein can be used together unless expressly or specifically excluded from the scope of that embodiment or aspect.
[0028] The above summary is illustrative only and is not intended to be in any way limiting. In addition to the exemplary embodiments and features described herein, further aspects, embodiments, objects and features of the present disclosure will become more fully apparent from the drawings, detailed description and claims. [Brief description of the drawings]
[0029] [Figure 1] 1A-1B diagrammatically illustrate a non-limiting example of modulation of cell surface receptor signaling by local phosphatase recruitment through the RIPR method, according to some embodiments of the present disclosure. An active kinase at the cell membrane induces a basal low level of receptor phosphorylation (FIG. 1A-left panel). Binding to a cognate ligand increases receptor phosphorylation and initiates signaling (FIG. 1A-right panel). As shown, a bispecific polypeptide that recruits a phosphatase to the spatial vicinity of a receptor of interest reduces both basal and ligand-induced phosphorylation (FIG. 1B, by enzymatically "shaving" phosphate groups from the receptor intracellular domain in both its basal and ligand-activated states). The receptor binding module of the RIPR molecule can be either competitive or non-competitive with the natural ligand, which can be secreted or membrane-bound.
[0030] [Diagram 2]FIG. 2 illustrates a non-limiting example of the application of the present RIPR method to modulate the activity of PD-1 surface receptor signaling by local CD45 recruitment, according to some embodiments of the present disclosure. PD-1 expression reduces T cell activity due to low basal phosphorylation of intracellular motifs by membrane-bound kinases such as Lck (FIG. 2-top; left panel). Upon binding to PD-L1, PD-1 phosphorylation increases, which further reduces T cell activity (FIG. 2-top; right panel). PD-1 blocking antibodies, which are "checkpoint inhibitors," confer receptor / ligand interactions, thereby reducing PD-L1-induced phosphorylation. As depicted, bispecific diabodies that recruit CD45 phosphatase to the spatial vicinity of the receptor of interest reduce both basal phosphorylation as well as PD-L1-induced phosphorylation (FIG. 2-bottom, left panel) and remove phosphate groups from the intracellular signaling motifs of the receptor (FIG. 2-bottom, right panel).
[0031] [Diagram 3] Figures 3A-3C graphically summarize the results of experiments performed to demonstrate that bispecific diabodies bind to HEK293 cells transfected with CD45 (Figure 3A), PD-1 (Figure 3B), or both molecules (Figure 3C).
[0032] [Figure 4] Figures 4A-4B graphically summarize the results of experiments performed to show that PD-1 expression reduces T cell activation, even in the absence of PD-1 ligand. In these experiments, PD-1 expressing Jurkat T cells were activated overnight with 2 μg / mL OKT3. Figure 4A: CD25 and CD69 upregulation was lower in PD-1 expressing cells. Figure 4B: Reduction of PD-1 expression in cells treated with CRISPR / Cas9 PD-1 targeting guide RNA resulted in higher levels of CD69 expression upon activation with OKT3.
[0033] [Diagram 5]Figures 5A-5B summarize the results of experiments performed to show the reconstitution of PD-1 phosphorylation by LcK and CD45 in HEK293 cells. PD-1 was not phosphorylated in wild-type HEK293 cells (lane 1). However, PD-1 was readily phosphorylated in the presence of LcK (lane 2). Coexpression of CD45 (lane 3) reduced total phosphorylation. A further reduction in PD-1 phosphorylation was observed upon incubation with the CD45-PD1 bispecific diabody (Db) (lane 4). A CD45 mutant (C856S) mutation with greatly reduced phosphatase activity did not affect PD-1 phosphorylation, either upon expression (lane 5) or upon recruitment after incubation with the CD45-PD1 bispecific diabody (Db; lane 6).
[0034] [Figure 6] 6A-6B summarize the results of experiments performed to demonstrate the reconstitution of multiple receptor phosphorylation by incubation with the lymphocyte-specific protein tyrosine kinase LcK and / or CD45 in HEK293 cells.
[0035] [Figure 7]Figures 7A-7F summarize the results of experiments performed to show that treatment of T cells with the CD45-PD1 bispecific diabody increases T cell activation in response to OKT3 and peptide-MHC stimulation. Jurkat T cells expressing PD-1 were stimulated overnight with OKT3 (2 μg / mL; black diamonds) in the presence of nivolumab antibody (white squares) or CD45-PD1 (Nivo) diabody (black circles). CD45-PD1 increased the expression of activation markers CD69 (Figure 7A) and CD25 (Figures 7B-7C), as well as IL-2 cytokine secretion (Figure 7D). In Figures 7E-7F, SKW-3 T cells transduced with the appropriate TCR and PD-1 were incubated with cells presenting agonist peptide-MHC ± PD-L1 (PD-L1-, closed diamonds; PD-L1+, open circles) and nivolumab antibody (open squares) or CD45-PD1 (Nivo) diabody (closed circles). Incubation with the CD45-PD1 diabody increased IL-2 cytokine secretion to levels similar to those achieved when PD-L1 was lacking.
[0036] [Figure 8] Figures 8A-8B summarize the results of experiments performed to show that CD45-PD1 diabody enhances proliferation of activated peripheral blood mononuclear cells (PBMCs). Figure 8A: Freshly isolated PBMCs were labeled with CFSE and incubated with OKT3 + nivolumab or CD45-PD1 diabody for 4 days. CD45-PD1 promoted T cell proliferation at a higher level than nivolumab antibody. Figure 8B: Quantification of T cell proliferation (%) for cells treated with OKT3 alone or OKT3 with nivolumab or CD45-PD1 (Nivo) (0.5 μM).
[0037] [Figure 9]Figures 9A-9F summarize the results of another experiment performed with activated PBMCs to show that the bispecific diabody CD45-PD1 can enhance CD4+ and CD8+ T cell activation in response to agonist peptides. It was observed that both CD45-PD1 (Nivo) and CD45-PD1 (Pembro) can enhance T cell activation, as indicated by elevated expression levels of CD69 (Figure 9A) and CD25 (Figure 9B), as well as secretion of IFNγ (Figure 9D) and the cytokine IL-2 (Figure 9C). When incubated with nivolumab, pembrolizumab, CD45-PD1 (Nivo) or CD45-PD1 (Pembro), staining with an anti-PD1 fluorescently labeled antibody (clone 29F.1A12; PD-1 / PD-L1 blocking antibody) was reduced, as indicated by PD1 MFI. On the other hand, incubation with agonist peptides alone or in combination with anti-CD45 bispecific diabodies did not affect the staining (Figure 9E). Increased expression levels of CD69 upon treatment with CD45-PD1 (Nivo) or CD45-PD1 (Pembro) were observed in both CD4+ and CD8+ T cells (Figure 9F).
[0038] [Figure 10]Figures 10A-10C summarize the results of another experiment performed with activated PBMCs to show that RIPR-PD1 is not strictly dependent on inhibition of PD-1 / PD-L1 interaction. When using a non-blocking scFv to bind PD-1, it was observed that the bispecific diabody CD45-PD1(Cl19) (clone 19, Cl19) was able to enhance T cell activation in response to agonist peptides, as indicated by elevated CD69 expression levels (Figure 10A) as well as by IFNγ secretion (Figure 10B). Whereas incubation with the bispecific diabody CD45-PD1(Cl19) caused a partial reduction in PD1 MFI after staining the cells with a fluorescently labeled anti-PD1 antibody (clone 29F.1A12; a PD-1 / PD-L1 blocking antibody), incubation with nivolumab or pembrolizumab was able to cause a strong reduction in PD-1 MFI (Figure 10C).
[0039] [Figure 11] Figures 11A-11C summarize the results of experiments performed to show that treatment of T cells with a second generation CD45-PD1 (VHH) bispecific binding module increases T cell activation in response to Muromonab-CD3® (OKT3). In these experiments, the bispecific diabodies CD45-PD1 (Nivo) and CD45-PD1 (VHH) increased the expression of activation markers CD69 (Figure 11A) and CD25 (Figure 11B), resulting in a higher fraction of CD69+ / CD25+ cells (Figure 11C).
[0040] [Figure 12] Figures 12A-12B summarize the results of experiments performed to show that treatment of mouse T cells with the anti-mouse CD45(VHH)-PD1F2 bispecific binding module increases T cell activation in response to anti-mouse CD3(2C11). In these experiments, the bispecific diabody CD45(VHH)-PD1F2 increased the expression of the activation markers CD69 (Figure 12A) and CD25 (Figure 12B).
[0041] [Figure 13] Figures 13A-13B summarize the results of experiments performed to show that treatment of mouse TCR transgenic (Pmel-1) CD8+ T cells with an anti-mouse CD45(VHH)-PD1(F2) bispecific binding module increases T activation in response to gp100 peptide. In these experiments, the bispecific CD45(VHH)-PD1F2 binding molecule increased the expression of the activation markers CD69 (Figure 13A) and CD25 (Figure 13B).
[0042] [Figure 14] Figures 14A-14B summarize the results of experiments performed to show that treatment of mouse T cells with an anti-mouse CD45(VHH)-CTLA4 bispecific binding module (designated mRIPR-CTLA4) increases T cell activation in response to anti-mouse CD3(2C11). In these experiments, treatment of T cells with the bispecific CD45(VHH)-CTLA4 binding molecule increased the fraction of cells with elevated CD69 and CD25 levels in both CD4+ and CD8+ T cells after 24 hours (Figure 14A) and 48 hours (Figure 14B) of incubation with the 2C11 antibody and CD45(VHH)-CTLA4.
[0043] [Figure 15] Figures 15A-15B summarize the results of experiments demonstrating that anti-mouse CD3 (2C11) reduces the expression of markers of T cell activation, such as CD25 and CD44. In these experiments, anti-mouse CD45 (VHH)-CD28 bispecific polypeptide reduced the expression of activation markers CD25 and CD44 for both CD4+ (Figure 15A) and CD8+ (Figure 15B) after 48 hours of incubation with the 2C11 antibody and mRIPR-CD28.
[0044] [Figure 16]Figures 16A-16C diagrammatically depict another non-limiting example of a bispecific protein binding molecule according to some embodiments of the present disclosure. In this case, the figures show an example of a RIPR consisting of a CD45 binding module linked to IL-2. IL-2 induces phosphorylation of its IL-2R-β and γ-c receptors. Binding of IL-2 to the binding module that recruits CD45 removes a phosphate group from a tyrosine residue on the IL-2 receptor, which causes a decrease in signaling. Similar RIPR designs are expected to attenuate signaling by other cytokine and growth factor receptors (Figure 16A). A multivalent polypeptide capable of binding to the phosphatase CD45 and the cell surface receptor IL-2R fluorescently labels YT+ cell surfaces (Figure 16B). Recruitment of CD45 to the IL-2 receptor reduces phosphorylation of STAT5 (pSTAT5, Figure 16C).
[0045] [Figure 17] Figures 17A-17B summarize the results of experiments performed to characterize trispecific RIPR designs according to some embodiments of the present disclosure. In these experiments, anti-mouse trispecific CD45-PD1-CTLA4 was designed and generated using anti-mouse CD45 VHH fused to anti-mouse PD1 scFv, which was further fused to anti-mouse CTLA-4 VHH. The resulting trispecific RIPR molecule was named double RIPR (dRIPR)-PD1 / CTLA4. This dRIPR-PD1 / CTLA4 molecule is set forth in SEQ ID NO: 28 of the Sequence Listing. Figure 17A: Protein purity after size exclusion chromatography (AKTA FPLC, GE Healthcare, Superdex 200 Increase; absorbance at 280 nm is shown). Figure 17B: Protein purity and integrity was confirmed by non-reducing SDS-PAGE electrophoresis followed by standard Coomassie staining. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] The present disclosure generally relates to the fields of molecular biology, immunology and medicine, including compositions and a novel method, named RIPR, for modulating cell surface receptors that signal by specifically recruiting membrane phosphatases in the spatial vicinity of the receptor of interest. This method for inhibiting receptor signaling represents an alternative approach to ECD ligand inhibition, and thus represents a new paradigm for receptor antagonism in general. More specifically, the present disclosure provides novel chimeric protein binding molecules that specifically bind to cell surface receptors and fully or partially antagonize receptor signaling through recruitment of phosphatase activity. In some embodiments, recruitment of phosphatase is achieved by physical binding (ligation). In some embodiments of the present disclosure, the chimeric protein binding molecule is a multivalent polypeptide (e.g., bivalent or trivalent) that includes a first polypeptide fragment that can bind to a receptor protein tyrosine phosphatase (RPTP) and a second polypeptide fragment that can bind to a cell surface receptor that signals through a phosphorylation mechanism. The disclosure also relates to compositions and methods useful for producing such multivalent (e.g., bispecific) protein binding molecules, as well as methods for treating diseases associated with the inhibition of signal transduction mediated by cell surface receptors.
[0047] As described in more detail below, the present disclosure provides, inter alia, engineered multivalent polypeptides each exhibiting binding affinity for at least two cellular targets: a receptor protein tyrosine phosphatase (RPTP) that signals through a phosphorylation mechanism and a cell surface receptor. Without being bound to any particular theory, it is believed that the multivalent polypeptide recruits the phosphatase activity encoded by the RPTP to the spatial vicinity of the cell surface receptor, subsequently reducing its phosphorylation. It is also believed that the multivalent molecule promotes the modulation of the activity of a cell surface receptor that signals through a phosphorylation mechanism by binding to the extracellular domain of the cell surface receptor and the extracellular domain of a transmembrane phosphatase such that the intracellular domain of the cell surface receptor and the phosphatase are in sufficiently close proximity that the phosphatase dephosphorylates the intracellular domain of the cell surface receptor (or an associated phosphorylated molecule), thereby reducing the activity of the cell surface receptor. In the case of checkpoint receptors, and where the RPTP is CD45, linking a module that binds to the extracellular domain of the checkpoint receptor to a module that binds to the extracellular domain of the receptor protein tyrosine phosphatase CD45 results in enhanced T cell signaling. Without being bound to any particular theory, decreasing the activity of "immune checkpoint" receptors is expected to enhance T cell activity and may be useful as a therapy for a wide range of diseases such as cancer and chronic infections. This novel approach circumvents the current traditional strategy of modulating cell receptor function through ligand blocking, which modulates cell receptor function by dephosphorylation of the receptor intracellular domain.
[0048] It is recognized that current clinical options for modulating cell surface receptors are limited to ECD-blocking antibodies that block receptor-ligand interactions from occurring at the surface of cells. For example, in the case of inhibitory receptors such as PD-1, blocking extracellular PD-1 / PD-L1 interactions with high affinity antibodies has been the only available means to reduce PD-1 signaling to date. However, antibody blocking does not directly affect PD-1 phosphorylation, and importantly, does not reverse the basal tonic phosphorylation of PD-1. As described in more detail below, the inventors have shown that PD-1 reduces T cell activation by nearly 50% even in the absence of PD-L1. Without being bound to a particular theory, it appears that existing blocking antibodies cannot completely eliminate PD-1 basal signaling to restore full T cell activity, as judged by high levels of T cell activation markers CD69 and CD25, and by high levels of IFNγ and IL-2 cytokine release. As described in some embodiments of the present disclosure, a novel engineered multivalent antibody addresses this challenge by directly recruiting phosphatases to dephosphorylate PD-1. Thus, the present disclosure shows that CD45 recruitment can abrogate the exhausted phenotype induced by PD-1, regardless of the presence or absence of PD-1 ligands (e.g., PD-L1). Thus, recruitment of phosphatases (especially CD45) to a receptor of interest represents a novel method to modulate the activity of a cell surface receptor of interest.
[0049] The approach disclosed herein presents several drawbacks. The concept of recruiting phosphatase activity towards a target of interest is highly modular and versatile, and theoretically can be easily modified to target various receptors. For example, the target phosphatase can be selected from a group of surface phosphatases expressed in the cells of interest (Alonso et al., 2004; Neel & Tonks, 1997). In addition, numerous receptors that signal through tyrosine phosphorylation can be targeted in a similar manner. Non-limiting examples of suitable receptors include growth factor receptors, cytokine receptors, and other checkpoint inhibitors. Furthermore, the degree of receptor inhibition can be tuned from complete to partial inhibition by varying the orientation and spatial proximity of the binding modules within the multivalent polypeptide (hereinafter also referred to as "RIPR molecule"). General experimental procedure
[0050] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology that are known to those of skill in the art and are explained in the literature. See, e.g., Molecular Cloning: A Laboratory Manual, Fourth Edition (Sambrook et al., 2012) and Molecular Cloning: A Laboratory Manual, Third Edition (Sambrook & Russel, 2001) (collectively referred to herein as "Sambrook"); Current Protocols in Molecular Biology (F. M. Ausubel et al., eds., 1987, including supplements through 2014); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Beaucage et al., Current Protocols in Nucleic Acid Chemistry, John Wiley & Sons, Inc., New York, 2000, including supplements through 2014), Gene Transfer and. Expression in Mammalian Cells (Makrides, eds., Elsevier Sciences BV, Amsterdam, 2003), and Current Protocols in Immunology (Horgan K & S. Shaw (1994) (including supplements up to 2014). Where appropriate, procedures involving the use of commercially available kits and reagents are typically performed according to protocols and / or parameters defined by the manufacturer. definition
[0051] Unless otherwise defined, all technical terms, notations and other technical terms or terminology used herein are intended to have the meanings commonly understood by those of ordinary skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or ready reference, and the inclusion of such definitions herein should not necessarily be considered to represent a substantial difference beyond that commonly understood in the art. Many of the techniques and procedures described and referenced herein are well understood and commonly used using routine methodology by those of ordinary skill in the art.
[0052] The singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise. For example, "a cell" includes one or more cells, including mixtures thereof. "A and / or B" is used herein to include all of the following options: "A," "B," "A or B," and "A and B."
[0053] The term "about" as used herein has its usual meaning of approximately. If the degree of approximation is not clear from the context, "about" means within ±10% of the given numerical value, or in all cases inclusive of the given numerical value, rounded to the nearest significant figure. When ranges are given, they include the boundary values.
[0054] As used herein, the terms "administration" and "administering" refer to the delivery of a bioactive composition or formulation by a route of administration including, but not limited to, oral, intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intramuscular and topical administration or a combination thereof. This term includes, but is not limited to, administration by a medical professional and by self-administration.
[0055] As used herein, the term "antibody" refers to a class of proteins that are defined as specifically binding to and thereby complementing a particular spatial and polar structure of another molecule. The term antibody includes full length monoclonal antibodies (mAbs), such as IgG2 monoclonal antibodies, and includes the immunoglobulin Fc region. The term antibody also encompasses multivalent antibodies, diabodies, single chain antibodies, single chain variable fragments (scFv), and antibody fragments, such as Fab, F(ab')2, and Fv. When the antibody is a multivalent antibody, the multivalent antibody can be in a number of different formats. The antibody can be a monoclonal or polyclonal antibody, and can be prepared by techniques well known in the art, such as by immunization of a host and a collection of serum (polyclonal), or by preparing a continuous hybrid cell line and harvesting the secreted protein (monoclonal), or by cloning and expressing a nucleotide sequence encoding at least the amino acid sequence required for specific binding of a natural antibody, or a mutant form thereof. As such, antibodies include complete immunoglobulins or fragments thereof, including the various classes and isotypes of immunoglobulins, such as IgA, IgD, IgE, IgG1, IgG2a, IgG2b and IgG3, IgM, etc. The fragments can include Fab, Fv and F(ab')2, Fab', etc. In addition, aggregates, polymers and conjugates of immunoglobulins or their fragments can be used as appropriate, so long as binding affinity for a particular target is maintained.
[0056] The terms "cancer" or "tumor" are used interchangeably herein. These terms refer to the typical characteristics of cancer-causing cells, such as uncontrolled proliferation, immortalization, metastatic potential, rapid growth and reproduction rate, and some characteristic morphological features. Although cancer cells are often in the form of tumors, such cells may exist only in animal subjects, or may be non-tumorigenic cancer cells, such as leukemia cells. These terms include solid tumors, soft tissue tumors, or metastatic lesions. As used herein, the term "cancer" includes pre-cancers, as well as malignant cancers. In some embodiments, the cancer is a solid tumor, a soft tissue tumor, or a metastatic lesion.
[0057] As used herein, the term "chimeric" polypeptide refers to a polypeptide that comprises at least two amino acid sequences operably linked to each other, which are not naturally linked in nature. The amino acid sequences may be present in separate proteins that are joined together in the chimeric polypeptide, or they may normally be present in the same protein, or they may be placed in a novel arrangement in the chimeric polypeptide. Chimeric polypeptides can be constructed, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship.
[0058] As used herein, the terms "cell," "cell culture," "cell line," "recombinant host cell," "recipient cell," and "host cell" include the primary subject cell and any progeny thereof, regardless of the number of transfers. It is understood that not all progeny are exactly identical to the parent cell (due to deliberate or unintentional mutations or differences in environment); however, so long as the progeny retain the same functionality as that of the originally transformed cell, such modified progeny are included within the terms.
[0059] As used herein, the term "construct" refers to any recombinant nucleic acid molecule, such as an expression cassette, a plasmid, a cosmid, a virus, an autonomously replicating polynucleotide molecule, a phage, or a linear or circular, single-stranded or double-stranded DNA or RNA polynucleotide molecule, derived from any origin and capable of genomic integration or autonomous replication, e.g., one or more nucleic acid sequences are linked in a functionally operable manner, e.g., operably linked nucleic acid molecules.
[0060] The term "effective amount", "therapeutically effective amount" or "pharmacologically effective amount" of a multivalent polypeptide or multivalent antibody of the subject of the present disclosure generally refers to an amount of a composition sufficient to achieve a particular purpose (e.g., treat a disease, attenuate a signal transduction pathway, or alleviate one or more symptoms of a disease or condition in a subject to which it is administered) compared to the absence of the composition. An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or alleviation of one or more symptoms of a disease, which may also be referred to as a "therapeutically effective amount". "Alleviation" of a symptom refers to a reduction in the severity or frequency of the symptom, or the elimination of the symptom. The precise amount of a composition that comprises a "therapeutically effective amount" will depend on the purpose of the treatment and will be ascertainable by one of ordinary skill in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (Vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th ed., 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
[0061] As used herein, the term "functional fragment thereof" or "functional variant thereof" refers to a molecule that has a qualitative biological activity in common with the wild-type molecule from which the fragment or variant is derived. For example, a functional fragment or variant of an antibody retains essentially the same ability to bind to the same epitope as the antibody from which it is derived. For example, an antibody capable of binding to an epitope of a cell surface receptor may be truncated at the N-terminus and / or C-terminus and its retention of epitope binding activity can be assessed using assays known to those skilled in the art, including the exemplary assays provided herein. When referring to a polypeptide having enzymatic activity (e.g., an enzyme such as a receptor protein tyrosine phosphatase (RPTP)), the term "functional variant" refers to an enzyme having a polypeptide sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identical to the polypeptide sequence encoding the enzyme. A "functional variant" enzyme retains amino acid residues that are considered conserved for the enzyme, but may have amino acid residues substituted with different amino acids or non-conserved amino acid residues found to be of different amino acids, or may have one or more amino acids inserted or deleted, but with no or insignificant effect on the enzyme activity when compared to the enzymes described herein. A "functional variant" enzyme has the same or essentially the same enzymatic activity as in the biological assays of the enzymes (e.g., RPTPs) described herein. One of skill in the art will appreciate that a "functional variant" enzyme can be found in nature, i.e., naturally occurring or an engineered variant thereof.
[0062] As used herein, the term "operably linked" refers to a physical or functional connection between two or more elements, such as polypeptide or polynucleotide sequences, that allows them to operate in an intended manner. For example, an operable connection between a polynucleotide of interest and a regulatory sequence (e.g., a promoter) is a functional connection that allows expression of the polynucleotide of interest. In this sense, the term "operably linked" refers to an arrangement of a regulatory region and a coding sequence in which the regulatory region can be transcribed to effect transcription or translation of the coding sequence of interest. In some embodiments disclosed herein, the term "operably linked" refers to a configuration in which the regulatory sequence is appropriately positioned with respect to the sequence encoding a polypeptide or functional RNA such that the regulatory sequence directs or controls the expression or subcellular localization of the mRNA encoding the polypeptide, the polypeptide, and / or the functional RNA. Thus, a promoter is in operable connection with a nucleic acid sequence if it is capable of mediating transcription of the nucleic acid sequence. An operably linked element can be contiguous or non-contiguous. In addition, in the context of a polypeptide, "operably linked" refers to a physical linkage (e.g., direct or indirect linkage) between amino acid sequences (e.g., different segments, modules, or domains) to provide the described activity of the polypeptide. In the present disclosure, the various segments, modules, or domains of a multivalent polypeptide or multivalent antibody of the present disclosure can be operably linked to retain the correct folding, processing, targeting, expression, binding, and other functional properties of the multivalent polypeptide or multivalent antibody in a cell. Unless otherwise specified, the various modules, domains, and segments of a multivalent polypeptide or multivalent antibody of the present disclosure are operably linked to each other. The operably linked modules, domains, and segments of a multivalent polypeptide or multivalent antibody of the present disclosure can be contiguous or discontinuous (e.g., linked to each other via a linker).
[0063] The term "% identity" in the context of two or more nucleic acids or proteins refers to two or more sequences or subsequences that are identical, or have a specified percentage of identical nucleotides or amino acids (e.g., about 60% sequence identity over a particular region, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity when compared and aligned for maximum correspondence over a comparison window or designated region) when measured using the BLAST or BLAST 2.0 sequence comparison algorithm, using the default parameters described below, or by manual alignment and visual inspection. See, e.g., the NCBI website at ncbi.nlm.nih.gov / BLAST. Such sequences are then said to be "substantially identical." This definition also refers to or can be applied to the complement of a test sequence. This definition includes sequences that have deletions and / or additions, as well as those that have substitutions. Sequence identity typically exists over a region that is at least about 20 amino acids or nucleotides in length, or over a region that is 10-100 amino acids or nucleotides in length, or over the entire length of the particular sequence.
[0064] If necessary, sequence identity can be calculated using published techniques and commonly used computer programs, such as the GCS program package (Devereux et al., Nucleic Acids Res. 12:387, 1984), BLASTP, BLASTN, FASTA (Atschul et al., J. Molecular Biol. 215:403, 1990). Sequence identity can be measured using sequence analysis software, such as the Sequence Analysis Software Package of the Genetics Computer Group at the University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, Wis. 53705), using default parameters.
[0065] The term "pharmaceutically acceptable excipient" as used herein refers to any suitable substance that provides a pharmaceutically acceptable carrier, excipient, or diluent for administration of a compound of interest to a subject. As such, "pharmaceutically acceptable excipient" can include substances that are referred to as pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" includes, but is not limited to, saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, and absorption delaying agents, which are compatible with pharmaceutical administration. Supplementary active compounds (e.g., antibiotics) can also be included in the composition.
[0066] As used herein, a "recombinant" or "genetically engineered" nucleic acid molecule or polypeptide refers to a nucleic acid molecule or polypeptide that has been altered through human intervention. As a non-limiting example, a cDNA is a recombinant DNA molecule that is any nucleic acid molecule created by in vitro polymerase chain reaction, or that has a linker attached to it or that has been incorporated into a vector, such as a cloning vector or an expression vector. As non-limiting examples, a recombinant nucleic acid molecule can be: 1) one that has been synthesized or modified in vitro, for example, using chemical or enzymatic techniques (e.g., by the use of chemical nucleic acid synthesis or by the use of enzymes for replication, polymerization, exonuclease digestion, endonuclease digestion, ligation, reverse transcription, transcription, base modification (including methylation), or recombination of nucleic acid molecules (including homologous and site-specific recombination); 2) one that contains linked nucleotide sequences that are not naturally linked; 3) one that has been genetically engineered using molecular cloning techniques such that it lacks one or more nucleotides relative to the naturally occurring nucleic acid molecule sequence; and / or 4) one that has been engineered using molecular cloning techniques such that it has one or more sequence changes or rearrangements relative to the naturally occurring nucleic acid sequence. As non-limiting examples, a cDNA is a recombinant DNA molecule, which is any nucleic acid molecule that has been generated by an in vitro polymerase reaction or to which a linker has been attached or which has been incorporated into a vector, such as a cloning vector or an expression vector. Another non-limiting example of recombinant nucleic acids and recombinant proteins is the multivalent or bispecific antigen-binding polypeptides disclosed herein.
[0067] A "signal peptide" or "signal sequence" is a targeting sequence composed of an amino acid sequence that, when operably linked to the terminus of a polypeptide (e.g., its N-terminus), directs the translocation of that sequence into the endoplasmic reticulum (ER) in a eukaryotic host cell.
[0068] As used herein, "subject" or "individual" includes animals, such as humans (e.g., human subjects) and non-human animals. In some embodiments, a "subject" or "individual" is a patient under the care of a physician. Thus, a subject can be a human patient or individual who has or is suspected of having a disease of interest (e.g., cancer) and / or one or more symptoms of a disease. A subject can also be an individual who is diagnosed as having a risk of a condition of interest at the time of diagnosis or thereafter. The term "non-human animal" includes all vertebrates, such as mammals, such as rodents, e.g., mice, and non-mammals, such as non-human primates, e.g., sheep, dogs, cows, chickens, amphibians, reptiles, etc.
[0069] As used herein, "transformation" and "transfection" refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran mediated transfection, lipofection, particle gun, or electroporation.
[0070] The term "vector" is used herein to refer to a nucleic acid molecule or sequence capable of transferring or transporting another nucleic acid molecule. The nucleic acid molecule to be transferred is usually linked to, e.g., inserted into, a vector nucleic acid molecule. Generally, a vector can replicate when associated with appropriate regulatory elements. The term "vector" includes cloning and expression vectors, as well as viral and integrating vectors. An "expression vector" is a vector that includes a regulatory region that allows DNA sequences or fragments to be expressed in vitro and / or in vivo. A vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into a host cell DNA. Useful vectors include, for example, plasmids (e.g., DNA or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. Useful viral vectors include, for example, replication-deficient retroviruses and lentiviruses. In some embodiments, the vector is a gene delivery vector. In some embodiments, the vector is used as a gene delivery vehicle to transfer genes into cells.
[0071] As used herein, the term "VHH" refers to the variable domain of a heavy chain antibody. As used herein, the terms "VH" and "VL" refer to the variable heavy and light chains of a conventional antibody, respectively.
[0072] As will be understood by one of ordinary skill in the art, for all purposes, in terms of providing a written specification, all ranges disclosed herein encompass all possible subranges and combinations of subranges. Any recited range can be readily understood as fully descriptive and capable of dividing the range into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range described herein can be readily divided into a lower third, middle third, and upper third, etc. As will be understood by one of ordinary skill in the art, all phrases such as "less than," "at least," "more than," "less than," etc., refer to ranges that are inclusive of the recited number and that can be subsequently divided into subranges as described above. Finally, as will be understood by one of ordinary skill in the art, ranges include each individual member. Thus, for example, a group having 1-3 items refers to a group having 1, 2, or 3 items. Similarly, a group having 1-5 items refers to a group having 1, 2, 3, 4, or 5 items, and so on.
[0073] Aspects and embodiments of the disclosure described herein include those aspects and embodiments that "comprise," "consist," or "consist essentially of." As used herein, "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended, and does not exclude additional, unrecited elements or method steps. As used herein, "consisting" excludes any element, step, or ingredient not specified in the composition or method referred to. As used herein, "consisting essentially" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the composition or method referred to. Any reference herein to the term "comprising," particularly with respect to a description of a component of a composition or with respect to a description of a step of a method, is to be construed as including those compositions and methods that consist essentially of and consist of the composition or step referred to.
[0074] Headings, e.g., (a), (b), (i), etc., are provided solely for convenience in reading the specification and claims. The use of headings in the specification and claims does not require that they be performed in alphabetical or numerical order or in the order in which they are written.
[0075] Cell Surface Receptors Cell surface receptors, often called transmembrane receptors, are proteins that mediate communication between cells and the outside world. These receptors are responsible for binding extracellular signaling molecules and transmitting their message to one or more intracellular signaling molecules, which alters the behavior of the cell. Cell surface receptors are essentially embedded in the plasma membrane. These receptors act as enzymes or associate with enzymes within the cell. Upon stimulation, the enzymes activate various intracellular signaling pathways. They were discovered through their role in responding to extracellular signal proteins that regulate the growth, proliferation, differentiation and survival of cells in animal tissues. Disorders of cell growth, proliferation, differentiation, survival and migration are the basis of cancer, and abnormalities in signaling through enzyme-coupled receptors play a major role in the development of this class of diseases.
[0076] Cell surface receptors affect cell signaling by receiving (binding to) extracellular molecules. The extracellular molecules can be hormones, neurotransmitters, cytokines, growth factors, cell adhesion molecules, or nutrients; they react with the receptors to induce changes in the metabolism and activity of the cell. In the process of cell signaling, the signaling process mediated by membrane receptors includes an external reaction in which a ligand binds to the membrane receptor, and an internal reaction in which an intracellular response is elicited.
[0077] Due to the critical nature of their pathways, mutations in cell surface receptors have been implicated in a wide range of diseases, including autoimmunity, cancer, neurodegeneration, achondroplasia, and atherosclerosis. In fact, nearly half of all pharmaceuticals in clinical use target cell surface receptors, and these proteins and their ligands remain critical targets for structure-based drug design and development. Cell surface receptors are classified into three major classes: (i) ion channel-linked receptors, (ii) enzyme-linked receptors, and (iii) G protein-coupled receptors. Of those, enzyme-linked receptors are typically single-pass transmembrane receptors that directly bind to intracellular enzymes. This class includes the widely studied receptor tyrosine kinases (RTKs), receptors that signal through Janus kinases (JAKS) and STATs that bind polypeptide growth factors that control cell proliferation and differentiation (the latter known as JAK / STAT cytokine receptors). As described in more detail below, RPTP recruitment is a method applicable to kinase-linked receptors that signal via phosphorylation mechanisms, primarily ITAM / ITIM-containing receptors and related immune receptors ( Bezbradica et al., 2012 ), JAK / STAT cytokine receptors ( Rawlings et al., 2004 ), and RTK receptors that are active in both ligand-dependent and -independent states ( Bergeron et al., 2016 ).
[0078] The largest family of enzyme-linked receptors are the receptor protein tyrosine kinases, which phosphorylate their substrate proteins on tyrosine residues. Because this family includes the receptors for most polypeptide growth factors, protein tyrosine phosphorylation has been particularly well studied as a signaling mechanism involved in the control of animal cell growth and differentiation. Indeed, the first protein tyrosine kinases were discovered in the 1980s during studies of oncogenic proteins of animal tumor viruses, particularly Rous sarcoma virus. The epidermal growth factor (EGF) receptor was subsequently found to function as a protein tyrosine kinase, clearly establishing protein tyrosine phosphorylation as a key signaling mechanism in the cellular response to growth factor stimulation.
[0079] Currently, over 50 receptor protein tyrosine kinases have been identified, including those for epidermal growth factor (EGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), insulin, and many other growth factors. All of these receptors share a common structural organization: an N-terminal extracellular ligand-binding domain, a single transmembrane α-helix, and a cytoplasmic C-terminal domain with protein tyrosine kinase activity. Most receptor protein tyrosine kinases consist of a single polypeptide, but the insulin receptor and several related receptors are dimers consisting of two pairs of polypeptide chains. Binding of ligands (e.g., growth factors) to the extracellular domains of these receptors activates their cytoplasmic kinase domains, leading to phosphorylation of both the receptor itself and intracellular target proteins, which propagate the signal initiated by growth factor binding. The first step in signal transduction from most receptor protein tyrosine kinases is ligand-induced receptor dimerization. Some growth factors, such as PDGF and NGF, are themselves dimers consisting of two identical polypeptide chains, and they directly induce dimerization by simultaneous binding to two different receptor molecules. Other growth factors, such as EGF, are monomeric but have two separate receptor-binding sites that function to cross-link the receptors.
[0080] Ligand-induced dimerization subsequently leads to autophosphorylation of the receptors when the dimerized polypeptide chains cross-phosphorylate with each other. Such autophosphorylation plays two important roles in signal transduction from those receptors. First, phosphorylation of tyrosine residues within the catalytic domain may play a regulatory role by increasing receptor protein kinase activity. Second, phosphorylation of tyrosine residues outside the catalytic domain establishes specific binding sites for additional proteins that transmit intracellular signals downstream of the activated receptor. The association of those downstream signaling molecules with the receptor protein tyrosine kinases is mediated by protein domains that bind specific phosphotyrosine-containing peptides. The most well-characterized of those domains are called SH2 domains (for Src homolog 2) because they were first recognized in protein tyrosine kinases related to Src (the oncogenic protein of Rous sarcoma virus). SH2 domains consist of approximately 100 amino acids and bind to specific short peptide sequences that contain phosphotyrosine residues. The resulting association of SH2-containing proteins with activated receptor protein tyrosine kinases can have several types of effects. It localizes SH2-containing proteins to the plasma membrane, brings them into association with other proteins, promotes their phosphorylation, and stimulates their enzymatic activity. The association of these proteins with autophosphorylated receptors represents the first step in the intracellular transduction of a signal initiated by growth factor binding to the cell surface.
[0081] Another family of enzyme-linked receptors are the cytokine receptors and non-receptor protein tyrosine kinases (also called the cytokine receptor superfamily). Besides having intrinsic enzymatic activity, many receptors act by stimulating intracellular protein tyrosine kinases (e.g., JAK / TYK) with which they non-covalently associate. This receptor family includes receptors for most cytokines (e.g., interleukin-2 and erythropoietin) and some polypeptide hormones (e.g., growth hormone). Like receptor protein tyrosine kinases, cytokine receptors contain an N-terminal extracellular ligand-binding domain, a single transmembrane α-helix, and a C-terminal cytoplasmic domain. However, the cytoplasmic domain of cytokine receptors lacks any known catalytic activity. Instead, cytokine receptors function in concert with non-receptor protein tyrosine kinases that are activated as a result of ligand binding.
[0082] The first step in signal transduction from cytokine receptors is thought to be ligand-induced receptor dimerization and cross-phosphorylation of associated non-receptor protein tyrosine kinases. These activated kinases then phosphorylate the receptor, providing phosphotyrosine binding sites for the recruitment of downstream signaling molecules that contain SH2 domains. Thus, the combination of cytokine receptors and associated non-receptor protein tyrosine kinases functions similarly to the family of receptor protein tyrosine kinases.
[0083] Non-receptor protein tyrosine kinases that associate with cytokine receptors fall into two main families. Many of these kinases are in the Src family, which consists of Src and eight closely related proteins. Src was originally identified as an oncogenic protein of the Rous sarcoma virus and was the first protein shown to have protein tyrosine kinase activity, and thus it played a key role in the experiments that led to our current understanding of cell signaling. In addition to Src family members, cytokine receptors associate with non-receptor protein tyrosine kinases that belong to the Janus kinase or JAK family. Members of the JAK family appear to be commonly required for signaling from cytokine receptors, and JAK family kinases have been shown to play a key role in linking those receptors to tyrosine phosphorylation of intracellular targets. In contrast, members of the Src family play an important role in signaling from antigen receptors on B and T lymphocytes, but do not appear to be required for signaling from most cytokine receptors.
[0084] Most enzyme-linked receptors stimulate protein-tyrosine phosphorylation, but some receptors are associated with other enzymatic activities. These receptors include protein tyrosine phosphatases, which act to remove phosphate groups from phosphotyrosine residues, thereby counteracting the action of protein tyrosine kinases. In many cases, protein tyrosine kinases play a negative regulatory role in cell signaling pathways by terminating signals initiated by protein tyrosine phosphorylation. However, some protein tyrosine phosphatases are cell surface receptors whose enzymatic activity plays a positive role in cell signaling. One example is provided by the phosphatase CD45, expressed on the surface of T and B lymphocytes. After antigen stimulation, CD45 is thought to dephosphorylate specific phosphotyrosine residues, which inhibit the enzymatic activity of Src family members.
[0085] Several members of cell surface receptors are regulators of the immune system, e.g. immune checkpoints that can be stimulatory or inhibitory checkpoints. They do not have intrinsic enzymatic activity, but instead function as substrates for kinases via their intracellular ITAM, ITSM, and / or ITIM motifs (see, e.g., Pardoll, 2012). These receptors' activity is regulated through a balance between phosphorylation and phosphatase activity acting on their intracellular domains, making them excellent candidates for signaling activity modulation by phosphatase ligation as described. Among them, inhibitory checkpoints have been increasingly considered as potential targets for cancer immunotherapy due to their potential use in numerous types of cancer (Topalian et al., 2015). Currently approved checkpoint inhibitors block CTLA-4 and PD-1 and PD-L1. Another two stimulatory checkpoint molecules belong to the B7-CD28 superfamily, the so-called CD28 itself and ICOS. Inhibitory checkpoints include, but are not limited to, PD-1, CTLA-4, A2AR, B7-H3, B7-H4, BTLA, CD5, CD132, IDO, KIR, LAG3, TIM-3, TIGIT, and VISTA, and functional variants thereof. PD-1
[0086] PD-1, also known as programmed cell death protein 1 and CD279 (cluster of differentiation 279), is a cell surface receptor that plays a key role in downregulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity. PD-1 is an immune checkpoint that defends against autoimmunity through a dual mechanism: promoting apoptosis (programmed cell death) of antigen-specific T cells in lymph nodes while simultaneously reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). Through these mechanisms, PD-1 is thought to inhibit the immune system. In humans, the PD-1 protein is encoded by the PDCD1 gene.
[0087] PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 protein is upregulated on macrophages and dendritic cells (DCs) in response to LPS and GM-CSF treatment, and on T cells and B cells following TCR and B cell receptor signaling, whereas in resting mice, PD-L1 mRNA can be detected in the heart, lung, thymus, spleen, and kidney. PD-L1 is expressed on nearly all mouse tumor cell lines, including P815 mastocytoma, PA1 myeloma, and B16 melanoma, following treatment with IFN-γ. PD-L2 expression is more restricted, being expressed primarily by DCs and a number of tumor lineages. CTLA-4
[0088] CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA4 is constitutively expressed in regulatory T cells, but is upregulated in normal T cells only after activation, especially in cancer. CTLA-4 acts as an "off" switch when it binds to CD80 or CD86 on the surface of antigen-presenting cells. The CTLA-4 protein is encoded by the Ctla4 gene in mice and the CTLA4 gene in humans. Mutations in this gene have been linked to insulin-dependent diabetes mellitus, Graves' disease, Hashimoto's thyroiditis, celiac disease, systemic lupus erythematosus, Graves' disease, Hashimoto's thyroiditis, celiac disease, thyroid-associated orbitopathy, primary biliary cirrhosis and other autoimmune diseases. Polymorphisms in the CTLA-4 gene have been associated with autoimmune diseases such as autoimmune thyroid disease and multiple sclerosis, but this association is often weak. In systemic lupus erythematosus (SLE), splice variants of CTLA-4 have been found to be aberrantly produced and are found in the serum of patients with active SLE.
[0089] CTLA-4 is expressed by activated T cells and transmits inhibitory signals to T cells. CTLA-4 is homologous to the T cell costimulatory protein CD28, and both molecules bind to CD80 and CD86 (also called B7-1 and B7-2, respectively) on antigen-presenting cells. CTLA-4 binds to CD80 and CD86 with higher affinity and avidity than CD28, allowing it to outcompete CD28 for CD28's ligands. However, CTLA-4 transmits inhibitory signals to T cells, whereas CD28 transmits stimulatory signals. CTLA-4 is also found on regulatory T cells, where it contributes to their inhibitory function. CD28
[0090] CD28 (cluster of differentiation 28) is one of the proteins expressed on T cells that provides costimulatory signals necessary for T cell activation and survival. It has been reported that T cell stimulation through CD28 in addition to the T cell receptor (TCR) provides a strong signal for the production of various interleukins (especially IL-6). The costimulatory receptor CD28 is activated by its ligands B7.1 (CD80) and B7.2 (CD86) and cooperates with TCR signaling to promote T cell proliferation and survival during T cell priming. Upon activation by Toll-like receptor ligands, CD80 expression on antigen-presenting cells (APCs) is upregulated. CD86 expression on antigen-presenting cells is constitutive (its expression is independent of environmental factors). CD28 is known to be a B7 receptor constitutively expressed on naive T cells. CD28 in a murine lupus (systemic lupus erythematosus) model - / - Inhibition of MRL-lpr has been shown to delay and attenuate glomerulonephritis, abrogate renal vasculitis and arthritis, implying that blocking CD28-B7 interactions may be a potential treatment for autoimmune lupus. TIM-3
[0091] TIM-3 (T cell immunoglobulin and mucin domain-containing-3), which belongs to the TIM family of cell surface receptor proteins, is a transmembrane receptor protein expressed, for example, on Th1 (T helper 1) CD4+ cells and cytotoxic CD8+ T cells that secrete IFN-γ. TIM-3 is not normally expressed on naive T cells, but rather is upregulated on activated effector T cells. TIM-3 plays a role in regulating immunity and tolerance in vivo.
[0092] In humans, TIM-3 was first described as a cell surface molecule expressed on IFNγ-producing CD4+ Th1 and CD8+ Tc1 cells and is encoded by the HAVCR2 gene. Expression of TIM-3 has subsequently been detected in Th17 cells, regulatory T cells and innate immune cells, such as dendritic cells, NK cells and monocytes. TIM-3 contains five conserved tyrosine residues that are believed to interact with multiple components of the T cell receptor (TCR) complex and negatively regulate its function. TIM-3 is thought to be an immune checkpoint drug, and together with other inhibitory receptors, including programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3), mediates CD8+ T cell exhaustion. TIM-3 has also been shown as a CD4+ Th1-specific cell surface protein that regulates macrophage activation and enhances the severity of experimental autoimmune encephalomyelitis in mice. CD5
[0093] CD5 is one of the clusters of differentiation (CD) expressed on the surface of T cells of various species and on a subset of murine B cells, also known as B-1a. CD5 is a type I glycoprotein and a member of the scavenger receptor family. CD5 is expressed by thymocytes, mature T cells, and a subset of mature B cells, and has been shown to be involved in the regulation of lymphocyte activation and differentiation processes. CD72, gp80-40, and Ig framework structures are the intended ligands for CD5, and their interactions with CD5 have been demonstrated in mice. CD5 has been used as a T cell marker until the development of monoclonal antibodies against CD3. It has been reported that CD5, possibly homophilic, can also bind to the surface of other cells. T cells express higher levels of CD5 than B cells. CD5 is upregulated on T cells upon strong activation. In the thymus, a correlation has been found between CD5 expression and the strength of T cell interaction with self-peptides.
[0094] CD5 associates with the CD79a and CD79b transduction partners of surface IgM in the vicinity of the B cell receptor (BCR), and CD5 signaling is mediated by co-precipitation of CD79a and CD79b with the BCR into lipid rafts.CD79a and CD79b are phosphorylated by other tyrosine kinases, including Syk and Zap70 in addition to Lyn, and the tyrosine phosphatase SHP-1 has been reported to be a mediator of this signaling. CD132
[0095] CD132 (common gamma chain-γc), also known as interleukin-2 receptor subunit gamma or IL-2RG, is a cytokine receptor subunit common to the receptor complexes for several different interleukin receptors, including the IL-2, IL-4, IL-7, IL-9, IL-15, and interleukin 21 receptors. The γc chain partners with these ligand-specific receptors to signal lymphocytes to respond to cytokines. The γc glycoprotein is a member of the type I cytokine receptor family expressed on most lymphocyte (white blood cell) populations. In humans, CD132 is encoded by the IL2RG gene.
[0096] CD132 is expressed on the surface of immature hematopoietic cells in bone marrow. One end of the CD132 protein is on the outside of the cell where it binds to cytokines, and the other end of the protein is on the inside of the cell where it transmits signals to the nucleus of the cell. CD132 cooperates with other proteins to direct hematopoietic cells to form lymphocytes. Lymphocytes expressing CD132 can form functional receptors for these cytokine proteins, which transmit signals from one cell to another and direct the program of cell differentiation. TIGIT
[0097] TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a member of the immunoglobulin (Ig) superfamily with immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic tail, and it is expressed on a subset of activated T cells and natural killer (NK) cells. Other names for TIGIT include WUCAM and Vstm3. TIGIT is known to interact with CD155 (also known as PVR or necl-5), CD112 (PVRL2 or nectin-2), and possibly CD113 (PVRL3 or nectin-3). Binding of TIGIT to the high-affinity ligand CD155 expressed on antigen-presenting cells has been reported to suppress T cell and NK cell functions. TIGIT has also been reported to indirectly inhibit T cells by modulating cytokine production by dendritic cells. It has been reported that TIGIT-Fc fusion protein can interact with PVR on dendritic cells, increase IL-10 secretion levels / decreased IL-12 secretion levels under LPS stimulation, and also inhibit T cell activation in vivo. The inhibitory activity of TIGIT on NK cytotoxicity is blocked by antibodies against its interaction with CD155, and its activity is directed through the ITIM domain. Receptor protein tyrosine phosphatases (RPTPs)
[0098] Reversible protein tyrosine phosphorylation is a major mechanism regulating cell signaling that affects fundamental cellular events, including metabolism, proliferation, adhesion, differentiation, migration, communication, and binding. For example, protein tyrosine phosphorylation determines protein functions, such as protein-protein interactions, conformation, stability, enzymatic activity, and subcellular localization. Disruption of this important regulatory mechanism contributes to a variety of human diseases, including cancer, diabetes, and autoimmune diseases. Net protein tyrosine phosphorylation is determined by a dynamic balance between protein tyrosine kinase (PTK) and protein tyrosine phosphatase (PTP) activities. Dysregulation of the delicate balance between PTKs and PTPs is involved in the pathogenesis of many human diseases, including cancer, diabetes, and autoimmune diseases.
[0099] PTPs constitute a large and structurally diverse family of enzymes. Sequencing data indicate that there are 107 PTP genes in the human genome, of which 81 encode active protein phosphatases. Among the PTP superfamily, 38 are classical tyrosine-specific PTPs, while the other 43 are dual-specificity tyrosine / serine, threonine phosphatases. Classical PTPs possess at least one catalytic domain, known as the PTP domain. The 280 amino acid PTP catalytic domain contains the invariant active site signature motif (I / V)HCXAGXXR(S / T)G, which contains an essential cysteine residue that catalyzes the nucleophilic attack on the phosphate group of the substrate and subsequent dephosphorylation of the substrate.
[0100] Based on their overall structure, PTPs can be further subdivided into transmembrane receptor-like PTPs (RPTPs) and non-transmembrane PTPs. Among these, receptor protein tyrosine phosphatases (RPTPs) are a family of integral cell surface proteins with intracellular PTP activity and an extracellular domain (ECD) with sequence homology to cell adhesion molecules (CAMs). The intracellular domain (ICD) of most RPTPs contains two tandem PTP domains, designated D1 and D2. In general, the membrane-proximal PTP domain (D1) possesses most of the catalytic activity, whereas the membrane-distal PTP domain (D2) possesses weak, if any, catalytic activity. The ECD of RPTPs contains a combination of CAM-like motifs and sequences homologous to fibronectin type III (FN3), meprin, A5, PTPμ (MAM), immunoglobulin (Ig), and carbonic anhydrase (CA). Taken together, the molecular structure of RPTPs allows direct linkage of extracellular adhesion-mediated events to the regulation of intracellular signaling pathways.
[0101] Based on their ECD structures, the RPTP family can be divided into eight subfamilies: R1 / R6, R2A, R2B, R3, R4, R5, R7 and R8. Representative members of these subfamilies include CD45, LAR, RPTP-κ, DEP1, RPTP-α, RPTP-ζ, PTPRR and IA2, respectively. Further information on the structural features that define each of these subfamilies, their molecular / biochemical structures, regulatory modes, substrate specificity and biological functions are well documented and can be found, for example, in Xu Y. et al. (J. Cell Commun. Signal. 6:125, 138, 2012). CD45
[0102] The receptor protein tyrosine phosphatase CD45, also called leukocyte common antigen (LCA), is the only member of the R1 / R6 subtype of RPTPs. CD45 is a type I transmembrane protein that is presented in various forms on all differentiated hematopoietic cells except erythrocytes and plasma cells and helps activate those cells (a form of costimulation). CD45 is expressed in lymphomas, B-cell chronic lymphocytic leukemia, hairy cell leukemia, and acute nonlymphocytic leukemia. Human CD45, encoded by the gene PTPRC, is a cell membrane tyrosine phosphatase expressed by all cells of lymphoid origin, including hematopoietic cells, except platelets and erythrocytes, and functions as a key regulator of T-cell and B-cell signaling. CD45 is composed of an extracellular region, a short transmembrane segment, and tandem PTP domains in the cytoplasmic region. Multiple isoforms of CD45 are generated by complex alternative splicing of exons in the extracellular domain of the molecule. These isoforms are expressed in a cell type-specific manner depending on the differentiation and activation state of the cell. Non-limiting examples of CD45 isoforms include CD45RA, CD45RB, CD45RC, CD45RAB, CD45RAC, CD45RBC, CD45R0, and CD45R(ABC). CD45RA is present on naive T cells and CD45R0 on memory T cells. CD45R is the longest protein and migrates at a molecular weight of 200 kDa when isolated from T cells. B cells also express CD45R with a higher (heavier) glycosylation that brings the molecular weight to 220 kDa, hence the 220 kDa B cell isoform, named B220. B220 expression is not limited to B cells, but can also be expressed on activated T cells, a subset of dendritic cells, and other antigen presenting cells. Naive T lymphocytes express the large CD45 isoform and are usually CD45RA positive. Activated memory T lymphocytes express the shortest CD45 isoform, CD45R0, which lacks the RA, RB, and RC exons and is thought to promote T cell activation.
[0103] CD45 plays a key role in the development and function of the immune system and is required for the stimulation and proliferation of antigen-specific lymphocytes. CD45 regulates the immune response by controlling TCR activation thresholds, modulating cytokine responses, and regulating lymphocyte survival. All of these processes are essential in the pathogenesis of autoimmune and infectious diseases.
[0104] CD45 is a suitable RPTP target for recruitment to many immune receptors because it acts on a wide range of substrates when placed in spatial proximity to each other, for example, when the two RPTP-binding modules and the receptor-binding module are placed close enough to achieve dephosphorylation of the intracellular domain of the receptor. CD45 mediates T and B cell receptor function by regulating tyrosine phosphorylation of the Src family of PTKs (SFKs), such as Lyn and Lck. CD45 dephosphorylates inhibitory C-terminal phosphorylation sites in Lyn and Lck. Attenuation of SFK activity by CD45-mediated dephosphorylation of other tyrosines has also been reported. Studies in CD45 knockout mice have shown that CD45-mediated activation of Fyn and Lck is important for thymocyte development. Upon TCR ligation, activated Fyn and Lck phosphorylate components of the TCR complex, such as TCR-ζ (zeta) and CD3-ε (epsilon). These tyrosine phosphorylated proteins provide docking sites for Src-homology 2 (SH2) domain-containing proteins to transmit downstream signals. In CD45 null thymocytes, ligation of the TCR does not result in activation of Lyn or Lck or subsequent tyrosine phosphorylation of the TCR complex. Thus, no downstream signaling events occur; suggesting a critical role for CD45 in TCR activation. CD45 has also been identified as a PTP that dephosphorylates CD3-ζ (zeta) and CD3-ε (epsilon) ITAMs, Janus kinases (JAKs), and negatively regulates cytokine receptor activation. Disclosed Compositions Multivalent Polypeptides and Multivalent Antibodies
[0105] In one aspect, some embodiments disclosed herein relate to novel chimeric polypeptides that include multivalent polypeptide modules, e.g., modular protein binding moieties, each capable of binding to one or more target proteins. In some embodiments, the disclosed chimeric polypeptides include (i) a first amino acid sequence that includes a first polypeptide module that can bind to a receptor protein tyrosine phosphatase (RPTP), and (ii) a second amino acid sequence that includes a second polypeptide module that can bind to a cell surface receptor that signals through a phosphorylation mechanism, where the first polypeptide module is operably linked to the second polypeptide module. In some embodiments, the chimeric polypeptide of the present disclosure is a multivalent polypeptide. In some embodiments, the multivalent polypeptide is a multivalent antibody. The binding of the first and second polypeptide modules to their respective targets can be in either a competitive or non-competitive manner with the natural ligand of the target. Thus, in some embodiments of the present disclosure, the binding of the first and / or second polypeptide modules to their respective targets can be ligand blocking. In some other embodiments, binding of the first polypeptide module and / or the second polypeptide module to their respective targets does not block binding of the natural ligand. As used herein, the term "multivalent polypeptide" refers to a polypeptide that includes two or more protein binding modules operably linked to each other. For example, a "bivalent" polypeptide of the present disclosure includes two protein binding modules, while a "trivalent" polypeptide of the present disclosure includes three protein binding modules. The amino acid sequences of the polypeptide modules may normally be present in separate proteins that are grouped together in the multivalent polypeptide, or may be present in the same protein, but they are arranged in a new configuration in the multivalent polypeptide. Multivalent polypeptides can be made, for example, by chemical synthesis or by making and translating a polynucleotide in which the peptide regions are encoded in the desired relationship.
[0106] The design of the amino acid sequences of the chimeric polypeptide, e.g., a multivalent polypeptide comprising a first polypeptide module capable of binding to a receptor protein tyrosine phosphatase (RPTP) as a "first" amino acid sequence, and a multivalent polypeptide comprising a polypeptide module capable of binding to a cell surface receptor as a "second" amino acid sequence, does not imply any particular structural arrangement of the "first" and "second" amino acid sequences within the multivalent polypeptide. As a non-limiting example, in some embodiments of the present disclosure, a multivalent polypeptide or multivalent antibody can comprise an N-terminal polypeptide module capable of binding to a RPTP and a C-terminal polypeptide module comprising a polypeptide capable of binding to a cell surface receptor. In another embodiment, a multivalent polypeptide or multivalent antibody can comprise an N-terminal polypeptide module capable of binding to a cell surface receptor and a C-terminal polypeptide module capable of binding to a RPTP. Additionally or alternatively, a multivalent polypeptide or multivalent antibody can comprise two or more polypeptide modules (e.g., modules) capable of binding to a RPTP and / or two or more polypeptide modules capable of binding to a cell surface receptor. Thus, in some embodiments, the first amino acid sequence of the multivalent polypeptide or multivalent antibody comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 polypeptide modules, each capable of binding to a RIPT. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 polypeptide modules of the first amino acid sequence are each capable of binding to the same RPTP. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 polypeptide modules of the first amino acid sequence are each capable of binding to a different RPTP.
[0107] In some embodiments, the second amino acid sequence of the multivalent polypeptide or multivalent antibody comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 polypeptide modules, each capable of binding to a cell surface receptor. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 polypeptide modules of the second amino acid sequence are capable of binding to the same cell surface receptor. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 polypeptide modules of the second amino acid sequence are each capable of binding to a different cell surface receptor. Non-limiting examples of such multivalent polypeptides or multivalent antibodies comprising multiple polypeptides, each capable of binding to a different cell surface receptor, are described in Example 17.
[0108] Additionally or alternatively, as alluded to above, the multivalent polypeptides and antibodies of the present disclosure can include both natural and unnatural amino acids that affect the binding affinity of the multivalent polypeptide or antibody to its respective target protein. As such, the binding affinity of the polypeptide module to its respective target (e.g., RPTP or cell surface receptor) can be adjusted (tuned) to achieve the desired target cell specificity. For example, because CD45 is widely expressed, a PD1 binding module can be configured to form a high affinity binding module, while a CD45 binding module can be configured to have a lower binding affinity. For example, in some embodiments, the cell surface receptor binding module has a higher affinity (lower K) for the cell surface receptor when compared to the binding affinity of the RPTP binding module for the RPTP. d In some embodiments, the difference in affinity is at least one order of magnitude, or at least two orders of magnitude (e.g., the K of the interaction of the RPTP binding module with the RPTP). d and the K of the interaction of the cell surface receptor binding module with the cell surface receptor. dis at least 10, at least 20, at least 50, or at least 100). One of skill in the art will recognize that this concept of a multivalent polypeptide or antibody having high affinity for the RPTP or its target receptor and low affinity for others can be an important part of fine tuning RIPR activity to target cell specificity. Thus, in some embodiments, the binding affinity of the RPTP-binding polypeptide module can be different from the binding affinity of the receptor-binding polypeptide module. For example, in some embodiments, the RPTP-binding polypeptide module has high affinity for its target and the receptor-binding polypeptide module has low affinity for its target. In some embodiments, the RPTP-binding polypeptide module has low affinity for its target and the cell surface receptor-binding polypeptide module has high affinity for its target. In some embodiments, the RPTP-binding module and the receptor-binding module have the same affinity for their respective target proteins.
[0109] In some embodiments, the binding affinity of the receptor binding module and the RPTP binding module, which have affinity for the extracellular domain of their respective targets, can be independently determined by a K d =10 -5 ~10 -12 M, for example, about 10 -5 ~about 10 -11 K of M d , or about 10 -5 ~about 10 -10 K of M d , or about 10 -6 ~about 10 -12 K of M d , or about 10 -7 ~about 10 -12 K of M d , or about 10 -8 ~about 10 -12 K of M d , or about 10 -9 ~about 10 -12 K of M d , or about 10 -10 ~about 10 -12 K of Md , or about 10 -11 ~about 10 -12 K of M d , or about 10 -5 ~about 10 -11 K of M d , or about 10 -5 ~about 10 -10 K of M d , or about 10 -5 ~about 10 -9 K of M d , or about 10 -5 ~about 10 -10 K of M d , or about 10 -5 ~about 10 -9 K of M d , or about 10 -5 ~about 10 -8 K of M d , or about 10 -5 ~about 10 -9 K of M d , about 10 -5 ~about 10 -8 K of M d , or about 10 -5 ~about 10 -7 K of M d , or about 10 -5 ~about 10 -6 K of M d It is.
[0110] In some embodiments, the multivalent polypeptide or multivalent antibody disclosed herein has a K of about 1000 nM, about 800 nM, about 700 nM, about 600 nM, about 500 nM, about 400 nM, about 200 nM, about 100 nM, about 10 nM, about 5 nM, or about 1 nM. d In some embodiments, the multivalent polypeptide or multivalent antibody of the present disclosure has a low binding affinity for the RPTP, e.g., about 10 -5 K over M d , for example about 10 -4 K over M d , for example about 10 -3 K over M d , for example about 10 -4 K over Md , for example about 10 -3 K over M d , for example about 10 -2 K over M d , or for example about 10 -1 K over M d In some embodiments, the antibody has a binding affinity (K d ) may be about 700 nM. In some embodiments, the binding affinity of a multivalent polypeptide or antibody to CD45 may be about 300 nM.
[0111] In some embodiments, a multivalent polypeptide or multivalent antibody of the disclosure has a K of 1,000 nM, about 800 nM, about 700 nM, about 600 nM, about 500 nM, about 400 nM, about 200 nM, about 150 nM, about 100 nM, about 80 nM, about 60 nM, about 40 nM, about 20 nM, about 10 nM, about 5 nM, or about 1 nM. d and can have binding affinity for a cell surface receptor (e.g., PD-1). In some embodiments, the multivalent polypeptides or multivalent antibodies disclosed herein can have a binding affinity of, for example, about 10 -8 Less than M, about 10 -9 Less than M, about 10 -10 Less than M, about 10 -11 Less than M or about 10 -12 K less than M d and has high binding affinity to the cell surface receptor. In some embodiments, the affinity to the cell surface receptor may be about 7 nM. In some embodiments, the binding affinity of the multivalent polypeptide or multivalent antibody to the cell surface receptor may be about 6 nM. In some embodiments, the binding affinity to the cell surface receptor may be about 5 nM.
[0112] In some embodiments, the first amino acid sequence of the multivalent polypeptide or multivalent antibody is directly linked to the second amino acid sequence. In some embodiments, the first amino acid sequence is directly linked to the second amino acid sequence by at least one covalent bond. In some embodiments, the first amino acid sequence is directly linked to the second amino acid sequence by at least one peptide bond. In some embodiments, the C-terminal amino acid of the first amino acid sequence may be operably linked to the N-terminal amino acid of the second polypeptide module. Alternatively, the N-terminal amino acid of the first polypeptide module may be operably linked to the C-terminal amino acid of the second polypeptide module.
[0113] In some embodiments, the first amino acid sequence of the multivalent polypeptide or multivalent antibody is operably linked to the second amino acid sequence via a linker. There is no particular limitation on the linker that can be used in the multivalent polypeptides described herein. In some embodiments, the linker is a synthetic compound linker, such as, for example, a chemical crosslinker. Non-limiting examples of suitable crosslinkers that are commercially available include N-hydroxysuccinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl)suberate (BS3), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycol bis(succinimidyl succinate) (EGS), ethylene glycol bis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone (BSOCOES), and bis[2-(sulfosuccinimidooxycarbonyloxy)ethyl]sulfone (sulfo-BSOCOES). Other examples of alternative structures and linkages suitable for the multivalent polypeptides and antibodies of the present disclosure include those described in Spiess et al., Mol. Immuno. 67:95-106, 2015.
[0114] In some embodiments, the first amino acid sequence of the multivalent polypeptide or multivalent antibody of the present disclosure is operably linked to the second amino acid sequence via a linker polypeptide sequence (peptide bond). In theory, there is no particular limit to the length and / or amino acid composition of the linker polypeptide sequence. In some embodiments, any single-chain polypeptide containing about 1 to about 100 amino acid residues (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. amino acid residues) can be used as a polypeptide linker. In some embodiments, the linker peptide sequence contains about 5-50, about 10-60, about 20-70, about 30-80, about 40-90, about 50-100, about 60-80, about 70-100, about 30-60, about 20-80, about 30-90 amino acid residues. In some embodiments, the linker polypeptide sequence comprises about 1-10, about 5-15, about 10-20, about 15-25, about 20-40, about 30-50, about 40-60, about 50-70 amino acid residues. In some embodiments, the linker polypeptide sequence comprises about 40-70, about 50-80, about 60-80, about 70-90, or about 80-100 amino acid residues. In some embodiments, the linker polypeptide sequence comprises about 1-10, about 5-15, about 10-20, or about 15-25 amino acid residues.
[0115] In some embodiments, the length and amino acid composition of the linker polypeptide sequence can be optimized to vary the orientation and / or proximity of the first and second polypeptide modules relative to each other to achieve a multivalent polypeptide of desired activity. In some embodiments, the orientation and / or proximity of the first and second polypeptide modules relative to each other can be varied as a "tuning" measure to achieve tuning effects that will enhance or reduce the RPTP activity of the multivalent polypeptide. In some embodiments, the orientation and / or proximity of the first and second polypeptide modules relative to each other can be optimized to create a range of partial to full antagonist variants of the bispecific polypeptide. In some embodiments, the ringer contains only glycine and / or serine residues (e.g., a glycine-serine linker). Examples of such polypeptide linkers include Gly, Ser; Gly Ser; Gly Gly Ser; Ser Gly Gly; Gly Gly Gly Ser; Ser Gly Gly Gly; Gly Gly Gly Gly Gly; Gly Gly Gly Gly Gly Gly Ser; Ser Gly Gly Gly Gly Gly; Gly Gly Gly Gly Gly Gly Gly Gly; (Gly Gly Gly Gly Ser)n, where n is an integer equal to or greater than 1; and (Ser Gly Gly Gly Gly)n, where n is an integer equal to or greater than 1. In some embodiments, the linker polypeptide is modified such that the amino acid sequence GlySerGly (GSG), which is present at the junction of a typical Gly / Ser linker polypeptide repeat sequence, is absent. For example, in some embodiments, the polypeptide linker comprises an amino acid sequence selected from the group consisting of (GGGXX)nGGGGS and GGGGS(XGGGS)n, where X is any amino acid that can be inserted into the sequence but that does not result in a polypeptide containing the sequence GSG, and n is 0-4.In some embodiments, the linker polypeptide has a sequence of (GGGX1X2)nGGGGS, where X1 is P and X2 is S, and n is 0-4. In some embodiments, the linker polypeptide has a sequence of (GGGX1X2)nGGGGS, where X1 is G and X2 is Q, and n is 0-4. In some other embodiments, the linker polypeptide has a sequence of (GGGX1X2)nGGGGS, where X1 is G and X2 is A, and n is 0-4. In some embodiments, the linker polypeptide has a sequence of GGGGS(XGGGS)n, where X is P, and n is 0-4. In some embodiments, the linker polypeptide of the present disclosure comprises or consists of the amino acid sequence (GGGGA)2GGGGS. In some embodiments, the linker polypeptide of the present disclosure comprises or consists of the amino acid sequence (GGGGQ)2GGGGS. In some embodiments, the linker polypeptide of the present disclosure comprises or consists of the amino acid sequence (GGGPS)2GGGGS. In some embodiments, the linker polypeptide comprises or consists of the amino acid sequence GGGGS(PGGGS)2. In some embodiments, the linker polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 7, 36, 38, 40, 42, 44, 46, 48, 50, or 52 in the Sequence Listing.
[0116] Additionally or alternatively, in some embodiments, the multivalent polypeptides and multivalent antibodies of the disclosure may comprise one or more RPTP binding modules chemically linked to one or more receptor binding modules. In some embodiments, the multivalent polypeptides and multivalent antibodies of the disclosure comprise: (i) one or more RPTP binding modules chemically linked to one or more receptor binding modules; and (ii) one or more RPTP binding modules linked to one or more receptor binding modules via peptide bonds.
[0117] In some embodiments disclosed herein, at least one of the first and second polypeptide modules of the multivalent polypeptide or multivalent antibody of the present disclosure comprises an amino acid sequence of a protein-binding ligand or antigen-binding portion. In some embodiments, at least one of the first and second polypeptide modules comprises an amino acid sequence of a protein-binding ligand. In general, any suitable protein-binding ligand can be used in the compositions and methods of the present disclosure, for example, any recombinant or natural polypeptide (e.g., a recombinant or natural ligand receptor of a receptor protein tyrosine phosphatase (RPTP) or a cell surface receptor) that has specific binding affinity for a target antibody or target protein (see also Verdoliva, et al., J. Immuno. Methods, 2002; Naik et al., J. Chromatography, 2011). For example, non-limiting examples of suitable ligands for the phosphatase CD45 include natural ligands such as, for example, lectin CD22 (Hermiston ML et al., Annu. Rev. Immunol. 2003) and galactin-1 (Walzel H. et al., J. Immunol. Lett. 1999 and Nguyen JT et al., J Immunol. 2001). In some embodiments, at least one of the first and second polypeptide modules of a multivalent polypeptide or multivalent antibody of the present disclosure comprises an amino acid sequence of one or more extracellular domains (ECDs) of a cell surface receptor or of a RPTP. Thus, in some embodiments, a first polypeptide module of a multivalent polypeptide of the present disclosure comprises one or more ECDs of a RPTP operably linked to a second module of the multivalent polypeptide. In some embodiments, a second polypeptide module of a multivalent polypeptide of the present disclosure comprises one or more ECDs of a RPTP operably linked to a first module of the multivalent polypeptide. In some embodiments, a second polypeptide module of a multivalent polypeptide of the disclosure comprises one or more ECDs of a cell surface receptor operably linked to a first module of the multivalent polypeptide.
[0118] As described above, non-limiting examples of protein binding ligands suitable for the compositions and methods of the present disclosure include natural ligands of cell surface receptors. For example, suitable natural ligands of PD-1 include B7 family members PD-L1 and PD-L2. Suitable natural ligands of CD5 include CD72, gp80-40, and Ig framework structures. As described in Example 18, recombinant interleukin-2 (IL-2), the natural ligand of IL-2R, can be operably linked to an anti-CD45 scFv to generate a multivalent polypeptide capable of binding to CD45 and IL-2R.
[0119] Additionally or alternatively, the protein binding ligand can be an agonist or antagonist version of the target's natural ligand. Thus, in some embodiments, the protein binding ligand is an agonist ligand of a receptor protein tyrosine phosphatase (RPTP) or cell surface receptor. In some other embodiments, the protein binding ligand is an antagonist ligand of a receptor protein tyrosine phosphatase (RPTP) or cell surface receptor. In some embodiments, the protein binding ligand can be a synthetic molecule, such as, for example, a peptide or a small molecule.
[0120] In some embodiments, at least one of the first and second polypeptide modules of the multivalent polypeptide or multivalent antibody of the present disclosure comprises an amino acid sequence of an antigen-binding portion that binds to a target protein, such as a receptor protein tyrosine phosphatase (RPTP) or a cell surface receptor. In some embodiments, the antigen-binding portion comprises one or more antigen-binding determinants of an antibody or antigen-binding fragment thereof. Both blocking and non-blocking antibodies are suitable. As used herein, the term "blocking" or "antagonist" antibody refers to an antibody that prevents, inhibits, blocks, or reduces the biological or functional activity of the antigen to which it binds. A blocking or antagonist antibody can substantially or completely prevent, inhibit, block, or reduce the biological activity of the antigen. For example, a blocking anti-PD-1 antibody can prevent, inhibit, block, or reduce the binding interaction between PD-1 and PD-L1, thereby preventing, inhibiting, blocking, or reducing the immunosuppressive function associated with the PD-1 / PD-L1 interaction. The term "non-blocking" antibody refers to an antibody that does not interfere with, inhibit, block or reduce the biological or functional activity of the antigen to which it binds.
[0121] The term "antigen-binding fragment" as used herein refers to an antibody fragment such as, for example, a diabody, a Fab, a Fab', an F(ab')2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), (dsFv)2, a bispecific dsFv (dsFv-dsFv'), a disulfide stabilized diabody (ds diabody), a single chain antibody molecule (scFv), a scFv dimer (e.g., a bivalent diabody-bi-scFv or a bivalent diabody-di-scFv), or a multispecific antibody formed from a portion of an antibody comprising one or more complementarity determining regions (CDRs) of an antibody. Antigen-binding moieties can include naturally occurring polypeptides, antibodies produced by immunization of non-human animals, or antigen-binding moieties obtained from other sources, e.g., camels (see, e.g., Bannas et al., Front. Immunol., Nov. 22, 2017; McMahon C. et al., Nat Struct Mol Biol. 25(3):289-296, 2018). Antigen-binding moieties can be engineered, synthesized, designed, humanized (see, e.g., Vincke et al., J. Biol. Chem. 30; 284(5):3273-84, 2009), or modified to provide desired and / or improved properties.
[0122] Thus, in some embodiments, at least one of the first and second polypeptide modules of the multivalent polypeptide or multivalent antibody of the present disclosure is an antigen-binding fragment (Fab), a single chain variable fragment (scFv), a nanobody, a VFv, a Fab fragment, a VFv ... H Domain, V L Domain, Single Domain Antibody (dAb), V NAR Domain, and V HIn some embodiments, the antigen binding portion comprises an amino acid sequence of an antigen binding portion selected from the group consisting of an H domain, a diabody, or a functional fragment of any one of the foregoing. In some embodiments, the antigen binding portion comprises a single chain variable fragment (scFv). In some embodiments, the antigen binding portion comprises a diabody. In some embodiments, the antigen binding portion comprises a bi-scFv or di-scFv in which two scFv molecules are operably linked to each other. In some embodiments, a bi-scFv or di-scFv comprises two V domains forming a tandem scFv. H Area and two Vs L In some embodiments, the antigen binding moiety comprises a single peptide chain having a heavy chain variable region and a light chain variable region. In some embodiments, the antigen binding moiety comprises a nanobody. In some embodiments, the antigen binding moiety comprises a heavy chain variable region and a light chain variable region.
[0123] In some embodiments, the heavy and light chain variable regions of the antigen-binding portion are operably linked to each other via one or more intervening amino acid residues disposed between the heavy and light chain variable regions. In some embodiments, the one or more intervening amino acid residues comprise a linker polypeptide sequence. In principle, there is no particular limit to the length and / or amino acid composition of the linker polypeptide sequence. In some embodiments, any single-chain polypeptide comprising about 1-100 amino acid residues (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. amino acid residues) can be used as a polypeptide linker. In some embodiments, the linker polypeptide sequence comprises, for example, about 5-50, about 10-60, about 20-70, about 30-80, about 40-90, about 50-100, about 60-80, about 70-100, about 30-60, about 20-80, or about 30-90 amino acid residues. In some embodiments, the linker polypeptide sequence comprises about 1-10, about 5-15, about 10-20, about 15-25, about 20-40, about 30-50, about 40-60, or about 50-70 amino acid residues. In some embodiments, the linker polypeptide sequence comprises about 40-70, about 50-80, about 60-80, about 70-90, or about 80-100 amino acid residues. In some embodiments, the linker polypeptide sequence comprises about 1-10, about 5-15, about 10-20, or about 15-25 amino acid residues. In some embodiments, the length and amino acid composition of the linker polypeptide sequence can be optimized to vary the orientation and / or proximity of the first and second polypeptide modules relative to each other to achieve a desired activity of the multivalent polypeptide. In some embodiments, the orientation and / or proximity of the first and second polypeptide modules relative to each other can be varied as a "tuning" measure to achieve tuning effects that may enhance or reduce the RPTP activity of the multivalent polypeptide. In some embodiments, the orientation and / or proximity of the first and second polypeptide modules relative to each other can be optimized to create partial to full length antagonists of the multivalent polypeptide.
[0124] In certain embodiments, the linker comprises only glycine and / or serine residues (e.g., glycine-serine linker). Examples of such polypeptide linkers include Gly, Ser; Gly Ser; Gly Gly Ser; Ser Gly Gly; Gly Gly Gly Ser; Ser Gly Gly Gly; Gly ... For example, in some embodiments, the polypeptide linker comprises an amino acid sequence selected from the group consisting of (GGGXX)nGGGGS and GGGGS(XGGGS)n, where X is any amino acid that can be inserted into the sequence but does not result in a polypeptide containing the sequence GSG, and n is 0-4. In some embodiments, the linker polypeptide sequence is (GGGX1X2)nGGGGS, where X1 is P and X2 is S, and n is 0-4. In some embodiments, the linker polypeptide sequence is (GGGX1X2)nGGGGS, where X1 is G and X2 is Q, and n is 0-4. In some other embodiments, the linker polypeptide sequence is (GGGX1X2)nGGGGS, where X1 is G and X2 is A, and n is 0-4. In some embodiments, the linker polypeptide sequence is GGGGS(XGGGS)n, where X is P, and n is 0-4. In some embodiments, a linker polypeptide of the disclosure comprises or consists of the amino acid sequence (GGGGA)2GGGGS.In some embodiments, the linker polypeptide of the disclosure comprises or consists of the amino acid sequence (GGGGQ)2GGGGS. In some embodiments, the linker polypeptide of the disclosure comprises or consists of the amino acid sequence (GGGPS)2GGGGS. In some embodiments, the linker polypeptide comprises or consists of the amino acid sequence GGGGS(PGGGS)2. In some embodiments, the linker polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 7, 36, 38, 40, 42, 44, 46, 48, 50, or 52 in the Sequence Listing.
[0125] In some embodiments, the first polypeptide module of the multivalent polypeptides and multivalent antibodies of the present disclosure comprises an antigen-binding portion capable of binding one or more target RPTPs. In general, there are no particular limitations regarding the RPTPs that can be targeted by the multivalent polypeptides and multivalent antibodies described herein. Non-limiting examples of suitable RPTPs include members of subfamilies R1 / R6, R2A, R2B, R3, R4. Members of subfamilies R5, R7 and R8 are also suitable for the compositions and methods disclosed herein. Examples of suitable RPTPs include, but are not limited to, Ptpn5 (STEP), Ptpra (RPTP-α), Ptprb (PTPB), Ptprc (CD45), Ptprd (RPTP-δ), Ptpre (RPTP-R), Ptprf (LAR), Ptprg (RPTP-γ), Ptprh (SAP1), Ptprj (DEP-1), Ptprk (RPTP-κ), and any functional mutants thereof. Further non-limiting examples of RPTPs suitable for the compositions and methods of the present disclosure include Ptprm (RPTP-μ), Ptprn (IA2), Ptprn2 (IA2β), Ptpro (GLEPP1), Ptprp (PTPS31), Ptprr (PCPTP1), Ptprs (RPTP-σ), Ptprt (RPTP-ρ), Ptpru (RPTP-λ), Ptprz (RPTP-ζ), and any functional variants thereof. In some embodiments, the first polypeptide module of the multivalent polypeptides and multivalent antibodies of the present disclosure comprises an antigen binding portion capable of binding a CD45 phosphatase or a functional variant (e.g., a homolog thereof) thereof. In some embodiments, the CD45 phosphatase is a human CD45 phosphatase. In general, any isoform of CD45 can be used. In some embodiments, the receptor protein tyrosine phosphatase comprises a CD45 isoform selected from the group consisting of CD45RA, CD45RB, CD45RC, CD45RAB, CD45RAC, CD45RBC, CD45R0, and CD45R. Examples of CD45 binding moieties suitable for the compositions and methods of the present disclosure include, but are not limited to, those described in U.S. Patent Nos. 7,825,222 and 9,701,756.
[0126] In some embodiments, the second polypeptide module of the multivalent polypeptides and multivalent antibodies of the present disclosure comprises an antigen binding moiety capable of binding a cell surface receptor that signals through a phosphorylation mechanism. Generally, the cell surface receptor can be any cell surface receptor known in the art. In some embodiments, the cell surface receptor is an immune checkpoint receptor, a cytokine receptor, or a growth factor receptor. In some embodiments, the cell surface receptor is an immune checkpoint receptor selected from the group consisting of an inhibitory checkpoint receptor and a stimulatory checkpoint receptor. In some embodiments, the cell surface receptor is an inhibitory checkpoint receptor. Generally, the inhibitory checkpoint receptor can be any inhibitory checkpoint receptor that signals through a phosphorylation mechanism. Non-limiting examples of inhibitory checkpoint receptors suitable for the compositions and methods of the present disclosure include PD-1, CTLA-4, A2AR, B7-H3, B7-H4, BTLA, CD5, CD132, IDO, KIR, LAG3, TIM-3, TIGIT, VISTA, and functional variants thereof. In some embodiments, the inhibitory checkpoint receptor is PD-1 or a functional variant thereof. In some embodiments, the inhibitory checkpoint receptor is CTLA-4 or a functional variant thereof. In some embodiments, the inhibitory checkpoint receptor is TIGIT or a functional variant thereof. In some embodiments, the inhibitory checkpoint receptor is CD5 or a functional variant thereof. In some embodiments, the inhibitory checkpoint receptor is CD132 or a functional variant thereof.
[0127] In some embodiments, the cell surface receptor is a stimulatory checkpoint receptor. In general, the stimulatory checkpoint receptor can be any one of the stimulatory checkpoint receptors that signal through phosphorylation mechanism. Non-limiting examples of stimulatory checkpoint receptors suitable for the compositions and methods disclosed herein include CD27, CD28, CD40, OX40, GITR, ICOS, CD137, and functional variants thereof. In some embodiments, the inhibitory checkpoint receptor is CD28 or its functional variants.
[0128] In some embodiments, the cell surface receptor transmits signals through a conserved amino acid motif that functions as a phosphorylation substrate, such as, for example, an immunoreceptor tyrosine-based activation motif (ITAM), or an immunoreceptor tyrosine-based switch motif (ITSM), or an immunoreceptor tyrosine-based inhibition motif (ITIM). In some embodiments, the cell surface receptor mediates signaling through a specific tyrosine-based motif selected from an ITAM motif, an ITSM motif, an ITIM motif, or a related intracellular motif that serves as a phosphorylation substrate. In some embodiments, the cell surface receptor is selected from the group consisting of DAP10, DAP12, SIRPa, CD3, CD28, CD4, CD8, CD200, CD200R, ICOS, KIR, FcR, BCR, CD5, CD2, G6B, LIR, CD7, and BTN, or any functional variant thereof.
[0129] In some embodiments, the cell surface receptor is a cytokine receptor, hi some embodiments, the cytokine receptor is selected from the group consisting of an interleukin receptor, an interferon receptor, a chemokine receptor, a growth hormone receptor, an erythropoietin receptor (EpoR), a thymic stromal lymphopoietin receptor (TSLPR), a thrombopoietin receptor (TpoR), a granulocyte macrophage colony stimulating factor (GM-SCF) receptor, and a granulocyte colony stimulating factor (G-CSF) receptor.
[0130] In some embodiments, the cell surface receptor is a growth factor receptor. In some embodiments, the growth factor receptor is a tyrosine receptor kinase (TRK), which is also interchangeably referred to herein as a tyrosine kinase receptor (TKR). In general, the TRK can be any TRK known in the art. Non-limiting examples of TRK suitable for the present disclosure include, but are not limited to, those belonging to RTK class I (EGF receptor family; ErbB family), RTK class II (insulin receptor family), RTK class III (PDGF receptor family), RTK class IV (VEGF receptor family), RTK class V (FGF receptor family), RTK class VI (CCK receptor family), RTK class VII (NGF receptor family). Additional TRKs suitable for the present disclosure include, but are not limited to, those belonging to RTK class VIII (HGF receptor family), RTK class IX (Eph receptor family), RTK class X (AXL receptor family), RTK class XI (TIE receptor family), RTK class XII (RYK receptor family), RTK class XIII (DDR receptor family), RTK class XIV (RET receptor family), RTK class XV (ROS receptor family), RTK class XVI (LTK receptor family), RTK class XVII (ROR receptor family), RTK class XVIII (MuSK receptor family), RTK class XIX (LMR receptor), RTK class XX. In some specific embodiments, the growth factor receptor is a stem cell growth factor receptor (SCFR) or epidermal growth factor receptor (EGFR) selected from the group consisting of ErbB-1, ErbB-2 (HER2), ErbB-3, ErbB-4, and c-Kit (CD117).
[0131] Some embodiments disclosed herein relate to a multivalent polypeptide comprising: (a) domain A comprising a binding region of a heavy chain variable region of a first scFv specific for an epitope of a RPTP; (b) domain B comprising a binding region of a light chain variable region of a second scFv specific for an epitope of a cell surface receptor; (c) domain C comprising a binding region of a heavy chain variable region of a second scFv specific for an epitope of a cell surface receptor; and (d) domain D comprising a binding region of the light chain variable region of a first scFv specific for an epitope of a RPTP.
[0132] The designation of the polypeptide domains of the multivalent polypeptides and multivalent antibodies of the present disclosure as "A", "B", "C", or "D" polypeptide domains does not imply any particular structural arrangement of the "first", "second", "third", or "fourth" polypeptide domains within the multivalent polypeptides and multivalent antibodies of the present disclosure. Additionally or alternatively, the multivalent polypeptides and multivalent antibodies of the present disclosure may comprise two or more polypeptide modules capable of binding to a RPTP and / or a cell surface receptor. In some embodiments, the multivalent polypeptides and multivalent antibodies of the present disclosure may comprise at least two polypeptide modules, each capable of binding to a different RPTP. In some embodiments, the multivalent polypeptides and multivalent antibodies of the present disclosure may comprise at least two polypeptide modules, each capable of binding to the same RPTP. In some embodiments, the multivalent polypeptides and multivalent antibodies of the present disclosure may comprise at least two polypeptide modules, each capable of binding to a different cell surface receptor. In some embodiments, the multivalent polypeptides and multivalent antibodies of the present disclosure may comprise at least two polypeptide modules, each capable of binding to the same cell surface receptor.
[0133] In some embodiments, multiple receptor binding modules are operably linked to a central RPTP binding module to form a multivalent polypeptide or multivalent antibody having the general formula (I).
[0134] [ka]
[0135] where n is an integer selected from the range of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0136] In some embodiments, multiple receptor binding modules are operably linked in tandem to form a multivalent polypeptide or multivalent antibody having the general formula (II).
[0137] [ka]
[0138] Some embodiments disclosed herein relate to a multivalent polypeptide comprising, from N-terminus to C-terminus, (a) domain A comprising a binding region of a heavy chain variable region of a first scFv specific for an epitope of an RPTP; (b) domain B comprising a binding region of a light chain variable region of a second scFv specific for an epitope of a cell surface receptor; (c) domain C comprising a binding region of a heavy chain variable region of a second scFv specific for an epitope of a cell surface receptor; and (d) domain D comprising a binding region of a light chain variable region of a first scFv specific for an epitope of an RPTP.
[0139] Exemplary polypeptides and antibodies described herein, such as non-limiting examples of multivalent polypeptides or multivalent antibodies of Formulas (I) and (II), are provided in Tables 1, 2, and 3. [Table 1-1]
[0140] [Table 1-2]
[0141] [Table 1-3]
[0142] [Table 2]
[0143] In some embodiments disclosed herein, the multivalent polypeptide comprises an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 10, 12, 14, 16, 20, 22, 24, 26, 28, and 54, or a functional fragment thereof. In some embodiments, the multivalent polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 10, 12, 14, 16, 20, 22, 24, 26, 28, and 54, or a functional fragment thereof. In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2, or a functional fragment thereof. In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 4, or a functional fragment thereof. In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 6, or a functional fragment thereof.
[0144] In some embodiments, the multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 10, or a functional fragment thereof. In some embodiments, the multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 12, or a functional fragment thereof. In some embodiments, the multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 14, or a functional fragment thereof.
[0145] In some embodiments, the multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 16, or a functional fragment thereof. In some embodiments, the multivalent polypeptide has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the multivalent polypeptide has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO:20.
[0146] In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 22, or a functional fragment thereof. In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 24, or a functional fragment thereof. In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 26, or a functional fragment thereof.
[0147] In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 28, or a functional fragment thereof. In some embodiments, a multivalent polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 54, or a functional fragment thereof.
[0148] In some embodiments, the multivalent polypeptide of the present disclosure can be a multivalent antibody (e.g., a bivalent or trivalent antibody) comprising at least two antigen-binding moieties, each having specific binding to a target protein. In some embodiments, at least two antigen-binding moieties have specific binding to the same target protein. Such an antibody is a multivalent monospecific antibody. In some embodiments, at least two antigen-binding moieties have specific binding to at least two different target proteins. Such an antibody is a multivalent multispecific antibody (e.g., bispecific, trispecific, etc.). Thus, some antibodies disclosed herein relate to a multivalent antibody or functional fragment thereof, which comprises (i) a first polypeptide module specific for one or more receptor protein tyrosine phosphatases (RPTPs), and (ii) a second polypeptide module specific for one or more cell surface receptors that signal via a phosphorylation mechanism, where the first polypeptide module is operably linked to the second polypeptide module. Thus, in some embodiments, the multivalent antibody of the present disclosure can be a bivalent monospecific antibody. In some embodiments, a multivalent antibody of the present disclosure can be a trivalent monospecific antibody. In some embodiments, a multivalent antibody of the present disclosure can be a bivalent bispecific antibody. In some embodiments, a multivalent antibody of the present disclosure can be a trivalent trispecific antibody.
[0149] Those skilled in the art will understand that the complete amino acid sequence can be used to generate a reverse-translated gene. For example, a DNA oligomer containing a nucleotide sequence that codes for a particular polypeptide can be synthesized. For example, several small oligonucleotides that code for a portion of a desired polypeptide can be synthesized and then linked. Each oligonucleotide typically contains a 5' or 3' overhang for complementary assembly.
[0150] In addition to producing mutant polypeptides through expression of nucleic acid molecules that have been altered by recombinant molecular biology techniques, the subject multivalent polypeptides or multivalent antibodies of the present disclosure can be chemically synthesized. Chemically synthesized polypeptides are routinely produced by one of ordinary skill in the art.
[0151] Once assembled (by synthesis, by site-directed mutagenesis, or by other methods), the DNA sequence encoding the multivalent polypeptide or multivalent antibody of the present disclosure will be inserted into an expression vector and operably linked to expression control sequences suitable for expression of the multivalent polypeptide or antibody in a desired transformed host. Proper assembly can be confirmed by nucleotide sequencing, restriction mapping, and expression of biologically active polypeptides in a suitable host. As is known in the art, to obtain high expression levels of a transfected gene in a host, the gene must be operably linked to transcriptional and translational expression control sequences that are functional in the selected expression host.
[0152] The binding activity of the multivalent polypeptides and antibodies of the present disclosure can be assayed by any suitable method known in the art. For example, the binding activity of the multivalent polypeptides and antibodies of the present disclosure can be determined, for example, by Scatchard analysis (Munsen et al., 1980.Analyt. Biochem. 107:220-239). Specific binding can be assessed using techniques known in the art, including, but not limited to, competitive ELISA, BIACORE® assay, and / or KINEXA® assay. Antibodies or polypeptides that "preferentially bind" or "specifically bind" (used interchangeably herein) to a target protein or target epitope are terms well understood in the art, and methods for measuring such specific or preferential binding are also known in the art. An antibody or polypeptide is said to exhibit "specific binding" or "preferential binding" if it reacts or associates with a particular protein or epitope more frequently, more rapidly, with a longer duration, and / or with greater affinity than it reacts or associates with alternative proteins or epitopes. An antibody or polypeptide "specifically binds" or "preferentially binds" a target if it binds with greater affinity, avidity, more readily, and / or for a longer duration than it binds to other substances. Also, an antibody or polypeptide "specifically binds" or "preferentially binds" a target if it binds with greater affinity, avidity, more readily, and / or for a longer duration to its target in a sample than it binds to another substance present in the sample. For example, an antibody or polypeptide that specifically or preferentially binds to a PD-1 epitope is an antibody or polypeptide that binds this epitope with greater affinity, avidity, more readily, and / or for a longer duration than it binds to another PD-1 epitope or a non-PD-1 epitope. By reading this definition, it is also understood that, for example, an antibody or polypeptide (or moiety or epitope) that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target.As such, "specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.
[0153] A variety of assay formats can be used to select antibodies or polypeptides that specifically bind to a molecule of interest, for example, solid-phase ELISA immunoassays, immunoprecipitation, Biacore TM (trademark) (GE Healthcare, Piscataway, NJ), KinExA, Fluorescence Activated Cell Sorting (FACS), Octet TM (Trademark) (ForteBio, Inc., Menlo Park, Calif.) and Western blot analysis, among other assays, can be used to identify antibodies that react specifically with an antigen or receptor, or a ligand-binding portion thereof, that specifically binds to a cognate ligand or binding partner. Generally, a specific or selective response will be at least twice the background signal or noise, more typically greater than 10 times background, even more typically greater than 50 times background, more typically greater than 100 times background, even more typically greater than 500 times background, more commonly greater than 1000 times background, and even more typically greater than 10,000 times background. Also, the equilibrium dissociation constant (K D ) is less than 7 nM (<7 nM).
[0154] The term "binding affinity" is used herein as a measure of the strength of a non-covalent interaction between two molecules, for example, an antibody or portion thereof and an antigen. The term "binding affinity" is used to describe a monovalent interaction (intrinsic activity). The binding affinity between two molecules is determined by the dissociation constant (K D ) can then be determined by measuring the kinetics of complex formation and dissociation, e.g., using surface plasmon resonance (SPR) techniques (Biacore). D The rate constants corresponding to the association and dissociation of the monovalent complex are the association rate constant ka (or k on ) and the dissociation rate constant k d (or k off ) are called respectively. D is the formula 、 K D =k d / k a From a and k d The value of the dissociation constant can be determined directly by well-known methods, and can also be computed for complex mixtures by methods such as those described in Caceci et al. (1984, Byte 9:340-362). For example, K D can be established using a double filter nitrocellulose filter binding assay, such as that disclosed by Wong & Lohman (1993, Proc. Natl. Acad. Sci. USA 90: 5428-5432). Other standard assays for evaluating the binding strength of the antibodies or polypeptides of the present disclosure to a target antigen are well known in the art, including, for example, ELISA, Western blot, RIA, and flow cytometric analysis, as well as other assays exemplified elsewhere herein. Antibody binding kinetics and binding affinity can also be evaluated by standard assays known in the art, such as by surface plasmon resonance (SPR), for example, using the Biacore™ system or KinExA. nucleic acid molecule
[0155] In one aspect, some embodiments of the present disclosure relate to recombinant nucleic acid molecules encoding the multivalent polypeptides and multivalent antibodies of the present disclosure, expression cassettes and expression vectors comprising those nucleic acid molecules operably linked to regulatory sequences allowing the expression of the multivalent polypeptides or multivalent antibodies in a host cell or in an ex vivo cell-free expression system.
[0156] The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably herein. It refers to both RNA and DNA molecules, including nucleic acid molecules including cDNA, genomic DNA, synthetic DNA, and DNA or RNA molecules including nucleic acid analogs. Nucleic acid molecules can be double-stranded or single-stranded (e.g., sense or antisense strands). Nucleic acid molecules can include non-conventional or modified nucleotides. As used herein, the terms "polynucleotide sequence" and "nucleic acid sequence" refer interchangeably to the sequence of a polynucleotide molecule. The nomenclature of nucleotide bases set forth in the United States Patent Act 37 CFR § 1.822 is used herein.
[0157] Nucleic acid molecules of the present disclosure can be of any length, including nucleic acid molecules that are generally from about 5 Kb to about 50 Kb, e.g., from about 5 Kb to about 40 Kb, from about 5 Kb to about 30 Kb, from about 5 Kb to about 20 Kb, or from about 10 Kb to about 50 Kb, e.g., from about 15 Kb to about 30 Kb, from about 20 Kb to about 50 Kb, from about 20 Kb to about 40 Kb, from about 5 Kb to about 25 Kb, or from about 30 Kb to about 50 Kb.
[0158] The term "recombinant" nucleic acid molecule as used herein refers to a nucleic acid molecule that has been modified by human intervention. As a non-limiting example, a cDNA is a recombinant DNA molecule, which is any nucleic acid molecule that has been produced by in vitro polymerase chain reaction or to which a linker has been linked, or that has been incorporated into a vector, such as a cloning vector or an expression vector. As a non-limiting example, a recombinant nucleic acid molecule is: 1) synthesized or modified in vitro, for example, using chemical or enzymatic techniques (e.g., by using chemical nucleic acid synthesis, or by using enzymes for replicating, polymerizing, exonuclease digestion, endonuclease digestion, ligating, reverse transcription, transcription, base modification (including, for example, methylation), or recombining (including homologous and site-specific recombination) of nucleic acid molecules; 2) contains linked nucleotide sequences that are not linked in nature; 3) has been engineered using molecular cloning techniques to lack one or more nucleotides with respect to the naturally occurring nucleic acid molecule sequence; and / or 4) has been engineered using molecular cloning techniques to have one or more sequence changes or rearrangements with respect to the naturally occurring nucleic acid sequence.
[0159] In some embodiments disclosed herein, the nucleic acid molecule of the present disclosure comprises a nucleotide sequence encoding a multivalent polypeptide, which comprises (i) a first amino acid sequence comprising a first polypeptide module capable of binding to a receptor protein tyrosine phosphatase (RPTP), and (ii) a second amino acid sequence comprising a second polypeptide module capable of binding to a cell surface receptor that signals via a phosphorylation mechanism, where the first polypeptide module is operably linked to the second polypeptide module. In some embodiments, the nucleic acid molecule of the present disclosure comprises a nucleotide sequence encoding a multivalent antibody comprising (i) a first polypeptide module specific for one or more receptor protein tyrosine phosphatases (RPTPs), and (ii) a second polypeptide module specific for one or more cell surface receptors that signal via a phosphorylation mechanism.
[0160] In some embodiments disclosed herein, the nucleic acid molecule comprises a nucleotide sequence encoding a polypeptide comprising: (i) an amino acid sequence having at least 80% sequence identity to the amino acid sequence of a multivalent polypeptide disclosed herein, or a functional fragment thereof; or (ii) an amino acid sequence having at least 80% sequence identity to a multivalent antibody disclosed herein, or a functional fragment thereof. The nucleic acid molecule comprises a nucleotide sequence encoding a polypeptide comprising: (i) an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of a multivalent polypeptide disclosed herein, or a functional fragment thereof; or (ii) an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a multivalent antibody disclosed herein, or a functional fragment thereof.
[0161] In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 9, 11, 13, 15, 19, 21, 23, 25, 27, and 53, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 1, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 3, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO:5, or a functional fragment thereof.
[0162] In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 9, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 11, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 13, or a functional fragment thereof.
[0163] In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 15, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 19, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 21, or a functional fragment thereof.
[0164] In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 23, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 25, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 27, or a functional fragment thereof. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the nucleotide sequence of SEQ ID NO:53, or a functional fragment thereof.
[0165] Some embodiments disclosed herein relate to vectors or expression cassettes comprising the recombinant nucleic acid molecules disclosed herein. As used herein, the term "expression cassette" refers to a composition of genetic material that includes a coding sequence and regulatory information sufficient to direct the proper transcription and / or translation of the coding sequence in a recipient cell in vivo and / or ex vivo. The expression cassette can be inserted into a vector for targeting to a desired host cell and / or subject. Thus, the term expression cassette can be used interchangeably with the term "expression construct."
[0166] Also provided herein are vectors, plasmids or viruses that contain one or more nucleic acid molecules encoding any of the multivalent polypeptides and multivalent antibodies disclosed herein. The nucleic acid molecules can be included, for example, in a vector that can direct their expression in a cell transduced with the vector. Vectors suitable for use in eukaryotic and prokaryotic cells are known in the art and are commercially available or readily prepared by one of ordinary skill in the art. Additional vectors can be found, for example, in Ausubel, FM et al., "Current Protocols in Molecular Biology, (Current Protocol, 1994) and Sambrook et al., "Molecular Cloning: A Laboratory Manual", 2nd ed. (1989).
[0167] It should be understood that not all vectors and expression control sequences work equally well to express the DMA sequences described herein. Also, not all hosts work equally well in the same expression system. However, one of skill in the art can make a selection among these vectors, expression control sequences, and hosts without undue experimentation. For example, when selecting a vector, the host must be considered since the vector must replicate in the host. The copy number of the vector, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be taken into consideration. For example, vectors that can be used include vectors that allow the DNA encoding the multivalent polypeptides and multivalent antibodies of the present disclosure to be amplified in terms of copy number. Such amplifiable vectors are known in the art. Examples include vectors that can be amplified by DHFR amplification (see, e.g., Kaufman, U.S. Pat. No. 4,470,461) or glutamine synthetase ("GS") amplification (see, e.g., U.S. Pat. No. 5,122,464 and European Patent Application Publication EP 338,841).
[0168] Thus, in some embodiments, the multivalent polypeptides and multivalent antibodies of the present disclosure can be expressed from a vector, usually an expression vector. The vector may be useful for autonomous replication in a host cell, or may be integrated into the genome of the host cell upon introduction into the host cell, thereby replicating together with the host genome (e.g., non-episomal mammalian vectors). Expression vectors are capable of directing the expression of coding sequences to which they are operably linked. In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids (vectors). However, other forms of expression vectors, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses, adeno-associated viruses), are also included.
[0169] Exemplary recombinant expression vectors are selected based on the host cell to be used for expression, and can contain one or more regulatory sequences operably linked to the nucleic acid sequence to be expressed.
[0170] DNA vectors can be introduced into prokaryotic or eukaryotic cells by conventional transformation or transfection techniques. Suitable methods for transforming or transfecting host cells can be found in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Plainview, NY) and other standard molecular biology research manuals.
[0171] The nucleic acid sequences encoding the multivalent polypeptides and multivalent antibodies of the present disclosure can be optimized for expression in a host cell of interest. For example, the GC content of the sequence can be adjusted to the average level of a given cellular host, as calculated by reference to known genes expressed in the host cell. Methods of codon optimization are known in the art. The codon usage in the coding sequences of the multivalent polypeptides and multivalent antibodies disclosed herein can be optimized to enhance expression in a host cell, such that about 1%, about 5%, about 10%, about 25%, about 50%, about 75%, or up to 100% of the codons in the coding sequence are optimized for expression in a particular host cell.
[0172] Suitable vectors for use include T7-based vectors for use in bacteria, pMSXND expression vectors for use in mammalian cells, and baculovirus-derived vectors for use in insect cells. In some embodiments, the nucleic acid inserts encoding the subject multivalent polypeptides or multivalent antibodies in such vectors can be operably linked to a promoter, which is selected, for example, based on the cell type in which expression is desired.
[0173] When selecting expression control sequences, various factors should also be considered. These factors include, for example, the relative strength of the sequence, its controllability, and compatibility with the actual DNA sequence encoding the subject multivalent polypeptide or multivalent antibody, especially with respect to potential secondary structures. Hosts should be selected taking into consideration compatibility with the selected vector, the toxicity of the products encoded by the DNA sequences of the present disclosure, their secretion characteristics, the ability to correctly fold the polypeptides, their fermentation or culture requirements, and the ease of purification of the products encoded by the DNA sequences.
[0174] Within these parameters, one skilled in the art can select a variety of vector / expression control sequence / host combinations that will express the desired DNA sequence in fermentation or large scale animal culture, for example using CHO or COS7 cells.
[0175] In some embodiments, the choice of expression control sequences and expression vectors will depend on the choice of host. A wide variety of expression host / vector combinations can be used. Non-limiting examples of useful expression vectors for eukaryotic hosts include, for example, vectors with expression control sequences from SV40, bovine papilloma virus, adenovirus, and cytomegalovirus. Non-limiting examples of useful expression vectors for bacterial hosts include known bacterial plasmids such as plasmids from E. coli, including col El, pCRI, pER32z, pMB9, and their derivatives, broader host range plasmids such as RP4, phage DNA, including many derivatives of phage lambda, such as NM989, and other DNA phages, such as M13 and filamentous single-stranded DNA phages. Non-limiting examples of expression vectors useful for yeast cells include the 2μ plasmid and its derivatives. Non-limiting examples of vectors useful for insect cells include pVL 941 and pFastBac TM 1 is one example.
[0176] Furthermore, any of a wide variety of expression control sequences can be used in these vectors. Such useful expression control sequences include expression control sequences associated with the structural genes of the expression vectors described above. Examples of useful expression control sequences include, for example, SV40 or adenovirus early and late promoters, lac system, trp system, TAC or TRC system, phage lambda major operator and promoter regions, such as PL, the control region of fd coat protein, promoters of 3-phosphoglycerate kinase or other glycolytic enzymes, promoters of acid phosphatases, such as PhoA, yeast a-mating type promoters, baculovirus polyhedron promoters, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or viruses thereof, and various combinations thereof.
[0177] T7 promoter can be used in bacteria, polyhedron promoter can be used in insect cells, and cytomegalovirus or metallothionein promoter can be used in mammalian cells. Also, for higher eukaryotes, tissue-specific and cell type-specific promoters are widely available. These promoters are named for their ability to direct the expression of nucleic acid molecules in specific tissues or cell types in the body. Those skilled in the art will readily recognize the numerous promoters and other regulatory elements that can be used to direct the expression of nucleic acids.
[0178] In addition to sequences that facilitate transcription of the inserted nucleic acid molecule, vectors can contain an origin of replication and other genes that encode selectable markers. For example, the neomycin resistance (neoR) gene confers G418 resistance to cells in which it is expressed, thus allowing phenotypic selection of transfected cells. Those skilled in the art can readily determine whether a given regulatory element or selectable marker is appropriate for use in a particular experimental situation.
[0179] Viral vectors that can be used in the present disclosure include, for example, retrovirus, adenovirus and adeno-associated vectors, herpesvirus, simian virus 40 (SV40), and bovine papilloma virus vectors (see, e.g., Gluzman, ed., Eukaryotic Viral Vectors, CSH Laboratory Press, Cold Spring Harbor, NY).
[0180] Prokaryotic or eukaryotic cells that contain and express a nucleic acid molecule encoding a multivalent polypeptide or a multivalent antibody of the subject matter disclosed herein are also a feature of the disclosure. The cells of the disclosure are transfected cells, e.g., cells into which a nucleic acid molecule, e.g., a nucleic acid molecule encoding a mutant IL-2 polypeptide, has been introduced by recombinant DNA techniques. The progeny of such cells are also considered to be within the scope of the disclosure.
[0181] The exact components of the expression system are not critical. For example, the multivalent polypeptide or multivalent antibody disclosed herein can be produced in a prokaryotic host, such as the bacterium Escherichia coli (E. coli), or in a eukaryotic host, such as an insect cell (e.g., Sf21 cell), or in a mammalian cell (e.g., COS cell, NIH 3T3 cell, or HeLa cell). Such cells are available from a number of sources, such as the American Type Culture Collection (ATCC), Mananas, Virginia, USA. When selecting an expression system, it is only important that the components are compatible with each other. The technician or skilled artisan can make such a decision. Furthermore, if guidance is needed in selecting an expression system, the skilled artisan can consult Ausubel et al. (Current Protocols in Molecular Biology, John Wiley and Sonsm, New York, NY, 1993) and Pouwels et al. (Cloning Vectors: A Laboratory Manual, 1985 Supplement, 1987).
[0182] The expressed polypeptides can be purified from the expression system using routine biochemical procedures and can be used, for example, as therapeutic agents, as described herein.
[0183] In some embodiments, the resulting multivalent polypeptide or multivalent antibody is glycosylated or non-glycosylated depending on the host organism used to produce the multivalent polypeptide or multivalent antibody. If a bacterium is selected as the host, the produced multivalent polypeptide or multivalent antibody will not be glycosylated (non-glycosylated form). Eukaryotic cells, on the other hand, will glycosylate the multivalent polypeptide or multivalent antibody, but probably not in the same way that the native polypeptide is glycosylated. The multivalent polypeptide or multivalent antibody produced by the transformed host can be purified according to any suitable method known in the art. The produced multivalent polypeptide or multivalent antibody can be isolated from inclusion bodies produced in bacteria such as E. coli, or from conditioned medium of mammalian or yeast cultures producing the given multivalent polypeptide or multivalent antibody using cation exchange, gel filtration, and / or reverse phase liquid chromatography.
[0184] Additionally or alternatively, another exemplary method of constructing a DNA sequence encoding a multivalent polypeptide or antibody of the present disclosure is by chemical synthesis. This includes direct peptide synthesis by chemical means of a protein sequence encoding a multivalent polypeptide or antibody exhibiting the described properties. This method can incorporate both natural and non-natural amino acids at positions that affect the binding affinity of the multivalent polypeptide or antibody to the target protein. Alternatively, genes encoding the desired multivalent polypeptide or antibody can be synthesized by chemical means using an oligonucleotide synthesizer. Such oligonucleotides are designed based on the amino acid sequence of the desired multivalent polypeptide or antibody, and are usually designed with a selection of codons that are favored in the host cell in which the recombinant multivalent polypeptide or antibody will be produced. In this regard, it is well recognized in the art that the genetic code is degenerate, i.e., an amino acid can be encoded by more than one codon. For example, Phe (F) is encoded by two codons, TIC or TTT, Tyr (Y) is encoded by TAC or TAT, and His (H) is encoded by CAC or CAT. Trp(W) is encoded by a single codon TGG. Thus, one skilled in the art will understand that for a given DNA sequence encoding a particular multivalent polypeptide or antibody, there are many degenerate DNA sequences that will encode that multivalent polypeptide or antibody. For example, in addition to the DNA sequences of the multivalent polypeptides or antibodies provided in the sequence listing, it will be understood that there are many degenerate DNA sequences that encode the multivalent polypeptides or antibodies disclosed herein. These degenerate DNA sequences are considered to be within the scope of this disclosure. Thus, in the context of this disclosure, "degenerate variants thereof" refers to all DNA sequences that encode a particular multivalent polypeptide or antibody, thereby allowing for their expression.
[0185] The DNA sequence encoding the subject multivalent polypeptide or antibody, whether prepared by site-directed mutagenesis, chemical synthesis or other methods, may also include a DNA sequence encoding a signal sequence. If present, such a signal sequence must be recognized by the cell selected for expression of the multivalent polypeptide or antibody. It may be prokaryotic, eukaryotic, or a combination of the two. In general, the inclusion of a signal sequence depends on whether it is desired to secrete the multivalent polypeptide or antibody of the present disclosure from the recombinant cell in which it is produced. If the selected cell is prokaryotic, the DNA sequence will not usually encode a signal sequence. If the selected cell is eukaryotic, a signal sequence will usually be included.
[0186] The nucleic acid molecules provided can include naturally occurring sequences, or sequences that are different from those that occur in nature, but because of the degeneracy of the genetic code, code for the same polypeptide.These nucleic acid molecules can be composed of RNA or DNA (e.g., genomic DNA, cDNA, or synthetic DNA, such as those produced by phosphoramidite method-based synthesis), or combinations or modifications of nucleotides within these nucleic acid types.Moreover, the nucleic acid molecules can be double-stranded or single-stranded (e.g., either the sense strand or the antisense strand).
[0187] Nucleic acid molecules are not limited to sequences that code for polypeptides. They can also include some or all of the non-coding sequences upstream or downstream of the coding sequence (e.g., the coding sequence for IL-2). Those skilled in the art of molecular biology are familiar with routine procedures for isolating nucleic acid molecules. These nucleic acid molecules can be generated, for example, by treating genomic DNA with restriction endonucleases or by carrying out polymerase chain reaction (PCR). If the nucleic acid molecule is ribonucleic acid (RNA), it can be generated, for example, by in vitro transcription.
[0188] Exemplary isolated nucleic acid molecules of the present disclosure can include fragments not found by themselves in nature. Thus, the present disclosure encompasses those in which a nucleic acid sequence (e.g., a sequence encoding a mutant IL-2) is incorporated into a vector (e.g., a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell at a location other than the natural chromosomal location). Pharmaceutical Compositions
[0189] In some embodiments, the multivalent polypeptides and multivalent antibodies of the present disclosure can be incorporated into compositions, including pharmaceutical compositions, which typically include the multivalent polypeptide and / or multivalent antibody and a pharma- ceutically acceptable excipient.
[0190] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM(trademark) (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium, including, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants, for example, sodium dodecyl sulfate. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is common to include isotonic agents in the composition, for example, polyalcohols such as sugars, mannitol, sorbitol, sodium chloride, and the like. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
[0191] Sterile injectable solution can be prepared by incorporating the active compound in the required amount in a suitable solvent with one or combination of the above-listed components as required, followed by filtration sterilization.Generally, dispersion is prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and other components required from the above-listed components.For the case of sterile powder for preparing sterile injectable solution, the general preparation method is vacuum drying and freeze-drying, which method obtains the powder of active ingredient plus any additional desired components from the solution already sterile-filtered.
[0192] Oral compositions, if used, generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound (e.g., the multivalent polypeptide, multivalent antibody, and / or nucleic acid molecule of the present disclosure) can be incorporated with an excipient and used in the form of tablets, troches, or capsules, such as gelatin capsules. Oral compositions can also be prepared using liquid carriers used as mouthwashes. Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: binders, such as microcrystalline cellulose, gum tragacanth, or gelatin; excipients, such as starch or lactose; alginic acid, Primogel TM Disintegrants such as magnesium stearate or Sterotes TM (trademark); a glidant, such as colloidal silicon dioxide; a sweetener, such as sucrose or saccharin; or a flavoring agent, such as peppermint, methyl salicylate, orange flavor, and the like.
[0193] For administration by inhalation, the multivalent polypeptides and multivalent antibodies of the presently disclosed subject matter are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Patent No. 6,468,798.
[0194] Systemic administration of the subject multivalent polypeptides and multivalent antibodies of the present disclosure can also be via transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be permeated is used in the formulation. Such penetrants are generally known in the art and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be achieved through the use of nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels, or creams as generally known in the art.
[0195] In some embodiments, the multivalent polypeptides and multivalent antibodies of this disclosure can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter or other glycerides) or retention enemas for rectal delivery.
[0196] In some embodiments, multivalent polypeptides and multivalent antibodies of the disclosure can also be administered by transfection or infection using methods known in the art, including, but not limited to, those described in McCaffrey et al. (Nature 418:6893, 2002), Xia et al. (Nature Biotechnol 20:1006-1010, 2002), or Putnam (Am. J. Health Syst. Pharm. 53:151-160, 1996, as amended in Am. J. Health Syst. Pharm. 53:325, 1996).
[0197] In some embodiments, the multivalent polypeptides and multivalent antibodies of the subject matter of the present disclosure are prepared with carriers that protect the multivalent polypeptides and multivalent antibodies against rapid elimination from the body, such as controlled release formulations, e.g., implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Such formulations can be prepared using standard techniques, and these materials are also commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes that target infected cells with monoclonal antibodies against viral antigens) can also be used as pharma- ceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
[0198] As described in more detail below, the multivalent polypeptides and multivalent antibodies of the present disclosure may also be modified to achieve extended duration of action by PEGylation, acylation, Fc fusion, conjugation to molecules such as albumin, etc. In some embodiments, the multivalent polypeptides or multivalent antibodies can be further modified to extend their half-life in vivo and / or ex vivo. Non-limiting examples of known strategies and methods suitable for modifying multivalent polypeptides include (1) chemical modification of the multivalent polypeptides or multivalent antibodies described herein with highly soluble polymers such as polyethylene glycol ("PEG") that prevent the multivalent polypeptides or multivalent antibodies described herein from contacting proteases; and (2) covalently linking or conjugating the multivalent polypeptides or multivalent antibodies described herein to a stable protein, such as, for example, albumin. Thus, in some embodiments, the multivalent polypeptides or multivalent antibodies of the present disclosure can be fused to a stable protein, such as albumin. For example, human albumin is known to be one of the most effective proteins for increasing the stability of a polypeptide fused to it, and many such fusion proteins have been reported.
[0199] In some embodiments, the pharmaceutical compositions of the present disclosure include one or more pegylation reagents. As used herein, the term "pegylation" refers to modifying a protein by covalently attaching polyethylene glycol (PEG) to the protein, and "pegylated" refers to a protein to which PEG is attached. A variety of chemistries can be used to attach PEG, or a range of PEG derivatives, with any size ranging from about 10,000 daltons to about 40,000 daltons, to the recombinant polypeptides of the present disclosure. In some embodiments, the PEGylation reagent is selected from methoxypolyethyleneglycol-succinimidylpropionate (mPEG-SPA), mPEG-succinimidylbutyrate (mPEG-SBA), mPEG-succinimidylsuccinate (mPEG-SS), mPEG-succinimidylcarbonate (mPEG-SC), mPEG-succinimidylglutarate (mPEG-SG), mPEG-N-hydroxylsuccinimide (mPEG-NHS), mPEG-tosylate and mPEG-aldehyde. In some embodiments, the PEGylation reagent is polyethylene glycol. For example, the PEGylation reagent is polyethylene glycol with an average molecular weight of 20,000 daltons covalently attached to the N-terminal methionine residue of the multivalent polypeptide and multivalent antibody of the present disclosure.
[0200] Thus, in some embodiments, the multivalent polypeptides and multivalent antibodies of the present disclosure are chemically modified with one or more polyethylene glycol moieties, e.g., pegylation, or similar modifications, e.g., PASylation. In some embodiments, the PEG or PAS molecule is conjugated to one or more amino acid side chains of the multivalent polypeptide or antibody. In some embodiments, the PEGylated or PASylated multivalent polypeptide or antibody contains a PEG or PAS moiety at only one amino acid. In other embodiments, the PEGylated or PASylated multivalent polypeptide or antibody contains PEG or PAS moieties attached to two or more amino acids, e.g., 2 or more, 5 or more, 10 or more, 15 or more, or 20 or more different amino acid residues. In some embodiments, the PEG or PAS chains are 2000, more than 2000, 5000, more than 5000, 10,000, more than 10,000, 20,000, more than 20,000, and 30,000 Da (Daltons). A PASylated multivalent polypeptide or antibody can be directly conjugated to PEG or PAS (e.g., without a linking group) via amino, sulfhydryl, hydroxyl, or carboxyl groups. In some embodiments, a multivalent polypeptide or antibody of the present disclosure is covalently conjugated to polyethylene glycol having an average molecular weight of 20,000 daltons.
[0201] In some embodiments, the multivalent polypeptides or multivalent antibodies of the present disclosure can be further modified to extend their half-life in vivo and / or ex vivo. Non-limiting examples of known strategies and methodologies suitable for modifying the multivalent polypeptides or multivalent antibodies of the present disclosure include (1) chemical modification of the multivalent polypeptides or multivalent antibodies described herein with ultra-soluble polymers such as polyethylene glycol ("PEG"), which prevent the multivalent polypeptides or multivalent antibodies from contacting proteases; and (2) covalently linking or conjugating the multivalent polypeptides or multivalent antibodies described herein with a stable protein, such as, for example, albumin. Thus, in some embodiments, the multivalent polypeptides or multivalent antibodies of the present disclosure can be fused to a stable protein, such as albumin. For example, human albumin is known as one of the most effective proteins for increasing the stability of a polypeptide fused thereto, and many such fusion proteins have been reported. treatment
[0202] Administration of any one of the therapeutic compositions described herein, e.g., multivalent polypeptides, multivalent antibodies, nucleic acids, recombinant cells, cell cultures, and pharmaceutical compositions, can be used to treat related diseases, such as cancer and chronic infections. In some embodiments, the multivalent polypeptides, multivalent antibodies, nucleic acids, recombinant cells, cell cultures, and / or pharmaceutical compositions described herein can be incorporated into therapeutic agents used in methods of treating individuals who have, are suspected of having, or are at risk of developing one or more health disorders or autoimmune diseases associated with checkpoint inhibition. Exemplary autoimmune and health diseases include, but are not limited to, cancer and chronic infections.
[0203] Thus, in one aspect, some embodiments of the present disclosure relate to a method of modulating cell signaling mediated by a cell surface receptor that signals via a phosphorylation mechanism in a subject, comprising administering to the subject a first treatment comprising an effective amount of (i) a multivalent polypeptide of the present disclosure, or (ii) a multivalent antibody of the present disclosure. In another aspect, some embodiments of the present disclosure relate to a method of treating a health disorder in a subject in need of such treatment, comprising administering to the subject a first treatment comprising an effective amount of (i) a multivalent polypeptide of the present disclosure, or (ii) a multivalent antibody of the present disclosure.
[0204] A pharmaceutical composition is formulated to be compatible with its intended route of administration. The multivalent polypeptides and multivalent antibodies of the present disclosure may be administered orally or by inhalation, but they are more likely to be administered via parenteral routes. Examples of parenteral routes of administration include, for example, intravenous, intradermal, subcutaneous, transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral application may include the following components: a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates; and agents to adjust isotonicity such as sodium chloride or dextrose (glucose). The pH may be adjusted (e.g., to a pH of about 7.2 to 7.8, e.g., 7.5) using an acid or base such as monobasic and / or dibasic sodium phosphate, hydrochloric acid or sodium hydroxide. Parenteral preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[0205] Dosage, toxicity and therapeutic effect of such subject multivalent polypeptides and multivalent antibodies of the present disclosure can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example to determine LD50 (the dose lethal to 50% of the population) and ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the LD50 / ED50 ratio. Compounds that exhibit high therapeutic indices are generally suitable. It is also possible to use compounds that exhibit toxic side effects, but care must be taken to design a delivery system that targets such compounds to the site of the affected tissue in order to minimize potential damage to uninfected cells, thereby reducing side effects.
[0206] The data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosages of such compounds are generally sufficient to achieve ED with little or no toxicity. 50 The therapeutically effective dose of any compound used in the disclosed method can be estimated initially from cell culture assays. The IC 50 Doses can be formulated in animal models to achieve a circulating plasma concentration range that includes (e.g., the concentration of the test compound that achieves 50% maximal inhibition of symptoms). Such information can be used to more accurately determine useful doses in humans. Plasma levels can be measured, for example, by high performance liquid chromatography.
[0207] Therapeutic compositions, e.g., multivalent polypeptides, multivalent antibodies, nucleic acids, recombinant cells, cell cultures, and pharmaceutical compositions described herein, can be administered from once or several times per day to once or more times per week (including once every other day). One of skill in the art will appreciate that certain factors, including, but not limited to, severity of disease, previous treatments, general health and / or age of the subject, and other diseases present, can affect the dosage and timing required to effectively treat a subject. Furthermore, treatment of a subject with a therapeutically effective amount of the multivalent polypeptides and multivalent antibodies of the presently disclosed subject matter can include a single treatment or can include a series of treatments. In some embodiments, the composition is administered every 8 hours for 5 days, followed by a rest period of 2-14 days, e.g., 9 days, followed by every 8 hours for an additional 5 days. With respect to multivalent polypeptides or multivalent antibodies, the therapeutically effective amount (e.g., effective amount) of the multivalent polypeptides or multivalent antibodies of the present disclosure will depend on the multivalent polypeptide or multivalent antibody selected. For example, a single dose in the range of about 0.001 to 0.1 mg / kg of patient body weight can be administered, and in some embodiments, about 0.005, 0.01, or 0.05 mg / kg can be administered.
[0208] In one aspect, a method is provided for modulating cell signaling mediated by a cell surface receptor that signals through a phosphorylation mechanism in a subject. The method is performed by administering to the subject an effective amount of (i) a multivalent polypeptide disclosed herein, or (ii) a multivalent antibody disclosed herein. In another aspect, provided herein is a method for treating a disease in a subject in need of treatment. The method is performed by administering to the subject an effective amount of (i) a multivalent polypeptide disclosed herein, or (ii) a multivalent antibody disclosed herein.
[0209] As discussed above, a therapeutically effective amount includes an amount of a therapeutic composition that is sufficient to promote a particular effect when administered to a subject, such as a person with, suspected of, or at risk of a disease. In some embodiments, an effective amount includes an amount sufficient to prevent or delay the onset of a disease symptom, alter the course of a disease symptom (such as, but not limited to, slow the progression of a disease symptom), or reverse a disease symptom. It will be understood that in any particular case, the appropriate effective amount can be determined by one of ordinary skill in the art using routine experimentation.
[0210] The efficacy of a therapy, including the disclosed therapeutic compositions for the treatment of a disease, can be determined by a skilled clinician. However, a therapy is considered effective if at least one or all of the signs or symptoms of a disease are improved or alleviated. Efficacy can also be measured by the individual's condition not worsening (e.g., progression of a disease state is stopped or at least slowed) as assessed by the need for hospitalization or medical intervention. Methods for measuring such indicators are known to those skilled in the art and / or described herein. Treatment includes any treatment of a disease in an individual or animal (including, in some non-limiting examples, humans and mammals), including: (1) inhibiting the disease, e.g., stopping or slowing the progression of a condition; or (2) relieving the disease, e.g., causing regression of a condition; and (3) preventing or reducing the likelihood of developing a condition.
[0211] In some embodiments of the disclosed methods, the administered multivalent polypeptide or multivalent antibody recruits RPTP activity to the spatial vicinity of the cell surface receptor and initiates phosphatase activity that reduces the phosphorylation level of the cell surface receptor. In some embodiments, the administered multivalent polypeptide or multivalent antibody recruits the RPTP to the spatial vicinity of the cell surface receptor, e.g., the distance between the RPTP and the cell surface receptor is less than about 500 angstroms, e.g., about 5 angstroms to about 500 angstroms. In some embodiments, the spatial vicinity is less than about 5 angstroms, less than about 20 angstroms, less than about 50 angstroms, less than about 75 angstroms, less than about 100 angstroms, less than about 150 angstroms, less than about 250 angstroms, less than about 300 angstroms, less than about 350 angstroms, less than about 400 angstroms, less than about 450 angstroms, or less than about 500 angstroms. In some embodiments, the spatial vicinity is less than about 100 angstroms. In some embodiments, the spatial vicinity will be less than about 50 angstroms. In some embodiments, the spatial vicinity will be less than about 20 angstroms. In some embodiments, the spatial vicinity will be less than about 10 angstroms. In some embodiments, the spatial vicinity is in the range of about 10-100 angstroms, about 50-150 angstroms, about 100-200 angstroms, about 150-250 angstroms, about 200-300 angstroms, about 250-350 angstroms, about 300-400 angstroms, about 350-450 angstroms, or about 400-500 angstroms. In some embodiments, the administered multivalent polypeptide or multivalent antibody recruits the RITP into spatial vicinity such that the RPTP is about 10-100 angstroms from the cell surface receptor. In some embodiments, the spatial vicinity will be less than about 100 angstroms.In some embodiments, the distance between the RPTP and the cell surface receptor is less than about 250 angstroms, alternatively less than about 200 angstroms, alternatively less than about 150 angstroms, alternatively less than about 120 angstroms, alternatively less than about 100 angstroms, alternatively less than about 80 angstroms, alternatively less than about 70 angstroms, alternatively less than about 50 angstroms.
[0212] In some embodiments, RITP and the cell surface receptor are located in spatial proximity with respect to one another, and the phosphorylation level of the cell surface receptor can be reduced by at least or at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%, or within a range of any two of the preceding values, for example, about 20% to about 60% (including values between those percentages), compared to the phosphorylation level of the cell surface receptor in an untreated subject under similar conditions.
[0213] In some embodiments, administration of the multivalent polypeptide or multivalent antibody results in a decrease in immune checkpoint receptor activity in the subject. The decrease in immune checkpoint receptor activity can be at least or at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%, or a range between any two of the preceding values, such as about 20% to about 60% (including values between those percentages), compared to the activity of the immune checkpoint receptor in an untreated subject under similar conditions.
[0214] In some embodiments of the disclosed methods, administration of the multivalent polypeptide or multivalent antibody confers enhanced T cell activity in the subject. T cell activity can be enhanced by at least or at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%, or a range of any two of the preceding values, such as about 20% to about 60%, including any values between those percentages, compared to T cell activity in an untreated subject under similar conditions. In some embodiments, enhanced T cell activity is determined by increased upregulation of CD69 and / or CD25 in activated T cells. In some embodiments, enhanced T cell activity is determined by increased IL-2 secretion in activated T cells. In some embodiments, enhanced T cell activity is determined by increased production of activated T cells.
[0215] In some embodiments of the method of the present disclosure, the subject is a mammal. In some embodiments, the mammal is a human. In some embodiments, the subject has or is suspected of having a disease associated with inhibition of cell signaling mediated by cell surface receptors. Diseases suitable for treatment by the compositions and methods of the present disclosure include, but are not limited to, cancer, autoimmune disease, inflammatory disease, and infectious disease. In some embodiments, the disease is cancer or chronic infectious disease.
[0216] As discussed above, any of the multivalent polypeptides, multivalent antibodies, nucleic acids, recombinant cells, cell cultures and / or pharmaceutical compositions of the present disclosure can be administered in combination with one or more additional therapeutic agents, such as chemotherapeutic or anti-cancer agents or anti-cancer therapies. Administering "in combination" with one or more additional therapeutic agents includes simultaneous (concurrent) and sequential administration in any order. In some embodiments, the one or more additional therapeutic agents, chemotherapeutic agents, anti-cancer agents, or anti-cancer therapies are selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, hormonal therapy, toxin therapy, and surgery. "Chemotherapy" and "anti-cancer agents" are used interchangeably herein. Various classes of anti-cancer agents can be used. Non-limiting examples include alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, podophyllotoxins, antibodies (e.g., monoclonal or polyclonal), tyrosine kinase inhibitors (e.g., imatinib mesylate (Gleevec® or Glivec®)), hormonal therapeutic agents, soluble receptors, and other anti-tumor agents.
[0217] Topoisomerase inhibitors are another class of anticancer agents that can be used herein. Topoisomerases are essential enzymes that maintain DNA topology. Inhibition of type I or type II topoisomerases disrupts both DNA transcription and replication by disrupting proper DNA supercoiling. Some type I topoisomerase inhibitors include camptothecin, irinotecan, and topotecan. Examples of type II inhibitors include amsacrine, etoposide, etoposide phosphate, and teniposide, which are semisynthetic derivatives of epipodophyllotoxin, an alkaloid that occurs naturally in the roots of American hawkweed (Podophyllum peltatum).
[0218] Antitumor drugs include the immunosuppressants dactinomycin, doxorubicin, epirubicin, bleomycin, mechlorethamine, cyclophosphamide, chlorambucil, and ifosfamide. Antitumor compounds generally function by chemically modifying the DNA of cells.
[0219] Alkylating agents are capable of alkylating a number of nucleophilic functional groups under conditions present within cells. Cisplatin, carboplatin, and oxaliplatin are alkylating agents. They impair cell function by forming covalent bonds with amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules.
[0220] Vinca alkaloids bind to specific sites on tubulin and inhibit the assembly of tubulin into microtubules (M phase of the cell cycle). Vinca alkaloids include vincristine, vinblastine, vinorelbine, and vindesine.
[0221] Antimetabolites mimic purines (azathioprine, mercaptopurine) or pyrimidines and prevent these substances from being incorporated into DNA during the "S" phase of the cell cycle, halting normal development and division. Antimetabolites also affect RNA synthesis.
[0222] Plant alkaloids and terpenoids are derived from plants and block cell division by preventing microtubule function. Microtubules are essential for cell division, so without them cell division cannot occur. Prime examples are the vinca alkaloids and taxanes. Podophyllotoxins are plant-derived compounds that are reported to aid in digestion as well as be used to produce two other cytostatic drugs, etoposide and teniposide. They prevent cells from entering the G1 phase (the initiation of DNA replication) and replicating DNA (S phase).
[0223] The taxanes as a group include paclitaxel and docetaxel. Paclitaxel is a natural product, originally known as taxol, which was first derived from the bark of the Pacific yew tree. Docetaxel is a semisynthetic analogue of paclitaxel. Taxanes increase microtubule stability and prevent chromosome segregation during anaphase of meiosis.
[0224] In some embodiments, the anticancer drug is Remicade™, docetaxel, celecoxib, melphalan, dexamethasone (Decadron®), steroids, gemcitabine, cisplatin, temozolomide, etoposide, cyclophosphamide, temodar, carboplatin, procarbazine, Gliadel, tamoxifen, topotecan, methotrexate, gefitinib (Iressa®), taxol, taxotere, fluorouracil, leucovorin, irinotecan, Xeloda, CPT-11, interferon alpha, pegylated interferon alpha (e.g., PEG-10 ... In some embodiments, the therapeutic agent may be selected from the group consisting of INTRON-A), capecitabine, cisplatin, thiotepa, fludarabine, carboplatin, liposomal daunorubicin, cytarabine, docetaxel (docetaxel), paclitaxel, vinblastine, IL-2, GM-CSF, dacarbazine, vinorelbine, zoledronic acid, palmitronate, biaxin, busulfan, prednisone, bortezomib (Velcade®), bisphosphonates, arsenic trioxide, vincristine, doxorubicin (Doxil®), paclitaxel, ganciclovir, adriamycin, estramustine sodium phosphate (Emcyt®), sulindac, etoposide, and any combination thereof.
[0225] In other embodiments, the anti-cancer agent can be selected from bortezomib, cyclophosphamide, dexamethasone, doxorubicin, interferon alpha, lenalidomide, melphalan, pegylated interferon alpha, prednisone, thalidomide, or vincristine.
[0226] In some embodiments, the methods of treatment described herein further comprise immunotherapy. In some embodiments, the immunotherapy comprises administration of one or more checkpoint inhibitors. Thus, some embodiments of the methods of treatment described herein further comprise administration of a compound that inhibits one or more immune checkpoint molecules. In some embodiments, the compound that inhibits one or more immune checkpoint molecules comprises an antagonist antibody. In some embodiments, the antagonist antibody is ipilimumab, nivolumab, pembrolizumab, durvalumab, atezolizumab, tremelimumab, or avelumab.
[0227] In some aspects, the one or more anti-cancer therapies include radiation therapy. In some embodiments, radiation therapy may include administration of radiation to kill cancer cells. Radiation interacts with molecules within the cell, such as DNA, inducing cell death. Radiation can damage cell membranes, nuclear membranes, and other organelles. Depending on the type of radiation, the mechanism of DNA damage may differ just as much as the relative biological effectiveness. For example, heavier particles (i.e., protons, neutrons) directly damage DNA, with heavier particles having greater relative biological effectiveness. Electromagnetic radiation results in indirect ionization, acting primarily through short-lived hydroxyl free radicals that are generated by ionization of cellular water. Clinical applications of radiation consist of external beam radiation (from an external source) and brachytherapy (using a radiation source implanted or inserted into the patient). External beam radiation consists of x-rays and / or gamma rays, while brachytherapy uses radionuclides that decay and emit beta particles along with alpha particles or gamma rays. Radiation as contemplated herein includes, for example, the direct delivery of radioisotopes to cancer cells. Other forms of DNA damaging agents, such as microwave and UV radiation, are also contemplated herein.
[0228] Radiation can be administered in a single dose or in a series of smaller doses in a dose fractionation schedule. The amount of radiation contemplated herein ranges from about 1 to 100 Gy (gray), e.g., about 5 to about 80 Gy, about 10 to about 50 Gy, or about 10 Gy. The total dose can be administered in a fractionation regimen. For example, the regimen can include fractionated individual doses of 2 Gy. Dose ranges for radioisotopes vary widely and depend on the half-life of the isotope and the strength and type of radiation emitted. When radiation involves the use of a radioisotope, the isotope can be attached to a targeting agent, such as a therapeutic antibody, which carries the radionucleotide to a target tissue (e.g., tumor tissue).
[0229] The surgical procedures described herein include resection, in which all or part of cancerous tissue is physically removed, excised and / or destroyed. Tumor resection refers to physically removing at least part of a tumor. In addition to tumor resection, surgical treatment includes laser surgery, cryosurgery, electrosurgery, and microsurgery (Mohs surgery). Removal of pre-cancerous or normal tissue is also considered herein.
[0230] Thus, in some embodiments, the therapeutic method of the present disclosure further comprises administering a second (secondary) therapy to the subject. In general, the second therapy can be any therapy known in the art. Non-limiting examples of suitable therapies for use in combination with the therapeutic compositions disclosed herein include chemotherapy, radiation therapy, immunotherapy, hormonal therapy, toxin therapy, and surgery. In some embodiments, the second therapy comprises one or more additional therapeutic agents, such as, for example, a chemotherapeutic agent or an anti-cancer agent or an anti-cancer therapy as described above. In some embodiments, the first therapy and the second therapy are administered simultaneously. In some embodiments, the first therapy is administered simultaneously with the second therapy. In some embodiments, the first therapy and the second therapy are administered sequentially. In some embodiments, the first therapy is administered before the second therapy. In some embodiments, the first therapy is administered after the second therapy. In some embodiments, the first therapy is administered before and / or after the second therapy. In some embodiments, the first therapy and the second therapy are administered in alternation. In some embodiments, the first therapeutic agent and the second therapeutic agent are administered together in a single formulation. System or Kit
[0231] The systems or kits of the present disclosure include any one or more of the polypeptides, antibodies, nucleic acids, vectors, or pharmaceutical compositions disclosed herein, as well as syringes (including pre-filled syringes) and / or catheters (including pre-filled syringes) used to administer any of the multivalent polypeptides, multivalent antibodies, nucleic acids, vectors, or pharmaceutical compositions to an individual. The kits also include written instructions for using any of the multivalent polypeptides, multivalent antibodies, nucleic acids, vectors, or pharmaceutical compositions disclosed herein, as well as the syringes and / or catheters used in administering them.
[0232] Every maximum numerical limitation given throughout this specification is intended to include every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within a broader numerical range, as if such narrower numerical ranges were all expressly written herein.
[0233] All publications and patent applications mentioned in this disclosure are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0234] No reference cited herein is admitted to constitute prior art. The discussion of the references states what their authors assert, and the inventors reserve the right to challenge the accuracy and pertinence of the cited documents. It will be clearly understood that many sources of information are referenced herein, including scientific journal articles, patent documents, textbooks, and the like. This reference does not constitute an admission that any of those documents forms part of the general knowledge in the art.
[0235] The discussion of general methods provided herein is intended for illustrative purposes only: other alternative methods and substitutes will be apparent to those of skill in the art upon review of this disclosure, and are to be included within the spirit and scope of this application.
[0236] Additional embodiments are disclosed in further detail in the following examples, which are provided for illustrative purposes only and are not intended to limit the scope of the disclosure and claims in any way. Example 1
[0237] This example describes experiments performed to demonstrate that cell surface receptor signaling can be modulated by local phosphatase recruitment in accordance with some embodiments of the present disclosure.
[0238] As shown in Figure 2, cell surface receptors such as PD-1 and checkpoint receptors present on the cell membrane undergo low basal levels of phosphorylation in the absence of ligand and in resting states (top left panel of Figure 2). Binding to cognate ligands increases phosphorylation and enhances signaling to inhibit T cell activation (top right panel of Figure 2). As an example, PD-1 blocking antibodies, "checkpoint inhibitors," confer receptor / ligand interactions to enhance T cell activation, but basal receptor signaling is unaffected, and thus enhancement of T cell activation by checkpoint Ab blockade is limited in its efficacy. In the present invention, bispecific diabodies that recruit CD45 phosphatase to the spatial vicinity of a receptor of interest are expected to reduce phosphorylation of PD-1 in both resting and ligand-activated states (bottom panel of Figure 2). Generation of bispecific diabodies targeting human CD45 and PD-1
[0239] A bispecific antibody targeting human CD45 and PD-1 was generated, the amino acid sequence of which comprises, from N-terminus to C-terminus, (i) a heavy chain variable region of an scFv specific for CD45, (ii) a light chain variable region of an scFv specific for the cell surface receptor PD-1, (iii) a heavy chain variable region of an scFv specific for the cell surface receptor PD-1; and a light chain variable region of an scFv specific for CD45. The amino acid sequence of the antibody is disclosed in SEQ ID NO: 2 in the Sequence Listing.
[0240] As shown in Figures 3A-3C, the bispecific diabody CD45 / PD-1 prepared as described above was demonstrated to bind to HEK293 cells transfected with CD45 (Figure 3A), PD-1 (Figure 3B), or both molecules (Figure 3C). In these experiments, approximately 1 million HEK293 cells were transfected with 1 μg of CD45 RA, PD-1, or both. Approximately 24 hours after transfection, cells were harvested and stained with CD45 / PD-1 bispecific diabody pre-labeled with Alexa Fluor® 647 fluorescent dye for 45 min on ice at the indicated concentrations according to the manufacturer's protocol (Thermo Fisher Scientific, Sunnyvale, USA). Untransfected HEK293 cells were stained at the indicated concentrations (grey lines). Quantification of surface staining was performed by FACS (CytoFLEX, Beckman Coulter, Indianapolis, USA). Representative data are shown as mean ± SD, n=3.
[0241] Another set of experiments was performed to demonstrate that the bispecific diabody CD45 / PD-1 described above can bind to the extracellular domains of human CD45 and human PD-1. In these experiments, an anti-human RIPR-PD1 multivalent antibody, αCD45-PD1(Nivo), was designed and generated. In this antibody, the bispecific module consisted of an anti-CD45 scFv operably linked to an anti-PD-1 scFv corresponding to the nivolumab sequence. The bispecific diabody CD45 / PD-1 was purified by size exclusion (AKTA FPLC, GE Healthcare, Superdex 200 Increase; absorbance at 280 nm). In addition, the protein integrity and purity of the bispecific diabody CD45 / PD1 were confirmed by non-reducing SDS-PAGE electrophoresis followed by standard Coomassie staining (data not shown). Surface plasmon resonance (SPR) technology was used to measure αCD45-PD1(Nivo) binding to the extracellular domains of human CD45 and human PD-1. Here, the affinity for CD45 (K D) was found to be approximately 300 nM, and the affinity for PD-1 was found to be approximately 6 nM.
[0242] Another exemplary multivalent antibody capable of binding to the phosphatase CD45 and the cell surface receptor PD-1 has been generated according to some embodiments of the present disclosure. The amino acid sequence of this multivalent polypeptide comprises, from N-terminus to C-terminus, (i) a heavy chain variable region of an scFv specific for CD45, (ii) a light chain variable region of an scFv specific for PD-1, (iii) a heavy chain variable region of an scFv specific for PD-1, and (iv) a light chain variable region of an scFv specific for CD45. The amino acid sequence of the multivalent antibody is disclosed in SEQ ID NO: 12 of the Sequence Listing. Example 2
[0243] This example describes experiments performed to demonstrate that PD-1 expression reduces T cell activation even in the absence of PD-1 ligand.
[0244] In these experiments, Jurkat T cells were lentivirally transduced with full-length wild-type PD-1, and surface expression of PD-1 was measured by FACS using an anti-PD-1 antibody (clone EH12.2H7, Biolegend). Approximately 56% of Jurkat T cells transduced with full-length wild-type PD-1 were found to present PD-1 on the cell surface. Jurkat T cells expressing PD-1 at a cell density of approximately 1 million / mL (Jurkat-PD1) were activated overnight with 2 μg / mL immobilized muromonab-CD3 (Orthoclone OKT3) in 96-well plates. As shown in Figure 4A, upregulation of CD25 and CD69 (Biolegend) elicited by overnight incubation with OKT3 was found to be low for cells expressing PD-1. As shown in Figure 4B, decreased PD-1 expression in cells treated with CRISPR / Cas9 PD-1 targeting guide RNA was observed, leading to higher CD69 expression upon activation with OKT3.
[0245] In these experiments, a DNA sequence targeting the human PD-1 sequence (5'- CACCGCGACTGGCCAGGGCGCCTGT- 3'; SEQ ID NO:8) was cloned into a CRISPR / Cas9 lentiviral delivery backbone (Addgene, plasmid #52961). Jurkat T cells were transduced with PD-1 / CRISPR / Cas9 7 days prior to OKT3 stimulation assay. Representative data are shown as mean ± SEM, n=3. Example 3
[0246] This example describes experiments performed to demonstrate the reconstitution of PD-1 phosphorylation by incubation with the lymphocyte-specific protein tyrosine kinase Lck and / or CD45 in HEK293 cells in the presence or absence of the CD45-PD1 bispecific diabody (see FIG. 5A).
[0247] As shown in Figure 5B, the cell surface receptor PD-1 was not phosphorylated in wild-type HEK293 cells (lane 1). However, phosphorylation of PD-1 was readily observed when Lck was also present (lane 2). Co-expression of CD45 was observed to reduce total phosphorylation (lane 3). A reduction in PD-1 phosphorylation was observed upon incubation with the CD45-PD1 bispecific diabody (Db). In these experiments, nearly 2 million cells were transiently transfected with genes encoding full-length human PD-1, Lck, and CD45. After 24 hours, cells were either left untreated or incubated with the multivalent antibody CD45-PD1 generated as described in Example 1 above for approximately 15 minutes at room temperature, after which the cells were lysed for 30 minutes on ice with lysis buffer (20 mM HEPES, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 2× Complete protease inhibitor cocktail (Roche), 2 mM sodium orthovanadate (NEB), 1× phosphatase inhibitor cocktail (Cell Signaling Technology), 1× DNase (NEB), 1% NP-40). After solubilization, cell lysates were pre-cleared by centrifugation at 21,000×g for 30 minutes at 4° C. PD-1 was then immunoprecipitated (IP) from cell lysates using biotinylated anti-PD-1 antibody (Biolegend, Cat. No. 367418) coupled to streptavidin-conjugated Dynabeads® (Thermo Fisher Scientific) for 1 h on ice. After washing four times with wash buffer (20 mM HEPES, 150 mM NaCl, 1% NP-40, 2× Complete protease inhibitor cocktail (Roche), 2 mM sodium orthovanadate, and 1× phosphatase inhibitor cocktail), the beads were incubated with non-reducing SDS sample buffer and heated at 95°C for 5 min.After electrophoresis using SDS-PAGE, IP samples were transferred to PVDF membranes (Bio-Rad) and incubated with anti-Tyr phosphorylation (upper panel; Cell Signaling; P-Tyr-100, cat. no. 9411S) or anti-PD-1 (lower panel; Biolegend, cat. no. 367402) antibodies for Western blotting assays (WB) as per the manufacturer's instructions. Example 4
[0248] This example describes experiments performed to demonstrate the reconstitution of multiple receptor phosphorylation by incubation with lymphocyte-specific protein tyrosine kinase Lck and / or CD45 in HEK293 cells. Because CD45 is a highly abundant phosphatase present in all lymphocytes, the experimental results described in this example demonstrate that recruitment of CD45 can be used to dephosphorylate a number of different receptors involved in a variety of cellular functions.
[0249] In these experiments, we observed that CD45 can dephosphorylate multiple targets, suggesting that CD45 activation is not specific to a particular target. TIGIT, CTLA-4, CD132, CD5, and to a lesser extent CD28 and TIM-3, were all found to be dephosphorylated by CD45. As shown in Figure 6A, the cell surface receptors TIGIT, CTLA4, CD28, TIM3, CD132, CD5, and B7H3 were essentially unphosphorylated in wild-type HEK293 cells. Receptor phosphorylation was readily observed when Lck was also present, with the exception of B7H3, which does not contain any signaling tyrosine residues (Figure 6A). As shown in Figure 6B, we observed that co-expression of CD45 reduced phosphorylation of all receptors tested, indicating that CD45 activity is not specific to a particular target. In these experiments, nearly 2 million cells were transiently transfected with genes encoding the intracellular domains of the human receptors Lck and CD45. After 24 hours, cells were lysed with lysis buffer (20 mM HEPES, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 2x Complete protease inhibitor cocktail (Roche), 2 mM sodium orthovanadate (NEB), 1x phosphatase inhibitor cocktail (Cell Signaling Technology), 1x DNase (NEB), 1% NP-40) for 30 minutes on ice. After solubilization, cell lysates were pre-cleared by centrifugation at 21,000xg for 30 minutes at 4°C. PD-1 was then immunoprecipitated (IP) from cell lysates using anti-HA magnetic beads for 1 hour on ice. After washing four times with wash buffer (20 mM HEPES, 150 mM NaCl, 1% NP-40, 2x Complete protease inhibitor cocktail (Roche), 2 mM sodium orthovanadate and 1x phosphatase inhibitor cocktail), the beads were incubated with non-reducing SDS sample buffer and heated at 95°C for 5 min.After electrophoresis using SDS-PAGE, IP samples were transferred to PVDF membranes (Bio-Rad) and incubated with anti-Tyr phosphorylation antibody (upper panel; Cell Signaling; P-Tyr-100, cat. no. 9411S) or anti-PD-1 antibody (lower panel; Biolegend, cat. no. 367402) for Western blotting assay (WB) as per the manufacturer's instructions. Example 5
[0250] This example describes experiments performed to demonstrate that treatment of T cells with the CD45-PD1 bispecific diabody increases T cell activation in response to muromonab-CD3 (OKT3) and peptide-MHC stimulation.
[0251] In this experiment, Jurkat T cells expressing PD-1 as described in Example 1 above were stimulated with plate-bound OKT3 (2 μg / ml) alone (black diamonds) or with nivolumab antibody (open squares) or CD45-PD1 (Nivo) diabody (black circles). We observed that the bispecific diabody CD45-PD1 increased expression of activation markers CD69 (Figure 7A) and CD25 (Figures 7B-7C), as well as high levels of IL-2 cytokine secretion (Figure 7D). Surface expression CD69 and CD25 were measured by FACS staining 16 hours after OKT3 stimulation. IL-2 concentrations were quantified by ELISA (Cat. No. 431804, Biolegend) after Jurkat T cell stimulation with OKT3 (2 μg / mL) in the presence of nivolumab antibody (open squares) or CD45-PD1 (Nivo) diabody (black circles). Similar experiments were performed with a different T cell line, SKW-3 T cells (catalog no. ACC 53; DSMZ, Leibniz, Germany). As shown in Figures 7E-7F, SKW-3 T cells transduced with the appropriate T cell receptor (TCR) and PD-1 were incubated with cells presenting agonist peptide-MHC±PD-L1 for 48 h (PD-L1-, closed diamonds; PD-L1+, open circles) in the presence of nivolumab antibody (open squares) or CD45-PD1 (Nivo) diabody (closed circles). Antigen-presenting cells were incubated with 10 μM agonist peptide for 1 h at 37°C and then incubated with SKW-3 T cells. Surface expression of TCR, PD-1, MHC and PD-L1 was confirmed by FACS. Incubation with the bispecific diabody CD45-PD1, described in Example 1 above, was found to increase IL-2 cytokine secretion to levels similar to those achieved in the absence of PD-1. Representative data are shown as mean±SEM, n=3 in Figures 7A-7F. Example 6
[0252] This example describes experiments performed to demonstrate that bispecific CD45-PD1 diabodies can enhance proliferation of activated peripheral blood mononuclear cells (PBMCs).
[0253] In these experiments, activated PBMC cells from healthy donors were isolated from leukapheresis chambers using standard Ficoll separation. PBMCs were placed overnight in complete RPMI (10% FBS, 1x1 Glutamax, 1x sodium pyruvate, 1x HEPES, and 1x Pen / Strep) prior to the experiment. PBMCs at a density of approximately 1 million / ml were labeled with 1 μM CFSE for 10 minutes at room temperature and incubated for 4 days with 1 μg / mL plate-bound OKT3 and the commercially available PD-1 antibody Nivolumab or the bispecific CD45-PD1 diabody described in Example 1 above. Data shown were gated on viable T cells (CD3+ / CD4+ / CD8+) as measured by FACS staining. As shown in Figure 8A, it was observed that CD45-PD1 enhanced T cell proliferation to a higher level than Nivolumab antibody.
[0254] In these experiments, CD45-PD1 and nivolumab were added at a final concentration of 0.5 μM. In addition, quantification of T cell proliferation (%) for cells treated with OKT3 alone or OKT3 in combination with nivolumab or CD45-PD1 was also performed by FACS (Figure 8B). Representative data are shown as mean ± SEM (n=3). Example 7
[0255] This example describes further experiments performed with activated PBMCs to show that the bispecific diabody CD45-PD1 can enhance CD4+ and CD8+ T cell activation in response to agonist peptides and that RIPR-PD1 is not strictly dependent on blocking the PD-1 / PD-L1 interaction.
[0256] PD-1 is known to reduce T-cell activity (also known as a "checkpoint inhibitor"). To do so, PD-1 must be phosphorylated by an unknown mechanism, which is speculated to be entirely dependent on binding to PD-1. We hypothesized that there are two components that contribute to PD-1 signaling: 1) ligand binding and 2) tonic signaling (i.e., PD-1 or any other receptor is expected to have a low but functionally relevant phosphorylation level even before ligand binding). Previously, many efforts have been made to control ligand binding, including the development of blocking antibodies such as nivolumab and pembrolizumab. However, the contribution of tonic signaling has been largely overlooked. Without being bound to any particular theory, recruitment of the phosphatase CD45 to PD-1 is expected to reduce PD-1 phosphorylation and thus both tonic signaling and ligand-induced PD-1 signaling. The consequence of reduced PD-1 activity was expected to be enhanced T-cell activation. In this example, we show that treatment of freshly isolated lymphocytes with nivolumab and pembrolizumab antibodies, which block PD-1 binding to PD-L1, enhances the expression or secretion of various activation markers, including CD69, CD25, and secreted cytokines (e.g., IL-2 and IFNγ). Furthermore, we show that treating these cells with RIPR, using the nivolumab or pembrolizumab arms to bind PD-1, induces even higher levels of activation.
[0257] In these experiments, PBMCs isolated as described in Example 7 above were activated by incubation with a peptide pool consisting of 176 peptides (JPT, PM-CEFX-1) at 50 μM (final concentration) for 24 hours, followed by addition of various antibodies or diabodies at 0.5 μM (final concentration). Tables 1 and 2 provide an overview and brief description of the diabody targets and compositions. The multivalent antibodies CD45-PD1 (Nivo) and CD45-PD-1 (Pembro) are listed in SEQ ID NO: 12 and SEQ ID NO: 14 in the Sequence Listing (see also Table 1).
[0258] After 24 hours of antibody or diabody treatment, treated cells and supernatants were harvested. It was observed that both CD45-PD1 (Nivo) and CD45-PD1 (Pembro) could enhance T cell activation as determined by increased expression levels of CD69 (Figure 9A) and CD25 (Figure 9B) as measured by FACS (CytoFLEX), as well as enhanced secretion of IFNγ (Figure 9D) and the cytokine IL-2 (Figure 9C) as determined by ELISA (IL-2 was quantified using Cat. No. 431804, Biolegend, and IFNγ was quantified using Cat. No. 430104, Biolegend, as per the manufacturer's instructions). Data shown for CD69 was gated on viable CD3+ / CD4+ / CD8+ cells. Summarized in Figure 9E, T cells were stained with fluorescently labeled anti-PD1 blocking antibody clone EH12.2H7 (Biolegend, Cat. No. 329904) after treatment with nivolumab, pembrolizumab, or CD45-PD1 (Nivo) and CD45-PD1 (Pembro). Clone EH12.2H7, nivolumab, and pembrolizumab have overlapping epitopes, and thus the fluorescence intensity (PD-1 MFI) from clone EH12.2H7 labeling was reduced after nivolumab or pembrolizumab treatment. RIPR-Nivo and RIPR-Pembro molecules attenuated clone EH12.2H7 labeling to a similar extent, thus indicating that RIPR-Nivo and RIPR-Pembro maintained the PD-1 binding properties of nivolumab and pembrolizumab, respectively.
[0259] [Table 3]
[0260] Example 8
[0261] This example describes another set of experiments performed to demonstrate that the bispecific diabody CD45-PD1(Cl19), linked to PD-1 using a non-blocking scFv, can promote T cell activation in response to an agonist peptide.
[0262] In this experiment, PBMCs isolated as described in Example 7 above were first activated by incubation with a peptide pool consisting of 176 peptides (JPT, PM-CEFX-1) at 50 μM (final concentration) for 24 hours, followed by addition of various antibodies or diabodies at 0.5 μM (final concentration). Treated cells and supernatants were harvested 24 hours after antibody or diabody treatment. It was observed that CD45-PD1 (Cl19) could enhance T cell activation as measured by increased expression levels of CD69 (Figure 10A), as well as IFNγ secretion as measured by ELISA (Figure 10B) (IFNγ was quantified using Biolegend catalog number 430104 as per the manufacturer's instructions).
[0263] Data shown for CD69 and CD25 were gated on viable CD3+ / CD4+ / CD8+ cells. Summarized in Figure 10C is a competition experiment in which T cells were stained with a fluorescently labeled anti-PD1 blocking antibody, clone EH12.2H7 (Biolegend, Cat. No. 329904), after treatment with nivolumab, pembrolizumab, or CD45-PD1 (Cl19). Clone EH12.2H7, nivolumab, and pembrolizumab have overlapping epitopes, and therefore the fluorescence intensity (PD-1 MFI) from clone EH12.2H7 labeling was lower when cells were treated with nivolumab or pembrolizumab. CD45-PD1(Cl19) was observed to be less effective at labeling clone EH12.2H7 (higher fluorescence, PD1 MFI), suggesting that the CD45-PD1(Cl19) epitope is distinct from that of nivolumab or pembrolizumab.
[0264] The experiments described in this example show that hRIPR-PD1 molecules using anti-PD-1 binding units that do not completely block PD-1 binding to PD-L1 also promote T cell activation. Without being bound to any particular theory, hRIPR-PD1 molecules are expected to attenuate PD-1 signaling because they directly target PD-1 phosphorylation, and therefore are expected to enhance T cell activation even in the absence of PD-1 / PD-L1 blockade. It was observed that αCD45-PD1(Cl19) appears to be weaker than nivolumab but more potent than pembrolizumab in enhancing T cell activation. Example 9
[0265] This example describes experiments conducted to develop a third hRIPR-PD1 molecule with a different structure, due to the use of a nanobody (single heavy chain) fused to an scFv. As described in more detail below, this new RIPR molecule (second generation) increases purification yields and maintains binding to PD-1 and CD45, as measured by surface plasmon resonance (SPR).
[0266] The second generation bispecific RIPR-PD1 molecule described in this example used the same anti-CD45 scFv as described in the previous example, but now fused to the nanobody (VHH) anti-human PD-1 (described in US Patent Application US20170137517A1). Thus, it was predicted that this novel αCD45-PD1 (VHH) bispecific molecule would bind human CD45 and human PD-1.
[0267] The second generation anti-human RIPR-PD1 (anti-CD45 / anti-PD1) bispecific molecule consisting of an anti-CD45 scFv coupled to an anti-PD1 nanobody (VHH) was purified by size exclusion (AKTA FPLC, GE Healthcare, Superdex 200 Increase; absorbance at 280 nm). Protein integrity and purity were confirmed by non-reducing SDS-PAGE electrophoresis followed by standard Coomassie staining (data not shown). It was observed that this CD45-PD1 (VHH) was able to bind to the extracellular domains of human CD45 and human PD-1 proteins as measured by surface plasmon resonance technology (data not shown). The affinity of CD45 (K D ) was found to be approximately 700 nM, with an affinity for PD-1 of approximately 5 nM. Example 10
[0268] This example describes experiments performed to show that treatment of T cells with a second generation CD45-PD1 (VHH) bispecific binding module as described in Example 9 above can increase T cell activation in response to muromonab-CD3 (OKT3).
[0269] In these experiments, Jurkatt T cells were stimulated with plate-bound OKT3 at various concentrations (0.625-5 μg / mL) in the absence or presence of 1.5 μM nivolumab (black diamond), CD45-PD1(Nivo) (black circle), CD45-PD1(VHH) (open circle), and anti-CD45 diabody #4 (black triangle). It was observed that the bispecific diabodies CD45-PD1(Nivo) and CD45-PD1(VHH) increased the expression of activation markers CD69 (Figure 11A) and CD25 (Figure 11B), resulting in a higher fraction of CD69+ / CD25+ cells (Figure 11C). Surface expression CD69 and CD25 were determined by FACS staining 24 hours after OKT3 stimulation. Example 11
[0270] This example describes experiments designed to develop a RIPR-PD1 molecule that targets mouse CD45 and mouse PD-1.
[0271] The mouse RIPR was constructed and composed of a nanobody (VHH) sequence targeting mouse CD45 directly fused to an scFv recognizing mouse PD-1 (PD-1 scFv; PD1-F2, previously described in WO2004056875A1). The recombinant mRIPR was constructed and composed of a nanobody (VHH) sequence targeting mouse CD45 directly fused to an scFv recognizing mouse PD-1 (PD-1 scFv; PD1-F2, previously described in WO2004056875A1). TM mRIPR was produced using a baculovirus-insect cell expression system in ELISA (ELISA Kit) cells. After Ni-NTA purification, mRIPR exhibited a monomeric form and a monodisperse elution profile upon size-exclusion chromatography using absorbance at 280 nm (data not shown). Purity of mRIPR was confirmed by non-reducing SDS-PAGE electrophoresis followed by standard Coomassie staining that matched the peak fraction SEC elution (data not shown). Example 12
[0272] This example describes experiments performed to show that treatment of mouse T cells with an anti-mouse CD45 (VHH)-PD1F2 bispecific binding module increases T cell activation in response to anti-mouse CD3 (2C11).
[0273] In these experiments, CD8+ T cells isolated from C57BL / 6 mice were stimulated with plate-bound 2C11 at various concentrations (1-10 μg / mL) in the absence (untreated; black diamonds) or presence of the CD45(VHH)-PD1F2 bispecific binding module described in Example 11 above. The bispecific diabody CD45(VHH)-PD1F2 was observed to increase the expression of activation markers CD69 (Figure 12A) and CD25 (Figure 12B). In these experiments, surface expression of CD69 and CD25 was determined by FACS staining 16 hours after 2C11 stimulation. The results of the FACS analysis are summarized in Table 4 below, showing the percentage of double positive cells (CD69+ CD25+) in each cohort.
[0274] [Table 4]
[0275] Example 13 This example describes experiments performed to demonstrate that treatment of mouse TCR transgenic (Pmel-1) CD8+ T cells with an anti-mouse CD45 (VHH)-PD1 (F2) bispecific binding module increases T cell activation in response to gp100 peptide.
[0276] In these experiments, murine CD8+ T cells expressing Pmel-1 TCR were incubated with whole splenocytes at a 1:1 ratio and stimulated with gp100 peptide (0.1-10 μM) in the absence (naive) or presence of C45(VHH)-PD1(F2) or with 1 μM of an anti-PD-1 blocking antibody. We observed that the bispecific CD45(VHH)-PD1F2 binding molecule increased the expression of activation markers CD69 (Figure 13A) and CD25 (Figure 13B). Surface expression of CD69 and CD25 was measured by FACS staining 24 hours after gp100 peptide stimulation. The results of the FACS analysis are summarized in Table 5 below. In the table, the percentage of double positive cells (CD69+ CD25+) in each cohort is shown.
[0277] [Table 5]
[0278] Example 14
[0279] This example describes experiments performed to demonstrate that treatment of mouse T cells with the anti-mouse CD45(VHH)-CTLA4 bispecific binding module, mRIPR-CTLA4, increases T cell activation.
[0280] Like PD-1, CTLA-4 reduces T cell activity. We have developed a RIPR molecule that recruits CD45 to CTLA4. As with PD-1, recruitment of CD45 activity is expected to reduce CTLA-4 phosphorylation, and since CTLA-4 is an inhibitor of T cell activity, RIPR-CTLA4 is expected to enhance T cell function.
[0281] In these experiments, T cells isolated from C57BL / 6 mice were stimulated with plate-bound 2C11 at 1 μg / ml in the absence or presence of mRIPR-CTLA4 at 250 nM or 1 μM. It was observed that mRIPR-CTLA4 increased expression of activation markers CD69 and CD25, resulting in an increased fraction of CD69+ / CD25+ cells upon both incubations with 2C11 antibody. Surface expressed CD69 and CD25 were measured by FACS staining at the indicated time points after 2C11 stimulation. Data shown were gated on viable CD3+ / CD4+ or CD3+ / CD8+ T cells. Example 15
[0282] This example describes experiments performed to show that treatment of mouse T cells with an anti-mouse CD45(VHH)-CTLA4 bispecific binding module, mRIPR-CTL4, increases T cell activation in response to anti-mouse CD3(2C11).
[0283] In these experiments, T cells isolated from C57BL / 6 mice were stimulated with 1 μg / mL plate-bound 2C11 in the absence (left panel) or presence (right panel) of 1 μM CD45(VHH)-mCTLA4. It was observed that the bispecific diabody CD45(VHH)-CTLA4 increased the expression of activation markers CD69 and CD25, which resulted in an increase in the fraction of CD69+ / CD25+ cells for both CD4+ and CD8+ after 24 and 48 hours of incubation with 2C11 antibody. Surface expressed CD69 and CD25 were measured by FACS staining at appropriate time points after 2C11 stimulation. Data shown in Table 4 were gated on viable CD3+ / CD4+ or CD3+ / CD8+ T cells. The data presented in Table 6 is an example of CD25 and CD69 surface staining consistent with activation with 1 μg / mL plate-bound 2C11 and 1 μM mRIPR-CTLA4 as described in Example 14 above.
[0284] [Table 6] Example 16
[0285] This example describes experiments performed to show that treatment of mouse T cells with the anti-mouse CD45(VHH)-CD28 bispecific binding module, mRIPR-CD28, reduces the expression of T cell activation markers such as CD25 and CD44 in response to anti-mouse CD3(2C11).
[0286] As mentioned above, CD28 is part of the same protein family as PD-1 and CTLA-4, which are cell surface coreceptors of the B7 family. Unlike PD-1 and CTLA-4, signaling by CD28 coreceptor enhances T cell activation. Without being bound to any particular theory, it is expected that recruitment of phosphatases such as CD45 to CD28 attenuates CD28 signaling and reduces (e.g., inhibits) T cell activation.
[0287] The mRIPR-CD28 used in these experiments comprised the nanobody anti-mouse CD28 (International Publication WO 2002 / 047721 A1) fused to the nanobody CD45 (PMOD: 25819371). T cells isolated from C57BL / 6 mice were stimulated with 0.5, 1, 2, 4, or 8 μg / ml plate-bound 2C11 in the absence or presence of 125, 250, 500, or 1000 μM mRIPR-CD28. It was observed that mRIPR-CD28 reduced the expression of activation markers CD25 and CD44 for both CD4+ (Figure 15A) and CD8+ (Figure 15B) after 48 hours of incubation with the 2C11 antibody and mRIPR-CD28. Surface expressed CD25 and CD44 were measured by FACS staining at the indicated time points after 2C11 stimulation. Data shown were gated on viable CD4+ or CD8+ T cells. Example 17
[0288] This example describes a trispecific version of the RIPR molecule designed to recruit CD45 to two different cell surface antigens, PD-1 and CTLA4, which we have named dual RIPR (dRIPR)-PD1 / CTLA4. This trispecific version of the RIPR molecule binds mouse CD45, PD-1, and CTLA4, and is predicted to enhance T cell activation.
[0289] This molecule is composed of nanobody anti-CD45 (PMID: 25819371) and nanobody anti-CTLA4 (PMID: 29581255) fused to scFv anti-PD-1 (PD1-F2, described in International Publication WO2004 / 056875A1). The amino acid sequence of dRIPR-PD1 / CTLA4 is set forth in SEQ ID NO: 28 of the Sequence Listing. Further information regarding dRIPR-PD1 / CTLA4 can also be found in Table 1. This anti-mouse trispecific CD45-PD1-CTLA4 was subsequently purified by size exclusion (AKTA FPLC, GE Healthcare, Superdex 200 Increase; absorbance at 280 nm is shown in Figure 17A). Furthermore, the protein integrity and purity of the trispecific CD45-PD1 / CTLA4 molecule was confirmed by non-reducing SDS-PAGE electrophoresis followed by standard Coomassie staining (Figure 17B). Example 18
[0290] This example describes experiments performed to demonstrate that a multivalent polypeptide comprising an anti-CD45 scFv fused to a cytokine, in this case interleukin-2, reduces phosphorylation of STAT5 (pSTAT5) and attenuates STAT5 signaling.
[0291] In these experiments, to recruit CD45 phosphatase to IL-2R, anti-human CD45 scFv was fused to wild-type IL-2 as follows: First, a multivalent polypeptide capable of binding to CD45 and IL-2R was generated, in which the amino acid sequence of the polypeptide included, from N-terminus to C-terminus: (i) a heavy chain variable region of a scFv specific for CD45, (ii) a light chain variable region of a scFv specific for CD45; and (iii) an amino acid sequence of a cytokine IL-2 having binding affinity to the cytokine receptor IL-2R. The amino acid sequence of the multivalent polypeptide anti-CD45-IL2 is disclosed in SEQ ID NO: 6 in the Sequence Listing. As summarized in FIG. 16A, IL-2 induces JAK Tyr phosphorylation upon binding to the IL-2 receptor, and it is believed that local phosphatase recruitment of CD45 to the cytokine receptor IL-2R reduces the phosphorylation of STAT5 (pSTAT5).
[0292] In these experiments, surface staining of HEK293 cells (gray) and YT+ cells (CD25+; light gray) with fluorescently labeled anti-CD45-IL2 multivalent polypeptides (labeled with Alexa® Fluor 647 according to the manufacturer's instructions; Thermo Fisher Scientific) is shown in FIG. 16B. Also shown in FIG. 16C, incubation of YT+ cells with anti-CD45-IL2 multivalent polypeptides at the indicated concentrations for 15 min at 37° C. results in a ∼50% decrease in pSTAT5 Emax compared to wild-type IL-2. Representative data are shown as mean ± SD, n=3. To determine the extent of pSTAT5 response to IL-2 or CD45-IL2 chimera, ∼100,000 cells were fixed in 4% PFA for 10 min at room temperature. After fixation, cells were permeabilized with methanol on ice for 1 h, followed by incubation at −80° C. overnight. After washing with MACS buffer (Miltenyi), cells were incubated with fluorescently labeled anti-human pSTAT5 antibody (AlexaFluor® 647; BD Biosciences, Cat. No. 61299) diluted 1:100 in MACS buffer for 1 h on ice. After washing three times in ice-cold MACS buffer, pSTAT5 was quantified by FACS (CytoFLEX).
[0293] While certain alternative embodiments of the present disclosure have been disclosed, it should be understood that various modifications and combinations are possible and contemplated within the true spirit and scope of the appended claims. Accordingly, no limitations to the precise abstract and disclosure presented herein are intended.
Claims
1. A multivalent polypeptide comprising: a first amino acid sequence comprising a first polypeptide module capable of binding to one or more receptor protein tyrosine phosphatases (RPTPs); and a second amino acid sequence comprising a second polypeptide module capable of binding to one or more cell surface receptors that signal through a phosphorylation mechanism. wherein said first polypeptide module is operably linked to said second polypeptide module.
2. 2. The multivalent polypeptide of claim 1, wherein the first polypeptide module is operably linked to the second polypeptide module via a polypeptide linker sequence.
3. 3. The multivalent polypeptide of claim 1, wherein at least one of the first and second polypeptide modules comprises an amino acid sequence of a protein-binding ligand or an antigen-binding portion.
4. The antigen-binding moiety may be an antigen-binding fragment (Fab), a single chain variable fragment (scFv), a nanobody, a V H Domain, V L Domain, Single Domain Antibody (dAb), V NAR Domain, and V H 4. The multivalent polypeptide of claim 3, selected from the group consisting of an H domain, a diabody, or a functional fragment of either thereof.
5. The multivalent polypeptide of any one of claims 3 to 4, wherein the antigen-binding portion comprises a heavy chain variable region and a light chain variable region.
6. 4. The multivalent polypeptide of claim 3, wherein the protein-binding ligand is a cytokine, a growth factor, a receptor extracellular domain (ECD) of a RPTP or of a cell surface receptor, or a functional fragment of any of these.
7. The multivalent polypeptide of any one of claims 1 to 6, wherein the one or more RPTPs comprise CD45 or a functional variant thereof.
8. The multivalent polypeptide of any one of claims 1 to 7, wherein the one or more cell surface receptors comprise an immune checkpoint receptor, a cytokine receptor or a growth factor receptor.
9. 9. The multivalent polypeptide of any one of claims 1 to 8, wherein the one or more cell surface receptors comprise an immune checkpoint receptor selected from the group consisting of inhibitory checkpoint receptors and stimulatory checkpoint receptors.
10. 9. The multivalent polypeptide of any one of claims 1 to 8, wherein the one or more cell surface receptors comprise an inhibitory checkpoint receptor selected from the group consisting of PD-1, CTLA-4, A2AR, B7-H3, B7-H4, BTLA, CD5, CD132, IDO, KIR, LAG3, TIM-3, TIGIT and VISTA, or a functional variant of any thereof.
11. 9. The multivalent polypeptide of claim 1, wherein the one or more cell surface receptors comprise a stimulatory checkpoint receptor selected from the group consisting of CD27, CD28, CD40, OX40, GITR, ICOS and CD137, or a functional variant of any of them.
12. 9. The multivalent polypeptide of claim 1, wherein the one or more cell surface receptors mediate signal transduction through specific tyrosine-based motifs selected from ITAM motifs, ITSM motifs, ITIM motifs, or related intracellular motifs that act as phosphorylation substrates.
13. 13. The multivalent polypeptide of claim 12, wherein the one or more cell surface receptors are selected from the group consisting of DAP10, DAP12, SIRPa, CD3, CD28, CD4, CD8, CD200, CD200R, ICOS, KIR, FcR, BCR, CD5, CD2, G6B, LIRs, CD7 and BTNs, or any functional variant thereof.
14. The multivalent polypeptide of any one of claims 1 to 8, wherein the one or more cell surface receptors comprise a cytokine receptor.
15. 15. The multivalent polypeptide of claim 14, wherein the one or more cytokine receptors are selected from the group consisting of interleukin receptors, interferon receptors, chemokine receptors, growth hormone receptors, erythropoietin receptors (EpoR), thymic stromal lymphopoietin receptors (TSLPR), thrombopoietin receptors (TpoR), granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors, and granulocyte-colony stimulating factor (G-CSF) receptors.
16. The multivalent polypeptide of any one of claims 1 to 8, wherein the one or more cell surface receptors comprises a growth factor receptor.
17. 17. The multivalent polypeptide of claim 16, wherein the growth factor receptor is a stem cell growth factor receptor (SCFR) or an epidermal growth factor receptor (EGFR) selected from the group consisting of ErbB-1, ErbB-2 (HER2), ErbB-3, ErbB-4 and c-Kit (CD117).
18. The multivalent polypeptide of any one of claims 2 to 17, wherein the polypeptide linker sequence comprises from about 1 to about 100 amino acid residues.
19. The multivalent polypeptide of any one of claims 2 to 18, wherein the polypeptide linker comprises at least one glycine residue.
20. The multivalent polypeptide of any one of claims 2 to 18, wherein the polypeptide linker comprises a glycine-serine linker.
21. 21. The multivalent polypeptide of any one of claims 5 to 20, wherein the heavy and light chain variable regions of the antigen-binding portion are operably linked to each other via one or more intervening amino acid residues located between the heavy and light chain variable regions.
22. 22. The multivalent polypeptide of claim 21, wherein the intervening amino acid residues comprise from about 1 to about 100 amino acid residues.
23. A multivalent polypeptide according to any one of claims 21 to 22, wherein the intervening amino acid residues include at least one glycine residue.
24. A multivalent polypeptide according to any one of claims 21 to 23, wherein the intervening amino acid residues comprise a glycine-serine linker.
25. From N-terminus to C-terminus: a) domain A comprising the binding region of the heavy chain variable region of a first scFv specific for an epitope of a RPTP; b) Domain B comprising the binding region of the light chain variable region of a second scFv specific for an epitope of a cell surface receptor; c) Domain C comprising the binding region of the heavy chain variable region of a second scFv specific for an epitope of a cell surface receptor; and d) Domain D comprising the binding region of the light chain variable region of the first scFv specific for an epitope of RPTP The multivalent polypeptide of any one of claims 1 to 24, comprising:
26. 26. A multivalent polypeptide according to any one of claims 1 to 25, further comprising an amino acid sequence of a signal peptide.
27. 27. The multivalent polypeptide of any one of claims 1 to 26, further comprising an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 10, 12, 14, 16, 20, 22, 24, 26, 28 and 54.
28. a first polypeptide module specific for one or more receptor protein tyrosine phosphatases (RPTPs); and A second polypeptide module specific for one or more cell surface receptors that signal through a phosphorylation mechanism. wherein a first polypeptide module is operably linked to a second polypeptide module.
29. 29. The multivalent antibody or functional fragment thereof of claim 28, wherein the first polypeptide module is operably linked to the second polypeptide module via a polypeptide linker sequence.
30. A multivalent antibody or functional fragment thereof according to any one of claims 28 to 29, wherein at least one of the first and second polypeptide modules comprises the amino acid sequence of a protein-binding ligand or an antigen-binding portion.
31. The antigen-binding moiety may be an antigen-binding fragment (Fab), a single chain variable fragment (scFv), a nanobody, a V H Domain, V L Domain, Single Domain Antibody (sdAb), V NAR Domain, and V H 31. The multivalent antibody or functional fragment thereof of claim 30, selected from the group consisting of an H domain, an H domain, or a functional fragment thereof.
32. A multivalent antibody or functional fragment thereof according to any one of claims 30 to 31, wherein the antigen-binding portion comprises a heavy chain variable region and a light chain variable region.
33. 31. The multivalent antibody or functional fragment thereof of claim 30, wherein the protein-binding ligand is a cytokine, a growth factor, a receptor extracellular domain (ECD) of a cell surface receptor, or any functional fragment thereof.
34. The multivalent antibody or functional fragment thereof according to any one of claims 28 to 33, wherein the one or more RPTPs comprise CD45 or a functional variant thereof.
35. The multivalent antibody or functional fragment thereof according to any one of claims 28 to 34, wherein the one or more cell surface receptors comprise an immune checkpoint receptor, a cytokine receptor or a growth factor receptor.
36. The multivalent antibody or functional fragment thereof according to any one of claims 28 to 35, wherein the one or more cell surface receptors comprise an immune checkpoint receptor selected from the group consisting of inhibitory checkpoint receptors and stimulatory checkpoint receptors.
37. The multivalent antibody or functional fragment thereof according to any one of claims 28 to 35, wherein the one or more cell surface receptors comprise an inhibitory checkpoint receptor selected from the group consisting of PD-1, CTLA-4, A2AR, B7-H3, B7-H4, BTLA, CD5, CD132, IDO, KIR, LAG3, TIM-3, TIGIT and VISTA, or any functional variant thereof.
38. The multivalent antibody or functional fragment thereof according to any one of claims 28 to 37, wherein the one or more cell surface receptors comprise a stimulatory checkpoint receptor selected from the group consisting of CD27, CD28, CD40, OX40, GITR, ICOS and CD137, or any functional variant thereof.
39. 40. The multivalent antibody or functional fragment thereof according to any one of claims 39, wherein the one or more cell surface receptors mediate signal transduction through specific tyrosine-based motifs selected from ITAM motifs, ITSM motifs, ITIM motifs, or related intracellular motifs that act as phosphorylation substrates.
40. The multivalent antibody or functional fragment thereof of claim 39, wherein the one or more cell surface receptors are selected from the group consisting of DAP10, DAP12, SIRPa, CD3, CD28, CD4, CD8, CD200, CD200R, ICOS, KIR, FcR, BCR, CD5, CD2, G6B, LIRs, CD7 and BTNs, or any functional variant thereof.
41. The multivalent antibody or functional fragment thereof according to any one of claims 28 to 35, wherein the one or more cell surface receptors comprise a cytokine receptor.
42. The multivalent antibody or functional fragment thereof according to claim 41, wherein the one or more cytokine receptors are selected from the group consisting of interleukin receptors, interferon receptors, chemokine receptors, growth hormone receptors, erythropoietin receptors (EpoR), thymic stromal lymphopoietin receptors (TSLPR), thrombopoietin receptors (TpoR), granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors, and granulocyte-colony stimulating factor (G-CSF) receptors.
43. The multivalent antibody or functional fragment thereof according to any one of claims 28 to 35, wherein the one or more cell surface receptors comprise a growth factor receptor.
44. The multivalent antibody or functional fragment thereof according to claim 43, wherein the growth factor receptor is a stem cell growth factor receptor (SCFR) or an epidermal growth factor receptor (EGFR) selected from the group consisting of ErbB-1, ErbB-2 (HER2), ErbB-3, ErbB-4 and c-Kit (CD117).
45. A multivalent antibody or functional fragment thereof according to any one of claims 28 to 44, wherein the polypeptide linker sequence comprises 1 to 100 amino acid residues.
46. A multivalent antibody or functional fragment thereof according to any one of claims 29 to 45, wherein the polypeptide linker comprises at least one glycine residue.
47. A multivalent antibody or functional fragment thereof according to any one of claims 29 to 46, wherein the polypeptide linker comprises a glycine-serine linker.
48. 48. The multivalent antibody or functional fragment thereof according to any one of claims 32 to 47, wherein the heavy and light chain variable regions of the antigen-binding portion are operably linked to each other via one or more intervening amino acid residues located between the heavy and light chain variable regions.
49. The multivalent antibody or functional fragment thereof according to claim 48, wherein the intervening amino acid residues comprise from about 1 to about 100 amino acid residues.
50. A multivalent antibody or functional fragment thereof according to any one of claims 48 to 49, wherein the intervening amino acid residues comprise at least one glycine residue.
51. A multivalent antibody or functional fragment thereof according to any one of claims 48 to 50, wherein the intervening amino acid residues comprise a glycine-serine linker.
52. From N-terminus to C-terminus: a) domain A comprising the binding region of the heavy chain variable region of a first scFv specific for an epitope of a RPTP; b) Domain B comprising the binding region of the light chain variable region of a second scFv specific for an epitope of a cell surface receptor; c) Domain C comprising the binding region of the heavy chain variable region of a second scFv specific for an epitope of a cell surface receptor; and d) Domain D comprising the binding region of the light chain variable region of the first scFv specific for an epitope of RPTP A multivalent antibody or a functional fragment thereof according to any one of claims 28 to 51, comprising:
53. A multivalent antibody or a functional fragment thereof according to any one of claims 28 to 52, further comprising an amino acid sequence of a signal peptide.
54. A multivalent antibody or a functional fragment thereof according to any one of claims 28 to 53, further comprising an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 10, 12, 14, 16, 20, 22, 24, 26, 28 and 54.
55. A multivalent polypeptide according to any one of claims 1 to 27; or A multivalent antibody or a functional fragment thereof according to any one of claims 28 to 54. and a pharma- ceutically acceptable excipient.
13. A pharmaceutical composition comprising:
56. 1. A recombinant nucleic acid molecule comprising: a) an amino acid sequence having at least 80% identity to the amino acid sequence of a multivalent polypeptide according to any one of claims 1 to 27; or b) an amino acid sequence having at least 80% identity to a multivalent antibody or a functional fragment thereof according to any one of claims 28 to 54; A recombinant nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising:
57. 57. The recombinant nucleic acid molecule of claim 56, wherein the nucleotide sequence has at least 80% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 9, 11, 13, 15, 19, 21, 23, 25, 27 and 53.
58. 58. An expression cassette or vector comprising a recombinant nucleic acid molecule according to any one of claims 56 to 57.
59. A recombinant cell comprising a recombinant nucleic acid molecule according to any one of claims 56 to 57.
60. 60. A cell culture comprising one or more recombinant cells of claim 59 and a medium.
61. 1. A method for producing a polypeptide or a multivalent antibody, comprising the steps of: providing one or more recombinant cells according to claim 59; and Culturing the one or more recombinant cells in a culture medium such that the cells produce the multivalent polypeptide or multivalent antibody encoded by the recombinant nucleic acid molecule. The method includes:
62. 1. A method for modulating cell signaling mediated by a cell surface receptor that signals through a phosphorylation mechanism in a subject, comprising: a) a multivalent polypeptide according to any one of claims 1 to 27; or b) A multivalent antibody or a functional fragment thereof according to any one of claims 28 to 54. administering to said subject a first treatment comprising an effective amount of
63. A method for treating a disease in a subject in need of treatment, the method comprising: a) a multivalent polypeptide according to any one of claims 1 to 27; or b) A multivalent antibody or a functional fragment thereof according to any one of claims 28 to 54. administering to said subject a first treatment comprising an effective amount of
64. 64. The method of any one of claims 62-63, wherein the administered multivalent polypeptide or multivalent antibody recruits receptor protein tyrosine phosphatase (RPTP) activity to the spatial vicinity of a cell surface receptor and reduces the phosphorylation level of the cell surface receptor.
65. The method of any one of claims 62 to 64, wherein administration of the multivalent polypeptide or multivalent antibody results in a decrease in activity of an immune checkpoint receptor in the subject.
66. The method of any one of claims 62 to 64, wherein administration of the multivalent polypeptide or multivalent antibody results in enhanced T cell activity in the subject.
67. The method of any one of claims 62 to 64, wherein administration of the multivalent polypeptide or multivalent antibody results in suppression of T cell activity in the subject.
68. The method of any one of claims 62 to 67, wherein the subject is a mammal.
69. 69. The method of claim 68, wherein the mammal is a human.
70. 70. The method of any one of claims 62 to 69, wherein the subject has or is suspected of having a disease associated with inhibition of signal transduction mediated by a cell surface receptor.
71. 71. The method of claim 70, wherein the disease is cancer or a chronic infectious disease.
72. 72. The method of any one of claims 62 to 71, further comprising administering a second therapeutic regimen to the subject.
73. 73. The method of claim 72, wherein the second therapy is selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, hormone therapy, and toxin therapy.
74. 74. The method of any one of claims 72 to 73, wherein the first and second therapeutic approaches are administered concomitantly.
75. 75. The method of any one of claims 72 to 74, wherein the first therapy is administered simultaneously with the second therapy.
76. 74. The method of any one of claims 72 to 73, wherein the first and second treatments are administered sequentially.
77. 77. The method of claim 76, wherein the first therapy is administered before the second therapy.
78. 77. The method of claim 76, wherein the first therapy is administered after the second therapy.
79. 74. The method of any one of claims 72 to 73, wherein the first therapy is administered before and / or after the second therapy.
80. 74. The method of any one of claims 72 to 73, wherein the first and second therapeutic approaches are administered cyclically.
81. 74. The method of any one of claims 72-73, wherein the first and second therapeutic agents are administered together in a single formulation.
